Journal of clinical oncology : official journal of the American Society of Clinical Oncology

publication venue for

Paradoxical immune reconstitution inflammatory syndrome associated with rituximab-containing regimen in a patient with lymphoma. 2013
Prioritizing phase I treatment options through preclinical testing on personalized tumorgraft. 2011
Seizures and radionecrosis from non-small-cell lung cancer presenting as increased fluorodeoxyglucose uptake on positron emission tomography. 2011
Clinical activity of mTOR inhibition with sirolimus in malignant perivascular epithelioid cell tumors: targeting the pathogenic activation of mTORC1 in tumors. 2010
Phase I trial of bevacizumab plus escalated doses of sunitinib in patients with metastatic renal cell carcinoma. 2009
Response and resistance in a non-small-cell lung cancer patient with an epidermal growth factor receptor mutation and leptomeningeal metastases treated with high-dose gefitinib. 2006
Aromatase inhibitor withdrawal response in metastatic breast cancer. 2006
Metastatic colon cancer to the ovaries in a Krukenberg-like pattern. 2005
Synchronous neuroblastoma and von Recklinghausen's disease: a review of the literature. 1985
TROPHY-U-01 Cohort 2: A Phase II Study of Sacituzumab Govitecan in Cisplatin-Ineligible Patients With Metastatic Urothelial Cancer Progressing After Previous Checkpoint Inhibitor Therapy. 2024
Molecular and Clinicopathologic Impact of GNAS Variants Across Solid Tumors. 2024
Association Between State Medicaid Policies and Accrual of Black or Hispanic Patients to Cancer Clinical Trials. 2024
Intratumoral Escherichia Is Associated With Improved Survival to Single-Agent Immune Checkpoint Inhibition in Patients With Advanced Non-Small-Cell Lung Cancer. 2024
Linvoseltamab for Treatment of Relapsed/Refractory Multiple Myeloma. 2024
Pediatric Leukemia Roadmaps Are a Guide for Positive Metastatic Bone Sarcoma Trials. 2024
Phase III Randomized, Placebo-Controlled Trial of Endocrine Therapy ± 1 Year of Everolimus in Patients With High-Risk, Hormone Receptor-Positive, Early-Stage Breast Cancer.. 42. 2024
Adjunctive Statistical Standardization of Adjuvant Estrogen Receptor and Progesterone Receptor in Canadian Cancer Trials Group MA.27 Postmenopausal Breast Cancer Trial of Exemestane Versus Anastrozole. 2024
Radiation Therapy With or Without Cisplatin for Local Recurrences of Endometrial Cancer: Results From an NRG Oncology/GOG Prospective Randomized Multicenter Clinical Trial. 2024
RESILIENT Part 2: A Randomized, Open-Label Phase III Study of Liposomal Irinotecan Versus Topotecan in Adults With Relapsed Small Cell Lung Cancer. 2024
PACE: A Randomized Phase II Study of Fulvestrant, Palbociclib, and Avelumab After Progression on Cyclin-Dependent Kinase 4/6 Inhibitor and Aromatase Inhibitor for Hormone Receptor-Positive/Human Epidermal Growth Factor Receptor-Negative Metastatic Breast Cancer. 2024
PRESTO: A Phase III, Open-Label Study of Intensification of Androgen Blockade in Patients With High-Risk Biochemically Relapsed Castration-Sensitive Prostate Cancer (AFT-19). 2024
Sacituzumab Govitecan in Combination With Pembrolizumab for Patients With Metastatic Urothelial Cancer That Progressed After Platinum-Based Chemotherapy: TROPHY-U-01 Cohort 3. 2024
Hypoxia-Directed Treatment of Human Papillomavirus-Related Oropharyngeal Carcinoma.. 42. 2024
Secondary Analysis of the Rate of Second Primary Lung Cancer From Cancer and Leukemia Group B 140503 (Alliance) Trial of Lobar Versus Sublobar Resection for T1aN0 Non-Small-Cell Lung Cancer. 2024
Germline Testing in Patients With Breast Cancer: ASCO-Society of Surgical Oncology Guideline.. 42. 2024
CD5 Gene Signature Identifies Diffuse Large B-Cell Lymphomas Sensitive to Bruton's Tyrosine Kinase Inhibition. 2023
SKYSCRAPER-02: Tiragolumab in Combination With Atezolizumab Plus Chemotherapy in Untreated Extensive-Stage Small-Cell Lung Cancer. 2023
Myths and Presumptions About Cancer Survivorship.. 42. 2023
Prostate-Specific Membrane Antigen-Targeting Alpha Emitter via Antibody Delivery for Metastatic Castration-Resistant Prostate Cancer: A Phase I Dose-Escalation Study of ²²⁵Ac-J591. 2023
Long-Term Results of Organ Preservation in Patients With Rectal Adenocarcinoma Treated With Total Neoadjuvant Therapy: The Randomized Phase II OPRA Trial.. 42. 2023
Reply to F. Dossa et al.. 42. 2023
Systemic Therapy for Tumor Control in Metastatic Well-Differentiated Gastroenteropancreatic Neuroendocrine Tumors: ASCO Guideline. 2023
Inaugural Results of the Individualized Screening Trial of Innovative Glioblastoma Therapy: A Phase II Platform Trial for Newly Diagnosed Glioblastoma Using Bayesian Adaptive Randomization. 2023
Pan-Cancer Analysis of Postdiagnosis Exercise and Mortality.. 41. 2023
Genomic Profiling Reveals Germline Predisposition and Homologous Recombination Deficien cy in Pancreatic Acinar Cell Carcinoma. 2023
Randomized Phase II Multicenter Trial of Abiraterone Acetate With or Without Cabazitaxel in the Treatment of Metastatic Castration-Resistant Prostate Cancer. 2023
High-Temporal/High-Spatial Resolution Breast Magnetic Resonance Imaging Improves Diagnostic Accuracy Compared With Standard Breast Magnetic Resonance Imaging in Patients With High Background Parenchymal Enhancement.. 41. 2023
Market, Gift, Everyday Ethics, and Emmanuel Levinas in Patient Care. 2023
Projected Savings for Generic Oncology Drugs Purchased via Mark Cuban Cost Plus Drug Company Versus in Medicare.. 41. 2023
Patient-Reported Outcomes During and After Treatment for Locally Advanced Rectal Cancer in the PROSPECT Trial (Alliance N1048).. 41. 2023
Randomized Phase II Trial of Endocrine Therapy With or Without Ribociclib After Progression on Cyclin-Dependent Kinase 4/6 Inhibition in Hormone Receptor-Positive, Human Epidermal Growth Factor Receptor 2-Negative Metastatic Breast Cancer: MAINTAIN Trial.. 41. 2023
Long-Term Outcomes and Molecular Correlates of Sotorasib Efficacy in Patients With Pretreated KRAS G12C-Mutated Non-Small-Cell Lung Cancer: 2-Year Analysis of CodeBreaK 100.. 41. 2023
Avelumab First-Line Maintenance for Advanced Urothelial Carcinoma: Results From the JAVELIN Bladder 100 Trial After ≥2 Years of Follow-Up. 2023
External Validation of a Prognostic Model of Overall Survival in Men With Chemotherapy-Naïve Metastatic Castration-Resistant Prostate Cancer. 2023
MANIFEST: Pelabresib in Combination With Ruxolitinib for Janus Kinase Inhibitor Treatment-Naïve Myelofibrosis. 2023
Darolutamide Plus Androgen-Deprivation Therapy and Docetaxel in Metastatic Hormone-Sensitive Prostate Cancer by Disease Volume and Risk Subgroups in the Phase III ARASENS Trial. 2023
Immunotherapy and Targeted Therapy for Advanced Gastroesophageal Cancer: ASCO Guideline. 2023
Multicenter Phase II Clinical Trial of Gemcitabine and Cisplatin as Neoadjuvant Chemotherapy for Patients With High-Grade Upper Tract Urothelial Carcinoma.. 41. 2023
Long-Term Morbidity and Mortality Among Survivors of Neuroblastoma Diagnosed During Infancy: A Report From the Childhood Cancer Survivor Study.. 41. 2022
Adjuvant Exemestane With Ovarian Suppression in Premenopausal Breast Cancer: Long-Term Follow-Up of the Combined TEXT and SOFT Trials.. 41. 2022
Molecular Classification of Appendiceal Adenocarcinoma.. 41. 2022
Positron Emission Tomography-Adapted Therapy in Bulky Stage I/II Classic Hodgkin Lymphoma: CALGB 50801 (Alliance).. 41. 2022
Randomized Trial of Olaparib With or Without Cediranib for Metastatic Castration-Resistant Prostate Cancer: The Results From National Cancer Institute 9984. 2022
FORT-1: Phase II/III Study of Rogaratinib Versus Chemotherapy in Patients With Locally Advanced or Metastatic Urothelial Carcinoma Selected Based on FGFR1/3 mRNA Expression. 2022
Combination dabrafenib and trametinib versus combination nivolumab and ipilimumab for patients with advanced BRAF-mutant melanoma: The DREAMseq Trial - ECOG-ACRIN EA6134. 2022
Phase II Study of Enzalutamide for Patients With Androgen Receptor-Positive Salivary Gland Cancers (Alliance A091404). 2022
Venetoclax Plus Gilteritinib for FLT3-Mutated Relapsed/Refractory Acute Myeloid Leukemia. 2022
Gene Expression Signatures for the Accurate Diagnosis of Peripheral T-Cell Lymphoma Entities in the Routine Clinical Practice. 2022
Randomized Phase II Trial of Proton Craniospinal Irradiation Versus Photon Involved-Field Radiotherapy for Patients With Solid Tumor Leptomeningeal Metastasis.. 40. 2022
Relevance of Bone Marrow Biopsies for Response Assessment in US National Cancer Institute National Clinical Trials Network Follicular Lymphoma Clinical Trials.. 41. 2022
Treatment Outcomes and Roles of Transplantation and Maintenance Rituximab in Patients With Previously Untreated Mantle Cell Lymphoma: Results From Large Real-World Cohorts. 2022
Phase III Randomized Trial of Maintenance Taxanes Versus Surveillance in Women With Advanced Ovarian/Tubal/Peritoneal Cancer: A Gynecologic Oncology Group 0212:NRG Oncology Study.. 40. 2022
Management of Metastatic Clear Cell Renal Cell Carcinoma: ASCO Guideline. 2022
Management of Advanced Human Epidermal Growth Factor Receptor 2-Positive Breast Cancer and Brain Metastases: ASCO Guideline Update.. 40. 2022
Systemic Therapy for Advanced Human Epidermal Growth Factor Receptor 2-Positive Breast Cancer: ASCO Guideline Update.. 40. 2022
Organ Preservation in Patients With Rectal Adenocarcinoma Treated With Total Neoadjuvant Therapy.. 40. 2022
Dynamics of Long-Term Patient-Reported Quality of Life and Health Behaviors After Adjuvant Breast Cancer Chemotherapy. 2022
Biomarkers for Adjuvant Endocrine and Chemotherapy in Early-Stage Breast Cancer: ASCO Guideline Update.. 40. 2022
Addition of Navitoclax to Ongoing Ruxolitinib Therapy for Patients With Myelofibrosis With Progression or Suboptimal Response: Phase II Safety and Efficacy. 2022
Somatic Genomic Testing in Patients With Metastatic or Advanced Cancer: ASCO Provisional Clinical Opinion.. 40. 2022
Neoadjuvant Atezolizumab With Gemcitabine and Cisplatin in Patients With Muscle-Invasive Bladder Cancer: A Multicenter, Single-Arm, Phase II Trial.. 40. 2022
Adjuvant Therapy for Stage II Colon Cancer: ASCO Guideline Update. 2021
Impact of TP53 Genomic Alterations in Large B-Cell Lymphoma Treated With CD19-Chimeric Antigen Receptor T-Cell Therapy.. 40. 2021
Randomized Phase III BMT CTN Trial of Calcineurin Inhibitor-Free Chronic Graft-Versus-Host Disease Interventions in Myeloablative Hematopoietic Cell Transplantation for Hematologic Malignancies.. 40. 2021
Long-Term Outcomes With Nivolumab Plus Ipilimumab or Nivolumab Alone Versus Ipilimumab in Patients With Advanced Melanoma.. 40. 2021
Venetoclax in Previously Treated Waldenström Macroglobulinemia.. 40. 2021
Ibrutinib Plus Venetoclax for First-Line Treatment of Chronic Lymphocytic Leukemia: Primary Analysis Results From the Minimal Residual Disease Cohort of the Randomized Phase II CAPTIVATE Study.. 39. 2021
Personalized Prediction Model to Risk Stratify Patients With Myelodysplastic Syndromes. 2021
Acalabrutinib Versus Ibrutinib in Previously Treated Chronic Lymphocytic Leukemia: Results of the First Randomized Phase III Trial. 2021
Phase II Trial of Pembrolizumab Plus Gemcitabine, Vinorelbine, and Liposomal Doxorubicin as Second-Line Therapy for Relapsed or Refractory Classical Hodgkin Lymphoma.. 39. 2021
Open-Label Phase II Prospective, Randomized, Controlled Study of Romyelocel-L Myeloid Progenitor Cells to Reduce Infection During Induction Chemotherapy for Acute Myeloid Leukemia. 2021
Therapeutic Implications of Germline Testing in Patients With Advanced Cancers.. 39. 2021
Risk of Breast Cancer Among Carriers of Pathogenic Variants in Breast Cancer Predisposition Genes Varies by Polygenic Risk Score.. 39. 2021
Adjuvant Trastuzumab Emtansine Versus Paclitaxel in Combination With Trastuzumab for Stage I HER2-Positive Breast Cancer (ATEMPT): A Randomized Clinical Trial.. 39. 2021
Development and Validation of a Breast Cancer Risk Prediction Model for Childhood Cancer Survivors Treated With Chest Radiation: A Report From the Childhood Cancer Survivor Study and the Dutch Hodgkin Late Effects and LATER Cohorts. 2021
Secondary Cytoreduction and Carboplatin Hyperthermic Intraperitoneal Chemotherapy for Platinum-Sensitive Recurrent Ovarian Cancer: An MSK Team Ovary Phase II Study.. 39. 2021
Updated Results of TBCRC026: Phase II Trial Correlating Standardized Uptake Value With Pathological Complete Response to Pertuzumab and Trastuzumab in Breast Cancer.. 39. 2021
Randomized Phase III Trial of Gemcitabine and Cisplatin With Bevacizumab or Placebo in Patients With Advanced Urothelial Carcinoma: Results of CALGB 90601 (Alliance).. 39. 2021
Lifileucel, a Tumor-Infiltrating Lymphocyte Therapy, in Metastatic Melanoma.. 39. 2021
TROPHY-U-01: A Phase II Open-Label Study of Sacituzumab Govitecan in Patients With Metastatic Urothelial Carcinoma Progressing After Platinum-Based Chemotherapy and Checkpoint Inhibitors.. 39. 2021
Phase III Study to Evaluate Efficacy and Safety of Andecaliximab With mFOLFOX6 as First-Line Treatment in Patients With Advanced Gastric or GEJ Adenocarcinoma (GAMMA-1).. 39. 2021
Addition of Lenalidomide to R-CHOP Improves Outcomes in Newly Diagnosed Diffuse Large B-Cell Lymphoma in a Randomized Phase II US Intergroup Study ECOG-ACRIN E1412.. 39. 2021
Burkitt Lymphoma International Prognostic Index.. 39. 2021
Radiation Therapy for Small-Cell Lung Cancer: ASCO Guideline Endorsement of an ASTRO Guideline.. 39. 2021
Beyond a Child's Question: Physicians and the Existential Unknown in End-of-Life Care.. 39. 2021
Clinical Calculator Based on Molecular and Clinicopathologic Characteristics Predicts Recurrence Following Resection of Stage I-III Colon Cancer.. 39. 2021
Survival Impact of Anti-GD2 Antibody Response in a Phase II Ganglioside Vaccine Trial Among Patients With High-Risk Neuroblastoma With Prior Disease Progression.. 39. 2020
B7H3-Directed Intraperitoneal Radioimmunotherapy With Radioiodinated Omburtamab for Desmoplastic Small Round Cell Tumor and Other Peritoneal Tumors: Results of a Phase I Study.. 38. 2020
COVID-19 Severity and Outcomes in Patients With Cancer: A Matched Cohort Study.. 38. 2020
Randomized Phase II Trial of Nivolumab With Stereotactic Body Radiotherapy Versus Nivolumab Alone in Metastatic Head and Neck Squamous Cell Carcinoma.. 39. 2020
Switch Control Inhibition of KIT and PDGFRA in Patients With Advanced Gastrointestinal Stromal Tumor: A Phase I Study of Ripretinib.. 38. 2020
Positron Emission Tomography-Directed Therapy for Patients With Limited-Stage Diffuse Large B-Cell Lymphoma: Results of Intergroup National Clinical Trials Network Study S1001.. 38. 2020
Ivosidenib in Isocitrate Dehydrogenase 1-Mutated Advanced Glioma.. 38. 2020
Pembrolizumab or Placebo Plus Etoposide and Platinum as First-Line Therapy for Extensive-Stage Small-Cell Lung Cancer: Randomized, Double-Blind, Phase III KEYNOTE-604 Study.. 38. 2020
Multicenter Study of Risk-Adapted Therapy With Dose-Adjusted EPOCH-R in Adults With Untreated Burkitt Lymphoma.. 38. 2020
Quest for Clinically Effective RAF Dimer Inhibitors.. 38. 2020
Diagnosis and Management of Squamous Cell Carcinoma of Unknown Primary in the Head and Neck: ASCO Guideline.. 38. 2020
Randomized Phase II Trial of Nivolumab Versus Nivolumab and Ipilimumab for Recurrent or Persistent Ovarian Cancer: An NRG Oncology Study.. 38. 2020
Phase I Study of the Mutant IDH1 Inhibitor Ivosidenib: Safety and Clinical Activity in Patients With Advanced Chondrosarcoma.. 38. 2020
State of the Art: Toward Improving Outcomes of Lung and Liver Tumor Biopsies in Clinical Trials-A Multidisciplinary Approach.. 38. 2020
Adjuvant Chemotherapy With Etoposide Plus Cisplatin for Patients With Pathologic Stage II Nonseminomatous Germ Cell Tumors.. 38. 2020
Long-Term Outcomes and Responses to Retreatment in Patients With Melanoma Treated With PD-1 Blockade.. 38. 2020
Clinical Cancer Advances 2020: Annual Report on Progress Against Cancer From the American Society of Clinical Oncology.. 38. 2020
Cascading After Peridiagnostic Cancer Genetic Testing: An Alternative to Population-Based Screening.. 38. 2020
Prospective Feasibility Trial of a Novel Strategy of Facilitated Cascade Genetic Testing Using Telephone Counseling.. 38. 2020
ASCO Clinical Practice Guideline Endorsements and Adaptations.. 38. 2019
Molecular Biomarkers in Localized Prostate Cancer: ASCO Guideline.. 38. 2019
Prognostic Impact of the 21-Gene Recurrence Score Assay Among Young Women With Node-Negative and Node-Positive ER-Positive/HER2-Negative Breast Cancer.. 38. 2019
Immune Checkpoint Inhibitor Therapy in Patients With Preexisting Inflammatory Bowel Disease.. 38. 2019
Phase II Study of Nonmetastatic Desmoplastic Medulloblastoma in Children Younger Than 4 Years of Age: A Report of the Children's Oncology Group (ACNS1221).. 38. 2019
Lesion-Level Response Dynamics to Programmed Cell Death Protein (PD-1) Blockade.. 37. 2019
PD-1 Blockade in Advanced Adrenocortical Carcinoma.. 38. 2019
Phase II Trial of Response-Based Radiation Therapy for Patients With Localized CNS Nongerminomatous Germ Cell Tumors: A Children's Oncology Group Study.. 37. 2019
Romiplostim Treatment of Chemotherapy-Induced Thrombocytopenia.. 37. 2019
Treatment-Free Survival: A Novel Outcome Measure of the Effects of Immune Checkpoint Inhibition-A Pooled Analysis of Patients With Advanced Melanoma.. 37. 2019
Phase II Study of Avelumab in Patients With Mismatch Repair Deficient and Mismatch Repair Proficient Recurrent/Persistent Endometrial Cancer.. 37. 2019
Pivotal Trial of Enfortumab Vedotin in Urothelial Carcinoma After Platinum and Anti-Programmed Death 1/Programmed Death Ligand 1 Therapy.. 37. 2019
Impact of Teratoma on the Cumulative Incidence of Disease-Related Death in Patients With Advanced Germ Cell Tumors.. 37. 2019
Treatment Outcomes of Immune-Related Cutaneous Adverse Events.. 37. 2019
Role of Patient and Disease Factors in Adjuvant Systemic Therapy Decision Making for Early-Stage, Operable Breast Cancer: Update of the ASCO Endorsement of the Cancer Care Ontario Guideline.. 37. 2019
Use of Biomarkers to Guide Decisions on Adjuvant Systemic Therapy for Women With Early-Stage Invasive Breast Cancer: ASCO Clinical Practice Guideline Update-Integration of Results From TAILORx.. 37. 2019
Randomized Double-Blind Phase II Study of Regorafenib in Patients With Metastatic Osteosarcoma.. 37. 2019
Final Results of a Randomized, Phase III Study of Rituximab With or Without Idelalisib Followed by Open-Label Idelalisib in Patients With Relapsed Chronic Lymphocytic Leukemia.. 37. 2019
Phthalate Exposure and Breast Cancer Incidence: A Danish Nationwide Cohort Study.. 37. 2019
Progression Risk Stratification of Asymptomatic Waldenström Macroglobulinemia.. 37. 2019
Dose-Adjusted EPOCH-R Compared With R-CHOP as Frontline Therapy for Diffuse Large B-Cell Lymphoma: Clinical Outcomes of the Phase III Intergroup Trial Alliance/CALGB 50303.. 37. 2019
Phase II Study of Lenvatinib in Patients With Progressive, Recurrent or Metastatic Adenoid Cystic Carcinoma.. 37. 2019
AUGMENT: A Phase III Study of Lenalidomide Plus Rituximab Versus Placebo Plus Rituximab in Relapsed or Refractory Indolent Lymphoma.. 37. 2019
Venetoclax Combined With Low-Dose Cytarabine for Previously Untreated Patients With Acute Myeloid Leukemia: Results From a Phase Ib/II Study.. 37. 2019
TBCRC026: Phase II Trial Correlating Standardized Uptake Value With Pathologic Complete Response to Pertuzumab and Trastuzumab in Breast Cancer.. 37. 2019
Buparlisib in Patients With Recurrent Glioblastoma Harboring Phosphatidylinositol 3-Kinase Pathway Activation: An Open-Label, Multicenter, Multi-Arm, Phase II Trial.. 37. 2019
Randomized Phase III Study of Alisertib or Investigator's Choice (Selected Single Agent) in Patients With Relapsed or Refractory Peripheral T-Cell Lymphoma.. 37. 2019
Autologous Transplantation, Consolidation, and Maintenance Therapy in Multiple Myeloma: Results of the BMT CTN 0702 Trial.. 37. 2019
Tumor-Infiltrating Lymphocytes and Prognosis: A Pooled Individual Patient Analysis of Early-Stage Triple-Negative Breast Cancers.. 37. 2019
EGFR-Mutant Adenocarcinomas That Transform to Small-Cell Lung Cancer and Other Neuroendocrine Carcinomas: Clinical Outcomes.. 37. 2018
Time Interval to Biochemical Failure as a Surrogate End Point in Locally Advanced Prostate Cancer: Analysis of Randomized Trial NRG/RTOG 9202.. 37. 2018
Underdiagnosis of Hereditary Breast Cancer: Are Genetic Testing Guidelines a Tool or an Obstacle?. 37. 2018
Phase I/II Trial to Evaluate the Efficacy and Safety of Nanoparticle Albumin-Bound Paclitaxel in Combination With Gemcitabine in Patients With Pancreatic Cancer and an ECOG Performance Status of 2.. 37. 2018
SELECT: A Phase II Trial of Adjuvant Erlotinib in Patients With Resected Epidermal Growth Factor Receptor-Mutant Non-Small-Cell Lung Cancer.. 37. 2018
Microsatellite Instability Is Associated With the Presence of Lynch Syndrome Pan-Cancer.. 37. 2018
Extensive Molecular and Clinical Heterogeneity in Patients With Histologically Diagnosed CNS-PNET Treated as a Single Entity: A Report From the Children's Oncology Group Randomized ACNS0332 Trial.. 36. 2018
Feasibility of Implementing the Patient-Reported Outcomes Version of the Common Terminology Criteria for Adverse Events in a Multicenter Trial: NCCTG N1048. 2018
Clinically Localized Prostate Cancer: ASCO Clinical Practice Guideline Endorsement of an American Urological Association/American Society for Radiation Oncology/Society of Urologic Oncology Guideline.. 36. 2018
Impact of Baseline Steroids on Efficacy of Programmed Cell Death-1 and Programmed Death-Ligand 1 Blockade in Patients With Non-Small-Cell Lung Cancer.. 36. 2018
Clinical and Genomic Characterization of Treatment-Emergent Small-Cell Neuroendocrine Prostate Cancer: A Multi-institutional Prospective Study.. 36. 2018
Randomized, Double-Blind, Phase II Study of Temozolomide in Combination With Either Veliparib or Placebo in Patients With Relapsed-Sensitive or Refractory Small-Cell Lung Cancer.. 36. 2018
Ibrutinib as Treatment for Patients With Relapsed/Refractory Follicular Lymphoma: Results From the Open-Label, Multicenter, Phase II DAWN Study.. 36. 2018
Metastatic Pancreatic Cancer: ASCO Clinical Practice Guideline Update.. 36. 2018
Multicenter Prospective Phase II Trial of Neoadjuvant Dose-Dense Gemcitabine Plus Cisplatin in Patients With Muscle-Invasive Bladder Cancer.. 36. 2018
Multicenter Phase IB Trial of Carboxyamidotriazole Orotate and Temozolomide for Recurrent and Newly Diagnosed Glioblastoma and Other Anaplastic Gliomas.. 36. 2018
Financial Impact of Breast Cancer in Black Versus White Women.. 36. 2018
Efficacy and Safety Outcomes in Patients With Advanced Melanoma Who Discontinued Treatment With Nivolumab and Ipilimumab Because of Adverse Events: A Pooled Analysis of Randomized Phase II and III Trials.. 35. 2018
Cumulative Burden of Morbidity Among Testicular Cancer Survivors After Standard Cisplatin-Based Chemotherapy: A Multi-Institutional Study.. 36. 2018
Alterations in DNA Damage Response and Repair Genes as Potential Marker of Clinical Benefit From PD-1/PD-L1 Blockade in Advanced Urothelial Cancers.. 36. 2018
Controversies in the Management of Clinical Stage I Seminoma: Carboplatin a Decade in-Time to Start Backing Out.. 36. 2018
Quality of Life Outcomes for Cabozantinib Versus Everolimus in Patients With Metastatic Renal Cell Carcinoma: METEOR Phase III Randomized Trial.. 36. 2018
Enzalutamide for the Treatment of Androgen Receptor-Expressing Triple-Negative Breast Cancer.. 36. 2018
Continued Excellent Outcomes in Previously Untreated Patients With Follicular Lymphoma After Treatment With CHOP Plus Rituximab or CHOP Plus ¹³¹I-Tositumomab: Long-Term Follow-Up of Phase III Randomized Study SWOG-S0016.. 36. 2018
Immune-Modified Response Evaluation Criteria In Solid Tumors (imRECIST): Refining Guidelines to Assess the Clinical Benefit of Cancer Immunotherapy.. 36. 2018
Molecular Determinants of Response to Anti-Programmed Cell Death (PD)-1 and Anti-Programmed Death-Ligand 1 (PD-L1) Blockade in Patients With Non-Small-Cell Lung Cancer Profiled With Targeted Next-Generation Sequencing.. 36. 2018
Durable Complete Response After Discontinuation of Pembrolizumab in Patients With Metastatic Melanoma.. 36. 2017
Phase II Study of BGJ398 in Patients With FGFR-Altered Advanced Cholangiocarcinoma.. 36. 2017
Modernizing Clinical Trial Eligibility Criteria: Recommendations of the American Society of Clinical Oncology-Friends of Cancer Research Brain Metastases Working Group.. 35. 2017
Modernizing Clinical Trial Eligibility Criteria: Recommendations of the American Society of Clinical Oncology-Friends of Cancer Research HIV Working Group.. 35. 2017
Pooled Analysis Safety Profile of Nivolumab and Ipilimumab Combination Therapy in Patients With Advanced Melanoma.. 35. 2017
Randomized Phase III Trial of Adjuvant Pazopanib Versus Placebo After Nephrectomy in Patients With Localized or Locally Advanced Renal Cell Carcinoma.. 35. 2017
Randomized Phase II Study of R-CHOP With or Without Bortezomib in Previously Untreated Patients With Non-Germinal Center B-Cell-Like Diffuse Large B-Cell Lymphoma.. 35. 2017
Activity of Eribulin in Patients With Advanced Liposarcoma Demonstrated in a Subgroup Analysis From a Randomized Phase III Study of Eribulin Versus Dacarbazine.. 35. 2017
Practice Makes Perfect: The Rest of the Story in Testicular Cancer as a Model Curable Neoplasm.. 35. 2017
Systemic Therapy for Stage IV Non-Small-Cell Lung Cancer: American Society of Clinical Oncology Clinical Practice Guideline Update.. 35. 2017
Therapeutic and Prognostic Implications of BRAF V600E in Pediatric Low-Grade Gliomas.. 35. 2017
Randomized, Noncomparative, Phase II Trial of Early Switch From Docetaxel to Cabazitaxel or Vice Versa, With Integrated Biomarker Analysis, in Men With Chemotherapy-Naïve, Metastatic, Castration-Resistant Prostate Cancer.. 35. 2017
HELOISE: Phase IIIb Randomized Multicenter Study Comparing Standard-of-Care and Higher-Dose Trastuzumab Regimens Combined With Chemotherapy as First-Line Therapy in Patients With Human Epidermal Growth Factor Receptor 2-Positive Metastatic Gastric or Gastroesophageal Junction Adenocarcinoma.. 35. 2017
KIR3DL1/HLA-B Subtypes Govern Acute Myelogenous Leukemia Relapse After Hematopoietic Cell Transplantation.. 35. 2017
AKT Inhibition in Solid Tumors With AKT1 Mutations.. 35. 2017
Perioperative Hepatic Arterial Infusion Pump Chemotherapy Is Associated With Longer Survival After Resection of Colorectal Liver Metastases: A Propensity Score Analysis.. 35. 2017
American Society of Clinical Oncology Position Statement: Strategies for Reducing Cancer Health Disparities Among Sexual and Gender Minority Populations.. 35. 2017
Complete Hematologic and Molecular Response in Adult Patients With Relapsed/Refractory Philadelphia Chromosome-Positive B-Precursor Acute Lymphoblastic Leukemia Following Treatment With Blinatumomab: Results From a Phase II, Single-Arm, Multicenter Study.. 35. 2017
Outcome of Lower-Risk Patients With Myelodysplastic Syndromes Without 5q Deletion After Failure of Erythropoiesis-Stimulating Agents.. 35. 2017
Pembrolizumab for Platinum- and Cetuximab-Refractory Head and Neck Cancer: Results From a Single-Arm, Phase II Study.. 35. 2017
Intestinal Microbiota and Relapse After Hematopoietic-Cell Transplantation.. 35. 2017
Efficacy and Safety of Anti-Trop-2 Antibody Drug Conjugate Sacituzumab Govitecan (IMMU-132) in Heavily Pretreated Patients With Metastatic Triple-Negative Breast Cancer.. 35. 2017
Targeting RET in Patients With RET-Rearranged Lung Cancers: Results From the Global, Multicenter RET Registry.. 35. 2017
Multi-Institutional Assessment of Adverse Health Outcomes Among North American Testicular Cancer Survivors After Modern Cisplatin-Based Chemotherapy.. 35. 2017
Myeloablative Versus Reduced-Intensity Hematopoietic Cell Transplantation for Acute Myeloid Leukemia and Myelodysplastic Syndromes.. 35. 2017
Management of Brain Metastases in Tyrosine Kinase Inhibitor-Naïve Epidermal Growth Factor Receptor-Mutant Non-Small-Cell Lung Cancer: A Retrospective Multi-Institutional Analysis.. 35. 2017
Safety and Activity of Mirvetuximab Soravtansine (IMGN853), a Folate Receptor Alpha-Targeting Antibody-Drug Conjugate, in Platinum-Resistant Ovarian, Fallopian Tube, or Primary Peritoneal Cancer: A Phase I Expansion Study.. 35. 2016
Evaluation of BGJ398, a Fibroblast Growth Factor Receptor 1-3 Kinase Inhibitor, in Patients With Advanced Solid Tumors Harboring Genetic Alterations in Fibroblast Growth Factor Receptors: Results of a Global Phase I, Dose-Escalation and Dose-Expansion Study.. 35. 2016
Cabozantinib Versus Sunitinib As Initial Targeted Therapy for Patients With Metastatic Renal Cell Carcinoma of Poor or Intermediate Risk: The Alliance A031203 CABOSUN Trial.. 35. 2016
Safety Profile of Nivolumab Monotherapy: A Pooled Analysis of Patients With Advanced Melanoma.. 35. 2016
Cautionary Note on Using Cross-Validation for Molecular Classification.. 34. 2016
Health-Related Quality-of-Life Results From the Open-Label, Randomized, Phase III ASPIRE Trial Evaluating Carfilzomib, Lenalidomide, and Dexamethasone Versus Lenalidomide and Dexamethasone in Patients With Relapsed Multiple Myeloma.. 34. 2016
Phase II Trial and Correlative Genomic Analysis of Everolimus Plus Bevacizumab in Advanced Non-Clear Cell Renal Cell Carcinoma.. 34. 2016
Efficacy and Safety of Nivolumab Alone or in Combination With Ipilimumab in Patients With Mucosal Melanoma: A Pooled Analysis.. 35. 2016
Protein Intake and Breast Cancer Survival in the Nurses' Health Study.. 35. 2016
T-Cell Therapy Using Interleukin-21-Primed Cytotoxic T-Cell Lymphocytes Combined With Cytotoxic T-Cell Lymphocyte Antigen-4 Blockade Results in Long-Term Cell Persistence and Durable Tumor Regression.. 34. 2016
Impact of Increasing Age on Cause-Specific Mortality and Morbidity in Patients With Stage I Non-Small-Cell Lung Cancer: A Competing Risks Analysis.. 35. 2016
Optimizing the Use of Gene Expression Profiling in Early-Stage Breast Cancer.. 34. 2016
Phase I Study Evaluating WEE1 Inhibitor AZD1775 As Monotherapy and in Combination With Gemcitabine, Cisplatin, or Carboplatin in Patients With Advanced Solid Tumors.. 34. 2016
Programmed Death-Ligand 1 Expression and Response to the Anti-Programmed Death 1 Antibody Pembrolizumab in Melanoma.. 34. 2016
Medicare D Subsidies and Racial Disparities in Persistence and Adherence With Hormonal Therapy.. 34. 2016
Safety, Antitumor Activity, and Immune Activation of Pegylated Recombinant Human Interleukin-10 (AM0010) in Patients With Advanced Solid Tumors.. 34. 2016
Conflicting Interpretation of Genetic Variants and Cancer Risk by Commercial Laboratories as Assessed by the Prospective Registry of Multiplex Testing.. 34. 2016
Genetic Determinants of Cisplatin Resistance in Patients With Advanced Germ Cell Tumors.. 34. 2016
PICASSO III: A Phase III, Placebo-Controlled Study of Doxorubicin With or Without Palifosfamide in Patients With Metastatic Soft Tissue Sarcoma.. 34. 2016
Pneumonitis in Patients Treated With Anti-Programmed Death-1/Programmed Death Ligand 1 Therapy.. 35. 2016
Subtype-Dependent Relationship Between Young Age at Diagnosis and Breast Cancer Survival.. 34. 2016
Phase IB Study of Selinexor, a First-in-Class Inhibitor of Nuclear Export, in Patients With Advanced Refractory Bone or Soft Tissue Sarcoma.. 34. 2016
Characteristics of Patients Who Survived < 3 Months or > 2 Years After Surgery for Spinal Metastases: Can We Avoid Inappropriate Patient Selection?. 34. 2016
CALGB 80403 (Alliance)/E1206: A Randomized Phase II Study of Three Chemotherapy Regimens Plus Cetuximab in Metastatic Esophageal and Gastroesophageal Junction Cancers.. 34. 2016
Endocrine Abnormalities in Aging Survivors of Childhood Cancer: A Report From the Childhood Cancer Survivor Study.. 34. 2016
Comprehensive Audiometric Analysis of Hearing Impairment and Tinnitus After Cisplatin-Based Chemotherapy in Survivors of Adult-Onset Cancer.. 34. 2016
Phase II Study of Hemithoracic Intensity-Modulated Pleural Radiation Therapy (IMPRINT) As Part of Lung-Sparing Multimodality Therapy in Patients With Malignant Pleural Mesothelioma.. 34. 2016
Baseline Prostate-Specific Antigen Levels in Midlife Predict Lethal Prostate Cancer.. 34. 2016
Age- and Tumor Subtype-Specific Breast Cancer Risk Estimates for CHEK2*1100delC Carriers.. 34. 2016
Nivolumab in Patients With Relapsed or Refractory Hematologic Malignancy: Preliminary Results of a Phase Ib Study.. 34. 2016
Plasma ESR1 Mutations and the Treatment of Estrogen Receptor-Positive Advanced Breast Cancer.. 34. 2016
Reduced-Intensity Transplantation for Lymphomas Using Haploidentical Related Donors Versus HLA-Matched Sibling Donors: A Center for International Blood and Marrow Transplant Research Analysis.. 34. 2016
Safety and Efficacy of Durvalumab (MEDI4736), an Anti-Programmed Cell Death Ligand-1 Immune Checkpoint Inhibitor, in Patients With Advanced Urothelial Bladder Cancer.. 34. 2016
Therapeutic Impact of Cytoreductive Surgery and Irradiation of Posterior Fossa Ependymoma in the Molecular Era: A Retrospective Multicohort Analysis.. 34. 2016
Locally Advanced, Unresectable Pancreatic Cancer: American Society of Clinical Oncology Clinical Practice Guideline.. 34. 2016
Updating the American Society of Clinical Oncology Value Framework: Revisions and Reflections in Response to Comments Received.. 34. 2016
Discussions of Life Expectancy and Changes in Illness Understanding in Patients With Advanced Cancer.. 34. 2016
Exercise and Risk of Cardiovascular Events in Women With Nonmetastatic Breast Cancer.. 34. 2016
Randomized Phase II Evaluation of Bevacizumab Versus Bevacizumab Plus Fosbretabulin in Recurrent Ovarian, Tubal, or Peritoneal Carcinoma: An NRG Oncology/Gynecologic Oncology Group Study.. 34. 2016
Paclitaxel, Ifosfamide, and Cisplatin Efficacy for First-Line Treatment of Patients With Intermediate- or Poor-Risk Germ Cell Tumors.. 34. 2016
Validation of a Prediction Tool for Chemotherapy Toxicity in Older Adults With Cancer.. 34. 2016
Evaluating Cancer of the Central Nervous System Through Next-Generation Sequencing of Cerebrospinal Fluid.. 34. 2016
Use and Costs of Disease Monitoring in Women With Metastatic Breast Cancer.. 34. 2016
Association of Androgen Deprivation Therapy With Depression in Localized Prostate Cancer.. 34. 2016
KIR3DL1 Allelic Polymorphism and HLA-B Epitopes Modulate Response to Anti-GD2 Monoclonal Antibody in Patients With Neuroblastoma.. 34. 2016
US Intergroup Trial of Response-Adapted Therapy for Stage III to IV Hodgkin Lymphoma Using Early Interim Fluorodeoxyglucose-Positron Emission Tomography Imaging: Southwest Oncology Group S0816.. 34. 2016
A Randomized Phase II Trial of Short-Course Androgen Deprivation Therapy With or Without Bevacizumab for Patients With Recurrent Prostate Cancer After Definitive Local Therapy.. 34. 2016
Cancer and Fertility Program Improves Patient Satisfaction With Information Received.. 34. 2016
Scoring System Prognostic of Outcome in Patients Undergoing Allogeneic Hematopoietic Cell Transplantation for Myelodysplastic Syndrome.. 34. 2016
Reliable Detection of Mismatch Repair Deficiency in Colorectal Cancers Using Mutational Load in Next-Generation Sequencing Panels.. 34. 2016
Prognostic Impact of 21-Gene Recurrence Score in Patients With Stage IV Breast Cancer: TBCRC 013.. 34. 2016
Randomized Open-Label Phase II Trial of Apitolisib (GDC-0980), a Novel Inhibitor of the PI3K/Mammalian Target of Rapamycin Pathway, Versus Everolimus in Patients With Metastatic Renal Cell Carcinoma.. 34. 2016
Docetaxel As Monotherapy or Combined With Ramucirumab or Icrucumab in Second-Line Treatment for Locally Advanced or Metastatic Urothelial Carcinoma: An Open-Label, Three-Arm, Randomized Controlled Phase II Trial.. 34. 2016
Active Surveillance for the Management of Localized Prostate Cancer (Cancer Care Ontario Guideline): American Society of Clinical Oncology Clinical Practice Guideline Endorsement.. 34. 2016
First-in-Human Phase I/II Study of NEOD001 in Patients With Light Chain Amyloidosis and Persistent Organ Dysfunction.. 34. 2016
Comparative Effectiveness of Minimally Invasive Hysterectomy for Endometrial Cancer.. 34. 2016
Randomized Trial of Hepatic Artery Embolization for Hepatocellular Carcinoma Using Doxorubicin-Eluting Microspheres Compared With Embolization With Microspheres Alone.. 34. 2016
Impact of Patient Factors on Recurrence Risk and Time Dependency of Oxaliplatin Benefit in Patients With Colon Cancer: Analysis From Modern-Era Adjuvant Studies in the Adjuvant Colon Cancer End Points (ACCENT) Database.. 34. 2016
Breast Cancer Risk in Childhood Cancer Survivors Without a History of Chest Radiotherapy: A Report From the Childhood Cancer Survivor Study.. 34. 2015
Symptom Monitoring With Patient-Reported Outcomes During Routine Cancer Treatment: A Randomized Controlled Trial.. 34. 2015
Complete Surgical Excision Is Essential for the Management of Patients With Breast Implant-Associated Anaplastic Large-Cell Lymphoma.. 34. 2015
Randomized Multicenter Phase II Study of Modified Docetaxel, Cisplatin, and Fluorouracil (DCF) Versus DCF Plus Growth Factor Support in Patients With Metastatic Gastric Adenocarcinoma: A Study of the US Gastric Cancer Consortium.. 33. 2015
Phase II Study of Allogeneic Transplantation for Older Patients With Acute Myeloid Leukemia in First Complete Remission Using a Reduced-Intensity Conditioning Regimen: Results From Cancer and Leukemia Group B 100103 (Alliance for Clinical Trials in Oncology)/Blood and Marrow Transplant Clinical Trial Network 0502.. 33. 2015
Brain Metastases in Patients With Germ Cell Tumors: Prognostic Factors and Treatment Options--An Analysis From the Global Germ Cell Cancer Group.. 34. 2015
Phase II Pilot Study of Vemurafenib in Patients With Metastatic BRAF-Mutated Colorectal Cancer.. 33. 2015
Cutaneous Lymphoma International Consortium Study of Outcome in Advanced Stages of Mycosis Fungoides and Sézary Syndrome: Effect of Specific Prognostic Markers on Survival and Development of a Prognostic Model.. 33. 2015
Extended Survival and Prognostic Factors for Patients With ALK-Rearranged Non-Small-Cell Lung Cancer and Brain Metastasis.. 34. 2015
Outcomes of Prognostic Disclosure: Associations With Prognostic Understanding, Distress, and Relationship With Physician Among Patients With Advanced Cancer.. 33. 2015
Psychosocial Outcomes in Adult Survivors of Retinoblastoma.. 33. 2015
Efficacy and Safety of Trabectedin or Dacarbazine for Metastatic Liposarcoma or Leiomyosarcoma After Failure of Conventional Chemotherapy: Results of a Phase III Randomized Multicenter Clinical Trial.. 34. 2015
Improved Outcomes After Autologous Hematopoietic Cell Transplantation for Light Chain Amyloidosis: A Center for International Blood and Marrow Transplant Research Study.. 33. 2015
Lobular Carcinoma in Situ: A 29-Year Longitudinal Experience Evaluating Clinicopathologic Features and Breast Cancer Risk.. 33. 2015
Randomized, Double-Blind, Phase II Study of Ruxolitinib or Placebo in Combination With Capecitabine in Patients With Metastatic Pancreatic Cancer for Whom Therapy With Gemcitabine Has Failed.. 33. 2015
Treatment of Small-Cell Lung Cancer: American Society of Clinical Oncology Endorsement of the American College of Chest Physicians Guideline.. 33. 2015
Adjuvant Erlotinib Versus Placebo in Patients With Stage IB-IIIA Non-Small-Cell Lung Cancer (RADIANT): A Randomized, Double-Blind, Phase III Trial.. 33. 2015
American Society of Clinical Oncology Policy Statement Update: Genetic and Genomic Testing for Cancer Susceptibility.. 33. 2015
Racial/Ethnic Differences in Inpatient Palliative Care Consultation for Patients With Advanced Cancer.. 33. 2015
Association Between Geographic Access to Cancer Care, Insurance, and Receipt of Chemotherapy: Geographic Distribution of Oncologists and Travel Distance.. 33. 2015
Randomized Trial of Lenalidomide Alone Versus Lenalidomide Plus Rituximab in Patients With Recurrent Follicular Lymphoma: CALGB 50401 (Alliance).. 33. 2015
Coffee Intake, Recurrence, and Mortality in Stage III Colon Cancer: Results From CALGB 89803 (Alliance).. 33. 2015
Evaluation of the Safety and Benefit of Phase I Oncology Trials for Patients With Primary CNS Tumors.. 33. 2015
Immune-Related Adverse Events, Need for Systemic Immunosuppression, and Effects on Survival and Time to Treatment Failure in Patients With Melanoma Treated With Ipilimumab at Memorial Sloan Kettering Cancer Center.. 33. 2015
Intestinal Obstruction in Survivors of Childhood Cancer: A Report From the Childhood Cancer Survivor Study.. 33. 2015
Solid Predominant Histologic Subtype in Resected Stage I Lung Adenocarcinoma Is an Independent Predictor of Early, Extrathoracic, Multisite Recurrence and of Poor Postrecurrence Survival.. 33. 2015
Phase II Investigator-Initiated Study of Brentuximab Vedotin in Mycosis Fungoides and Sézary Syndrome With Variable CD30 Expression Level: A Multi-Institution Collaborative Project.. 33. 2015
Early Relapse of Follicular Lymphoma After Rituximab Plus Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone Defines Patients at High Risk for Death: An Analysis From the National LymphoCare Study.. 33. 2015
Belinostat in Patients With Relapsed or Refractory Peripheral T-Cell Lymphoma: Results of the Pivotal Phase II BELIEF (CLN-19) Study.. 33. 2015
Phase II Intergroup Trial of Alisertib in Relapsed and Refractory Peripheral T-Cell Lymphoma and Transformed Mycosis Fungoides: SWOG 1108.. 33. 2015
Community-Based Phase IIIB Trial of Three UPFRONT Bortezomib-Based Myeloma Regimens.. 33. 2015
Mental Health Services for Parents Who Lost a Child to Cancer: If We Build Them, Will They Come?. 33. 2015
Racial and Ethnic Differences in Breast Cancer Survival: Mediating Effect of Tumor Characteristics and Sociodemographic and Treatment Factors.. 33. 2015
Definitive and Adjuvant Radiotherapy in Locally Advanced Non-Small-Cell Lung Cancer: American Society of Clinical Oncology Clinical Practice Guideline Endorsement of the American Society for Radiation Oncology Evidence-Based Clinical Practice Guideline.. 33. 2015
Phase I/II Study of HSP90 Inhibitor AUY922 and Erlotinib for EGFR-Mutant Lung Cancer With Acquired Resistance to Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitors.. 33. 2015
Concerns about cancer risk and experiences with genetic testing in a diverse population of patients with breast cancer.. 33. 2015
EMERGE: A Randomized Phase II Study of the Antibody-Drug Conjugate Glembatumumab Vedotin in Advanced Glycoprotein NMB-Expressing Breast Cancer.. 33. 2015
TBCRC009: A Multicenter Phase II Clinical Trial of Platinum Monotherapy With Biomarker Assessment in Metastatic Triple-Negative Breast Cancer.. 33. 2015
Circulating tumor cell biomarker panel as an individual-level surrogate for survival in metastatic castration-resistant prostate cancer.. 33. 2015
Early Versus Delayed Initiation of Concurrent Palliative Oncology Care: Patient Outcomes in the ENABLE III Randomized Controlled Trial.. 33. 2015
Five-year survival rates for treatment-naive patients with advanced melanoma who received ipilimumab plus dacarbazine in a phase III trial.. 33. 2015
Randomized phase III trial of gemcitabine plus docetaxel plus bevacizumab or placebo as first-line treatment for metastatic uterine leiomyosarcoma: an NRG Oncology/Gynecologic Oncology Group study.. 33. 2015
Molecular profiling and targeted therapy for advanced thoracic malignancies: a biomarker-derived, multiarm, multihistology phase II basket trial.. 33. 2015
Meaning-centered group psychotherapy: an effective intervention for improving psychological well-being in patients with advanced cancer.. 33. 2015
Clinical Experience With Crizotinib in Patients With Advanced ALK-Rearranged Non-Small-Cell Lung Cancer and Brain Metastases.. 33. 2015
Radiographic progression-free survival as a response biomarker in metastatic castration-resistant prostate cancer: COU-AA-302 results.. 33. 2015
RTOG 9804: a prospective randomized trial for good-risk ductal carcinoma in situ comparing radiotherapy with observation.. 33. 2015
Electronic nicotine delivery systems: a policy statement from the American Association for Cancer Research and the American Society of Clinical Oncology.. 33. 2015
Anterior hypopituitarism in adult survivors of childhood cancers treated with cranial radiotherapy: a report from the St Jude Lifetime Cohort study.. 33. 2015
Phase II study of paclitaxel given once per week along with trastuzumab and pertuzumab in patients with human epidermal growth factor receptor 2-positive metastatic breast cancer.. 33. 2014
Bone marrow or peripheral blood for reduced-intensity conditioning unrelated donor transplantation.. 33. 2014
American Society of Clinical Oncology policy statement update: the critical role of phase I trials in cancer research and treatment.. 33. 2014
Treatment-associated musculoskeletal and vasomotor symptoms and relapse-free survival in the NCIC CTG MA.27 adjuvant breast cancer aromatase inhibitor trial.. 33. 2014
Multicenter Phase II Trial of Temsirolimus and Bevacizumab in Pancreatic Neuroendocrine Tumors.. 33. 2014
Nivolumab for Metastatic Renal Cell Carcinoma: Results of a Randomized Phase II Trial.. 33. 2014
Hospital volume, complications, and cost of cancer surgery in the elderly.. 33. 2014
American Society of Clinical Oncology policy statement on medicaid reform.. 32. 2014
Individual patient data analysis of progression-free survival versus overall survival as a first-line end point for metastatic colorectal cancer in modern randomized trials: findings from the analysis and research in cancers of the digestive system database.. 33. 2014
Endocrine therapy with or without inhibition of epidermal growth factor receptor and human epidermal growth factor receptor 2: a randomized, double-blind, placebo-controlled phase III trial of fulvestrant with or without lapatinib for postmenopausal women with hormone receptor-positive advanced breast cancer-CALGB 40302 (Alliance).. 32. 2014
Association between BRAF V600E mutation and recurrence of papillary thyroid cancer.. 33. 2014
Exercise and risk of major cardiovascular events in adult survivors of childhood hodgkin lymphoma: a report from the childhood cancer survivor study.. 32. 2014
Intense androgen-deprivation therapy with abiraterone acetate plus leuprolide acetate in patients with localized high-risk prostate cancer: results of a randomized phase II neoadjuvant study.. 32. 2014
Individual prediction of heart failure among childhood cancer survivors.. 33. 2014
American Society of Clinical Oncology position statement on obesity and cancer.. 32. 2014
Phase I/II study of the antibody-drug conjugate glembatumumab vedotin in patients with advanced melanoma.. 32. 2014
Prevalence, management, and clinical consequences of QT interval prolongation during treatment with arsenic trioxide.. 32. 2014
Association of age with survival in patients with metastatic colorectal cancer: analysis from the ARCAD Clinical Trials Program.. 32. 2014
Prognostic value of tumor-infiltrating lymphocytes in triple-negative breast cancers from two phase III randomized adjuvant breast cancer trials: ECOG 2197 and ECOG 1199.. 32. 2014
Randomized phase III trial of concurrent accelerated radiation plus cisplatin with or without cetuximab for stage III to IV head and neck carcinoma: RTOG 0522.. 32. 2014
Cabozantinib in chemotherapy-pretreated metastatic castration-resistant prostate cancer: results of a phase II nonrandomized expansion study.. 32. 2014
Comparison of local recurrence with conventional and intensity-modulated radiation therapy for primary soft-tissue sarcomas of the extremity.. 32. 2014
Risk of fracture after radical cystectomy and urinary diversion for bladder cancer.. 32. 2014
Risk of subsequent malignant neoplasms in long-term hereditary retinoblastoma survivors after chemotherapy and radiotherapy.. 32. 2014
Hematopoietic stem-cell transplantation for advanced systemic mastocytosis.. 32. 2014
Brentuximab vedotin in the front-line treatment of patients with CD30+ peripheral T-cell lymphomas: results of a phase I study.. 32. 2014
Psychosexual functioning among adult female survivors of childhood cancer: a report from the childhood cancer survivor study.. 32. 2014
In vivo treatment sensitivity testing with positron emission tomography/computed tomography after one cycle of chemotherapy for Hodgkin lymphoma.. 32. 2014
Phase II randomized trial comparing sequential first-line everolimus and second-line sunitinib versus first-line sunitinib and second-line everolimus in patients with metastatic renal cell carcinoma.. 32. 2014
Effect of depression on diagnosis, treatment, and mortality of men with clinically localized prostate cancer.. 32. 2014
Safety and efficacy of aerobic training in patients with cancer who have heart failure: an analysis of the HF-ACTION randomized trial.. 32. 2014
Impact of brachytherapy on local recurrence rates after sublobar resection: results from ACOSOG Z4032 (Alliance), a phase III randomized trial for high-risk operable non-small-cell lung cancer.. 32. 2014
Long-term central venous catheter use and risk of infection in older adults with cancer.. 32. 2014
Comparison of doxorubicin and cyclophosphamide versus single-agent paclitaxel as adjuvant therapy for breast cancer in women with 0 to 3 positive axillary nodes: CALGB 40101 (Alliance).. 32. 2014
Cancer-specific outcomes among young adults without health insurance.. 32. 2014
Cognitive impairment in older patients with breast cancer before systemic therapy: is there an interaction between cancer and comorbidity?. 32. 2014
International randomized phase III study of elacytarabine versus investigator choice in patients with relapsed/refractory acute myeloid leukemia.. 32. 2014
Active idiotypic vaccination versus control immunotherapy for follicular lymphoma.. 32. 2014
Myasthenia Gravis Induced by Ipilimumab in Patients With Metastatic Melanoma.. 33. 2014
Breast cancer after chest radiation therapy for childhood cancer.. 32. 2014
Comparative effectiveness of robot-assisted and open radical prostatectomy in the postdissemination era.. 32. 2014
Randomized, controlled, double-blind, cross-over trial assessing treatment preference for pazopanib versus sunitinib in patients with metastatic renal cell carcinoma: PISCES Study.. 32. 2014
Prolonged administration of azacitidine with or without entinostat for myelodysplastic syndrome and acute myeloid leukemia with myelodysplasia-related changes: results of the US Leukemia Intergroup trial E1905.. 32. 2014
Aging and risk of severe, disabling, life-threatening, and fatal events in the childhood cancer survivor study.. 32. 2014
Pathologic and molecular features correlate with long-term outcome after adjuvant therapy of resected primary GI stromal tumor: the ACOSOG Z9001 trial.. 32. 2014
Randomized controlled trial of early zoledronic acid in men with castration-sensitive prostate cancer and bone metastases: results of CALGB 90202 (alliance).. 32. 2014
Prospective study of fertility concerns and preservation strategies in young women with breast cancer.. 32. 2014
Pharmacokinetics-based integration of multiple doses of intravenous pegaspargase in a pediatric regimen for adults with newly diagnosed acute lymphoblastic leukemia.. 32. 2014
Hyaluronan synthase 3 variant and anthracycline-related cardiomyopathy: a report from the children's oncology group.. 32. 2014
Updated prognostic model for predicting overall survival in first-line chemotherapy for patients with metastatic castration-resistant prostate cancer.. 32. 2014
Neoadjuvant chemotherapy without routine use of radiation therapy for patients with locally advanced rectal cancer: a pilot trial.. 32. 2014
Nomogram to predict cycle-one serious drug-related toxicity in phase I oncology trials.. 32. 2014
Phase II trial of imatinib in AIDS-associated Kaposi's sarcoma: AIDS Malignancy Consortium Protocol 042.. 32. 2013
Autologous or reduced-intensity conditioning allogeneic hematopoietic cell transplantation for chemotherapy-sensitive mantle-cell lymphoma: analysis of transplantation timing and modality.. 32. 2013
Serum 2-hydroxyglutarate production in IDH1- and IDH2-mutated de novo acute myeloid leukemia: a study by the Acute Leukemia French Association group.. 32. 2013
Sustained complete responses in patients with lymphoma receiving autologous cytotoxic T lymphocytes targeting Epstein-Barr virus latent membrane proteins.. 32. 2013
Randomized phase III trial of temsirolimus versus sorafenib as second-line therapy after sunitinib in patients with metastatic renal cell carcinoma.. 32. 2013
TMPRSS2:ERG gene fusion predicts subsequent detection of prostate cancer in patients with high-grade prostatic intraepithelial neoplasia.. 32. 2013
False-Positive [18F]fluorodeoxyglucose-avid lymph nodes on positron emission tomography-computed tomography after allogeneic but not autologous stem-cell transplantation in patients with lymphoma.. 32. 2013
Physiologic frailty as a sign of accelerated aging among adult survivors of childhood cancer: a report from the St Jude Lifetime cohort study.. 31. 2013
Delivering high-quality and affordable care throughout the cancer care continuum.. 31. 2013
Level of HER2 gene amplification predicts response and overall survival in HER2-positive advanced gastric cancer treated with trastuzumab.. 31. 2013
Tumor-infiltrating lymphocyte grade in primary melanomas is independently associated with melanoma-specific survival in the population-based genes, environment and melanoma study.. 31. 2013
Rituximab, methotrexate, procarbazine, and vincristine followed by consolidation reduced-dose whole-brain radiotherapy and cytarabine in newly diagnosed primary CNS lymphoma: final results and long-term outcome.. 31. 2013
Marital status and survival in patients with cancer.. 31. 2013
Lymphoma occurring during pregnancy: antenatal therapy, complications, and maternal survival in a multicenter analysis.. 31. 2013
Tivozanib versus sorafenib as initial targeted therapy for patients with metastatic renal cell carcinoma: results from a phase III trial.. 31. 2013
Modifiable risk factors and major cardiac events among adult survivors of childhood cancer.. 31. 2013
Hematopoietic cell transplantation for systemic mature T-cell non-Hodgkin lymphoma.. 31. 2013
Prevalence and co-occurrence of actionable genomic alterations in high-grade bladder cancer.. 31. 2013
Molecular profiling improves classification and prognostication of nodal peripheral T-cell lymphomas: results of a phase III diagnostic accuracy study.. 31. 2013
Gene patents and personalized cancer care: impact of the Myriad case on clinical oncology.. 31. 2013
Feasibility of long-term patient self-reporting of toxicities from home via the Internet during routine chemotherapy.. 31. 2013
Impact of age on the efficacy of newer adjuvant therapies in patients with stage II/III colon cancer: findings from the ACCENT database.. 31. 2013
Lumpectomy plus tamoxifen with or without irradiation in women age 70 years or older with early breast cancer: long-term follow-up of CALGB 9343.. 31. 2013
Harnessing technology to improve clinical trials: study of real-time informatics to collect data, toxicities, image response assessments, and patient-reported outcomes in a phase II clinical trial.. 31. 2013
Pharmacodynamic effects and mechanisms of resistance to vemurafenib in patients with metastatic melanoma.. 31. 2013
Phase II trial of the CDK4 inhibitor PD0332991 in patients with advanced CDK4-amplified well-differentiated or dedifferentiated liposarcoma.. 31. 2013
DNA mismatch repair in prostate cancer.. 31. 2013
Patient-oncologist alliance, psychosocial well-being, and treatment adherence among young adults with advanced cancer.. 31. 2013
Abagovomab as maintenance therapy in patients with epithelial ovarian cancer: a phase III trial of the AGO OVAR, COGI, GINECO, and GEICO--the MIMOSA study.. 31. 2013
Effect of ruxolitinib therapy on myelofibrosis-related symptoms and other patient-reported outcomes in COMFORT-I: a randomized, double-blind, placebo-controlled trial.. 31. 2013
Lack of specificity of plasma concentrations of inhibin B and follicle-stimulating hormone for identification of azoospermic survivors of childhood cancer: a report from the St Jude lifetime cohort study.. 31. 2013
Prevalence of off-label use and spending in 2010 among patent-protected chemotherapies in a population-based cohort of medical oncologists.. 31. 2013
Exemestane versus anastrozole in postmenopausal women with early breast cancer: NCIC CTG MA.27--a randomized controlled phase III trial.. 31. 2013
Phase II study of gemcitabine, carboplatin, and bevacizumab in patients with advanced unresectable or metastatic urothelial cancer.. 31. 2013
Clinical impact of immune microenvironment in stage I lung adenocarcinoma: tumor interleukin-12 receptor β2 (IL-12Rβ2), IL-7R, and stromal FoxP3/CD3 ratio are independent predictors of recurrence.. 31. 2012
Risk of asynchronous contralateral breast cancer in noncarriers of BRCA1 and BRCA2 mutations with a family history of breast cancer: a report from the Women's Environmental Cancer and Radiation Epidemiology Study.. 31. 2012
Phase II study of bendamustine in relapsed and refractory Hodgkin lymphoma.. 31. 2012
Phase II study of the MEK1/MEK2 inhibitor Trametinib in patients with metastatic BRAF-mutant cutaneous melanoma previously treated with or without a BRAF inhibitor.. 31. 2012
Why is spiritual care infrequent at the end of life? Spiritual care perceptions among patients, nurses, and physicians and the role of training.. 31. 2012
Randomized controlled trial of a video decision support tool for cardiopulmonary resuscitation decision making in advanced cancer.. 31. 2012
Positron emission tomography/computed tomography identification of clear cell renal cell carcinoma: results from the REDECT trial.. 31. 2012
Absolute risk prediction of second primary thyroid cancer among 5-year survivors of childhood cancer.. 31. 2012
Pegylated liposomal doxorubicin, rituximab, cyclophosphamide, vincristine, and prednisone in AIDS-related lymphoma: AIDS Malignancy Consortium Study 047.. 31. 2012
Postoperative adjuvant chemotherapy use in patients with stage II/III rectal cancer treated with neoadjuvant therapy: a national comprehensive cancer network analysis.. 31. 2012
Randomized controlled trial of interval-compressed chemotherapy for the treatment of localized Ewing sarcoma: a report from the Children's Oncology Group.. 30. 2012
Research participants' high expectations of benefit in early-phase oncology trials: are we asking the right question?. 30. 2012
Phase I trial and pharmacokinetic study of lexatumumab in pediatric patients with solid tumors.. 30. 2012
Bruton tyrosine kinase inhibitor ibrutinib (PCI-32765) has significant activity in patients with relapsed/refractory B-cell malignancies.. 31. 2012
Effectiveness of first-line management strategies for stage I follicular lymphoma: analysis of the National LymphoCare Study.. 30. 2012
Comparative outcomes of donor graft CD34+ selection and immune suppressive therapy as graft-versus-host disease prophylaxis for patients with acute myeloid leukemia in complete remission undergoing HLA-matched sibling allogeneic hematopoietic cell transplantation.. 30. 2012
Murine anti-GD2 monoclonal antibody 3F8 combined with granulocyte-macrophage colony-stimulating factor and 13-cis-retinoic acid in high-risk patients with stage 4 neuroblastoma in first remission.. 30. 2012
Validation of a prognostic model and the impact of mutations in patients with lower-risk myelodysplastic syndromes.. 30. 2012
Neuropathy is not associated with clinical outcomes in patients receiving adjuvant taxane-containing therapy for operable breast cancer.. 30. 2012
Six cycles of doxorubicin and cyclophosphamide or Paclitaxel are not superior to four cycles as adjuvant chemotherapy for breast cancer in women with zero to three positive axillary nodes: Cancer and Leukemia Group B 40101.. 30. 2012
Lymphatic mapping and sentinel lymph node biopsy in women with squamous cell carcinoma of the vulva: a gynecologic oncology group study.. 30. 2012
Alterations in brain activation during working memory processing associated with breast cancer and treatment: a prospective functional magnetic resonance imaging study.. 30. 2012
Comparative genomic analysis of primary versus metastatic colorectal carcinomas.. 30. 2012
Phase II trial of trastuzumab in combination with cytotoxic chemotherapy for treatment of metastatic osteosarcoma with human epidermal growth factor receptor 2 overexpression: a report from the children's oncology group.. 30. 2012
A phase II study of trastuzumab emtansine in patients with human epidermal growth factor receptor 2-positive metastatic breast cancer who were previously treated with trastuzumab, lapatinib, an anthracycline, a taxane, and capecitabine.. 30. 2012
Atypical melanocytic proliferations and new primary melanomas in patients with advanced melanoma undergoing selective BRAF inhibition.. 30. 2012
Cardiopulmonary function and age-related decline across the breast cancer survivorship continuum.. 30. 2012
Efficacy and safety of regorafenib in patients with metastatic and/or unresectable GI stromal tumor after failure of imatinib and sunitinib: a multicenter phase II trial.. 30. 2012
Bevacizumab in combination with chemotherapy as first-line therapy in advanced gastric cancer: a biomarker evaluation from the AVAGAST randomized phase III trial.. 30. 2012
Phase II study of ganitumab, a fully human anti-type-1 insulin-like growth factor receptor antibody, in patients with metastatic Ewing family tumors or desmoplastic small round cell tumors.. 30. 2012
Marked, homogeneous, and early [18F]fluorodeoxyglucose-positron emission tomography responses to vemurafenib in BRAF-mutant advanced melanoma.. 30. 2012
Randomized, double-blind, placebo-controlled phase III trial comparing docetaxel and prednisone with or without bevacizumab in men with metastatic castration-resistant prostate cancer: CALGB 90401.. 30. 2012
Randomized phase II trial of sunitinib on an intermittent versus continuous dosing schedule as first-line therapy for advanced renal cell carcinoma.. 30. 2012
Cost effectiveness of fracture prevention in postmenopausal women who receive aromatase inhibitors for early breast cancer.. 30. 2012
Pilot randomized controlled trial of individual meaning-centered psychotherapy for patients with advanced cancer.. 30. 2012
Long-term follow-up of children treated for high-grade gliomas: children's oncology group L991 final study report.. 30. 2012
Variation of second cancer risk by family history of retinoblastoma among long-term survivors.. 30. 2012
Predictors of aromatase inhibitor discontinuation as a result of treatment-emergent symptoms in early-stage breast cancer.. 30. 2012
Results from a pivotal, open-label, phase II study of romidepsin in relapsed or refractory peripheral T-cell lymphoma after prior systemic therapy.. 30. 2012
Bone scan index: a quantitative treatment response biomarker for castration-resistant metastatic prostate cancer.. 30. 2012
Activation of peripheral-blood granulocytes is strongly correlated with patient outcome after immunotherapy with anti-GD2 monoclonal antibody and granulocyte-macrophage colony-stimulating factor.. 30. 2011
Summary report on the graded prognostic assessment: an accurate and facile diagnosis-specific tool to estimate survival for patients with brain metastases.. 30. 2011
Risk factors for obesity in adult survivors of childhood cancer: a report from the Childhood Cancer Survivor Study.. 30. 2011
Predicting survival after curative colectomy for cancer: individualizing colon cancer staging.. 29. 2011
From node to pathway blockade: lessons learned from targeting mammalian target of rapamycin.. 30. 2011
Phase II study of intraperitoneal paclitaxel plus cisplatin and intravenous paclitaxel plus bevacizumab as adjuvant treatment of optimal stage II/III epithelial ovarian cancer.. 29. 2011
R1507, a monoclonal antibody to the insulin-like growth factor 1 receptor, in patients with recurrent or refractory Ewing sarcoma family of tumors: results of a phase II Sarcoma Alliance for Research through Collaboration study.. 29. 2011
Vandetanib in patients with locally advanced or metastatic medullary thyroid cancer: a randomized, double-blind phase III trial.. 30. 2011
Challenging the feasibility and clinical significance of current guidelines on lymph node examination in rectal cancer in the era of neoadjuvant therapy.. 29. 2011
Occult metastases in lymph nodes predict survival in resectable non-small-cell lung cancer: report of the ACOSOG Z0040 trial.. 29. 2011
Gemcitabine alone versus gemcitabine plus radiotherapy in patients with locally advanced pancreatic cancer: an Eastern Cooperative Oncology Group trial.. 29. 2011
Gemcitabine plus nab-paclitaxel is an active regimen in patients with advanced pancreatic cancer: a phase I/II trial.. 29. 2011
Bevacizumab in combination with chemotherapy as first-line therapy in advanced gastric cancer: a randomized, double-blind, placebo-controlled phase III study.. 29. 2011
Phase IB study of gene-mediated cytotoxic immunotherapy adjuvant to up-front surgery and intensive timing radiation for malignant glioma.. 29. 2011
High incidence of thromboembolic events in patients treated with cisplatin-based chemotherapy: a large retrospective analysis.. 29. 2011
Documenting the natural history of patients with resected stage II adenocarcinoma of the colon after random assignment to adjuvant treatment with edrecolomab or observation: results from CALGB 9581.. 29. 2011
Microsatellite instability and loss of heterozygosity at chromosomal location 18q: prospective evaluation of biomarkers for stages II and III colon cancer--a study of CALGB 9581 and 89803.. 29. 2011
Variability of lung tumor measurements on repeat computed tomography scans taken within 15 minutes.. 29. 2011
Spinal instability neoplastic score: an analysis of reliability and validity from the spine oncology study group.. 29. 2011
Exercise behavior, functional capacity, and survival in adults with malignant recurrent glioma.. 29. 2011
Phase II study of aflibercept in recurrent malignant glioma: a North American Brain Tumor Consortium study.. 29. 2011
Characteristics and outcomes of breast cancer in women with and without a history of radiation for Hodgkin's lymphoma: a multi-institutional, matched cohort study.. 29. 2011
Pazopanib efficacy in renal cell carcinoma: evidence for predictive genetic markers in angiogenesis-related and exposure-related genes.. 29. 2011
Phase II trial of bevacizumab in recurrent or persistent endometrial cancer: a Gynecologic Oncology Group study.. 29. 2011
Vitamin D receptor protein expression in tumor tissue and prostate cancer progression.. 29. 2011
mRNA expression signature of Gleason grade predicts lethal prostate cancer.. 29. 2011
Prognostic significance of mitotic rate in localized primary cutaneous melanoma: an analysis of patients in the multi-institutional American Joint Committee on Cancer melanoma staging database.. 29. 2011
Phase II study of belinostat in patients with recurrent or refractory advanced thymic epithelial tumors.. 29. 2011
American Society of Clinical Oncology provisional clinical opinion: epidermal growth factor receptor (EGFR) Mutation testing for patients with advanced non-small-cell lung cancer considering first-line EGFR tyrosine kinase inhibitor therapy.. 29. 2011
Clinical characteristics of patients with lung adenocarcinomas harboring BRAF mutations.. 29. 2011
Incidence of EGFR exon 19 deletions and L858R in tumor specimens from men and cigarette smokers with lung adenocarcinomas.. 29. 2011
Randomized, open-label phase III trial of docetaxel plus high-dose calcitriol versus docetaxel plus prednisone for patients with castration-resistant prostate cancer.. 29. 2011
Validation of a novel staging system for disease-specific survival in patients with breast cancer treated with neoadjuvant chemotherapy.. 29. 2011
Clinical management factors contribute to the decision for contralateral prophylactic mastectomy.. 29. 2011
Cost implications of the rapid adoption of newer technologies for treating prostate cancer.. 29. 2011
Successful treatment of postchemotherapy azoospermia with microsurgical testicular sperm extraction: the Weill Cornell experience.. 29. 2011
Implementing a geriatric assessment in cooperative group clinical cancer trials: CALGB 360401.. 29. 2011
Successful multifold dose escalation of anti-GD2 monoclonal antibody 3F8 in patients with neuroblastoma: a phase I study.. 29. 2011
Phase I/II study of pemetrexed with or without ABT-751 in advanced or metastatic non-small-cell lung cancer.. 29. 2011
First-in-man study of CPX-351: a liposomal carrier containing cytarabine and daunorubicin in a fixed 5:1 molar ratio for the treatment of relapsed and refractory acute myeloid leukemia.. 29. 2011
Phase I study of Navitoclax (ABT-263), a novel Bcl-2 family inhibitor, in patients with small-cell lung cancer and other solid tumors.. 29. 2011
Pralatrexate in patients with relapsed or refractory peripheral T-cell lymphoma: results from the pivotal PROPEL study.. 29. 2011
Bortezomib plus CHOP-rituximab for previously untreated diffuse large B-cell lymphoma and mantle cell lymphoma.. 29. 2010
Phase II study of modified docetaxel, cisplatin, and fluorouracil with bevacizumab in patients with metastatic gastroesophageal adenocarcinoma.. 29. 2010
Randomized phase II trial of adjuvant hepatic arterial infusion and systemic chemotherapy with or without bevacizumab in patients with resected hepatic metastases from colorectal cancer.. 29. 2010
Second primary cancers after an index head and neck cancer: subsite-specific trends in the era of human papillomavirus-associated oropharyngeal cancer.. 29. 2010
Prophylaxis of graft-versus-host disease in unrelated donor transplantation with pentostatin, tacrolimus, and mini-methotrexate: a phase I/II controlled, adaptively randomized study.. 29. 2010
Disease course patterns after discontinuation of bevacizumab: pooled analysis of randomized phase III trials.. 29. 2010
Clinical cancer advances 2010: annual report on progress against cancer from the American Society of Clinical Oncology.. 28. 2010
Genome-wide associations and functional genomic studies of musculoskeletal adverse events in women receiving aromatase inhibitors.. 28. 2010
Longitudinal assessment of cognitive changes associated with adjuvant treatment for breast cancer: impact of age and cognitive reserve.. 28. 2010
Place of death: correlations with quality of life of patients with cancer and predictors of bereaved caregivers' mental health.. 28. 2010
Temsirolimus has activity in non-mantle cell non-Hodgkin's lymphoma subtypes: The University of Chicago phase II consortium.. 28. 2010
Molecular anatomy of breast cancer stroma and its prognostic value in estrogen receptor-positive and -negative cancers.. 28. 2010
Multivitamin use is not associated with cancer recurrence or survival in patients with stage III colon cancer: findings from CALGB 89803.. 28. 2010
Randomized, phase II study of the insulin-like growth factor-1 receptor inhibitor IMC-A12, with or without cetuximab, in patients with cetuximab- or panitumumab-refractory metastatic colorectal cancer.. 28. 2010
Clinical value of fluorine-18 2-fluoro-2-deoxy-D-glucose positron emission tomography/computed tomography in bladder cancer.. 28. 2010
Fatty acid synthase polymorphisms, tumor expression, body mass index, prostate cancer risk, and survival.. 28. 2010
Scale to predict survival after surgery for recurrent glioblastoma multiforme.. 28. 2010
Nomogram for predicting the risk of local recurrence after breast-conserving surgery for ductal carcinoma in situ.. 28. 2010
Randomized clinical trial of telephone-administered cognitive-behavioral therapy to reduce post-traumatic stress disorder and distress symptoms after hematopoietic stem-cell transplantation.. 28. 2010
Siltuximab, a novel anti-interleukin-6 monoclonal antibody, for Castleman's disease.. 28. 2010
Gemcitabine plus bevacizumab compared with gemcitabine plus placebo in patients with advanced pancreatic cancer: phase III trial of the Cancer and Leukemia Group B (CALGB 80303).. 28. 2010
Pain and emotional well-being outcomes in Southwest Oncology Group-directed intergroup trial S0205: a phase III study comparing gemcitabine plus cetuximab versus gemcitabine as first-line therapy in patients with advanced pancreas cancer.. 28. 2010
Phase III study comparing gemcitabine plus cetuximab versus gemcitabine in patients with advanced pancreatic adenocarcinoma: Southwest Oncology Group-directed intergroup trial S0205.. 28. 2010
Oral bisphosphonate use and breast cancer incidence in postmenopausal women.. 28. 2010
Phase II study to evaluate the efficacy and safety of neoadjuvant lapatinib plus paclitaxel in patients with inflammatory breast cancer.. 28. 2010
Integrated positron emission tomography/computed tomography may render bone scintigraphy unnecessary to investigate suspected metastatic breast cancer.. 28. 2010
Phase II proof-of-concept study of pazopanib monotherapy in treatment-naive patients with stage I/II resectable non-small-cell lung cancer.. 28. 2010
Phase II study of the anti-cytotoxic T-lymphocyte-associated antigen 4 monoclonal antibody, tremelimumab, in patients with refractory metastatic colorectal cancer.. 28. 2010
Dose-dense doxorubicin and cyclophosphamide followed by weekly paclitaxel with trastuzumab and lapatinib in HER2/neu-overexpressed/amplified breast cancer is not feasible because of excessive diarrhea.. 28. 2010
Site and timing of first relapse in stage III melanoma patients: implications for follow-up guidelines.. 28. 2010
Advanced hepatocellular carcinoma: which staging systems best predict prognosis?. 28. 2010
Cyclophosphamide, vincristine, and prednisone followed by tositumomab and iodine-131-tositumomab in patients with untreated low-grade follicular lymphoma: eight-year follow-up of a multicenter phase II study.. 28. 2010
Phase I study of trastuzumab-DM1, an HER2 antibody-drug conjugate, given every 3 weeks to patients with HER2-positive metastatic breast cancer.. 28. 2010
Reducing unnecessary biopsy during prostate cancer screening using a four-kallikrein panel: an independent replication.. 28. 2010
Acupuncture for pain and dysfunction after neck dissection: results of a randomized controlled trial.. 28. 2010
Multivariate analysis of prognostic factors among 2,313 patients with stage III melanoma: comparison of nodal micrometastases versus macrometastases.. 28. 2010
Population-based study of the risk of second primary contralateral breast cancer associated with carrying a mutation in BRCA1 or BRCA2.. 28. 2010
Patterns and correlates of adjuvant radiotherapy receipt after lumpectomy and after mastectomy for breast cancer.. 28. 2010
Do radiation-associated soft tissue sarcomas have the same prognosis as sporadic soft tissue sarcomas?. 28. 2010
Effect of age on outcome of reduced-intensity hematopoietic cell transplantation for older patients with acute myeloid leukemia in first complete remission or with myelodysplastic syndrome.. 28. 2010
Risk-adapted dose-dense immunochemotherapy determined by interim FDG-PET in Advanced-stage diffuse large B-Cell lymphoma.. 28. 2010
Ofatumumab as single-agent CD20 immunotherapy in fludarabine-refractory chronic lymphocytic leukemia.. 28. 2010
TI-CE high-dose chemotherapy for patients with previously treated germ cell tumors: results and prognostic factor analysis.. 28. 2010
Gene expression profiling uncovers molecular classifiers for the recognition of anaplastic large-cell lymphoma within peripheral T-cell neoplasms.. 28. 2010
Metastasis after radical prostatectomy or external beam radiotherapy for patients with clinically localized prostate cancer: a comparison of clinical cohorts adjusted for case mix.. 28. 2010
Phase II multicenter study of abiraterone acetate plus prednisone therapy in patients with docetaxel-treated castration-resistant prostate cancer.. 28. 2010
Significant and sustained antitumor activity in post-docetaxel, castration-resistant prostate cancer with the CYP17 inhibitor abiraterone acetate.. 28. 2010
Phase II study of sunitinib in patients with metastatic urothelial cancer.. 28. 2010
Sentinel lymph node biopsy accurately stages the regional lymph nodes for T1-T2 oral squamous cell carcinomas: results of a prospective multi-institutional trial.. 28. 2010
End-of-life discussions, goal attainment, and distress at the end of life: predictors and outcomes of receipt of care consistent with preferences.. 28. 2010
Finasteride to prevent prostate cancer: should all men or only a high-risk subgroup be treated?. 28. 2010
Phase III study of enzastaurin compared with lomustine in the treatment of recurrent intracranial glioblastoma.. 28. 2010
Pazopanib in locally advanced or metastatic renal cell carcinoma: results of a randomized phase III trial.. 28. 2010
Multicenter analysis of 80 solid organ transplantation recipients with post-transplantation lymphoproliferative disease: outcomes and prognostic factors in the modern era.. 28. 2010
Prospective multicenter study of the impact of the 21-gene recurrence score assay on medical oncologist and patient adjuvant breast cancer treatment selection.. 28. 2010
Vandetanib for the treatment of patients with locally advanced or metastatic hereditary medullary thyroid cancer.. 28. 2010
Provision of spiritual care to patients with advanced cancer: associations with medical care and quality of life near death.. 28. 2009
Clinical definition of acquired resistance to epidermal growth factor receptor tyrosine kinase inhibitors in non-small-cell lung cancer.. 28. 2009
Fertility of male survivors of childhood cancer: a report from the Childhood Cancer Survivor Study.. 28. 2009
Phase I study of intravenous vascular endothelial growth factor trap, aflibercept, in patients with advanced solid tumors.. 28. 2009
Final version of 2009 AJCC melanoma staging and classification.. 27. 2009
Dose-dense adjuvant Doxorubicin and cyclophosphamide is not associated with frequent short-term changes in left ventricular ejection fraction.. 27. 2009
Nodal staging score: a tool to assess adequate staging of node-negative colon cancer.. 27. 2009
Survival effect of venous thromboembolism in patients with multiple myeloma treated with lenalidomide and high-dose dexamethasone.. 28. 2009
Feasibility trial of letrozole in combination with bevacizumab in patients with metastatic breast cancer.. 28. 2009
Phase II multi-institutional trial of the histone deacetylase inhibitor romidepsin as monotherapy for patients with cutaneous T-cell lymphoma.. 27. 2009
Multinational, double-blind, phase III study of prednisone and either satraplatin or placebo in patients with castrate-refractory prostate cancer progressing after prior chemotherapy: the SPARC trial.. 27. 2009
Racial and ethnic disparities in the use of postmastectomy breast reconstruction: results from a population- based study.. 27. 2009
Racial differences in predictors of intensive end-of-life care in patients with advanced cancer.. 27. 2009
Timed sequential treatment with cyclophosphamide, doxorubicin, and an allogeneic granulocyte-macrophage colony-stimulating factor-secreting breast tumor vaccine: a chemotherapy dose-ranging factorial study of safety and immune activation.. 27. 2009
Young adults with acute lymphoblastic leukemia have an excellent outcome with chemotherapy alone and benefit from intensive postinduction treatment: a report from the children's oncology group.. 27. 2009
Identification and validation of a gene expression signature that predicts outcome in adult men with germ cell tumors.. 27. 2009
Immunophenotypic analysis of AIDS-related diffuse large B-cell lymphoma and clinical implications in patients from AIDS Malignancies Consortium clinical trials 010 and 034.. 27. 2009
Risk of fracture after single fraction image-guided intensity-modulated radiation therapy to spinal metastases.. 27. 2009
Multicenter phase II trial of YM155, a small-molecule suppressor of survivin, in patients with advanced, refractory, non-small-cell lung cancer.. 27. 2009
Distress in older patients with cancer.. 27. 2009
Phase II study of clofarabine in pediatric patients with refractory or relapsed acute myeloid leukemia.. 27. 2009
Phase II-I-II study of two different doses and schedules of pralatrexate, a high-affinity substrate for the reduced folate carrier, in patients with relapsed or refractory lymphoma reveals marked activity in T-cell malignancies.. 27. 2009
Pomalidomide is active in the treatment of anemia associated with myelofibrosis.. 27. 2009
Final results of sequential doxorubicin plus gemcitabine and ifosfamide, paclitaxel, and cisplatin chemotherapy in patients with metastatic or locally advanced transitional cell carcinoma of the urothelium.. 27. 2009
Phase I study of the humanized anti-CD40 monoclonal antibody dacetuzumab in refractory or recurrent non-Hodgkin's lymphoma.. 27. 2009
Prostate cancer-specific mortality after radical prostatectomy for patients treated in the prostate-specific antigen era.. 27. 2009
Talampanel with standard radiation and temozolomide in patients with newly diagnosed glioblastoma: a multicenter phase II trial.. 27. 2009
Single-agent bortezomib in previously untreated multiple myeloma: efficacy, characterization of peripheral neuropathy, and molecular correlations with response and neuropathy.. 27. 2009
Pretreatment prostate-specific antigen (PSA) velocity and doubling time are associated with outcome but neither improves prediction of outcome beyond pretreatment PSA alone in patients treated with radical prostatectomy.. 27. 2009
Randomized phase II trial of chemoradiotherapy followed by either dose-dense or metronomic temozolomide for newly diagnosed glioblastoma.. 27. 2009
Dasatinib in the treatment of chronic myeloid leukemia in accelerated phase after imatinib failure: the START a trial.. 27. 2009
Outcome of primary tumor in patients with synchronous stage IV colorectal cancer receiving combination chemotherapy without surgery as initial treatment.. 27. 2009
Overall survival and updated results for sunitinib compared with interferon alfa in patients with metastatic renal cell carcinoma.. 27. 2009
Conversion to resectability using hepatic artery infusion plus systemic chemotherapy for the treatment of unresectable liver metastases from colorectal carcinoma.. 27. 2009
Circulating tumor cells and [18F]fluorodeoxyglucose positron emission tomography/computed tomography for outcome prediction in metastatic breast cancer.. 27. 2009
Humanized anti-CD20 antibody, veltuzumab, in refractory/recurrent non-Hodgkin's lymphoma: phase I/II results.. 27. 2009
Multicenter phase II trial of sunitinib in the treatment of nongastrointestinal stromal tumor sarcomas.. 27. 2009
Phase II multicenter trial of imatinib in 10 histologic subtypes of sarcoma using a bayesian hierarchical statistical model.. 27. 2009
Phase II study of sorafenib in patients with metastatic or recurrent sarcomas.. 27. 2009
Gleason score and lethal prostate cancer: does 3 + 4 = 4 + 3?. 27. 2009
Placebo-controlled phase III trial of patient-specific immunotherapy with mitumprotimut-T and granulocyte-macrophage colony-stimulating factor after rituximab in patients with follicular lymphoma.. 27. 2009
[18F]fluorodeoxyglucose positron emission tomography correlates with Akt pathway activity but is not predictive of clinical outcome during mTOR inhibitor therapy.. 27. 2009
Fertility of female survivors of childhood cancer: a report from the childhood cancer survivor study.. 27. 2009
Multicenter phase II trial of neoadjuvant pemetrexed plus cisplatin followed by extrapleural pneumonectomy and radiation for malignant pleural mesothelioma.. 27. 2009
Phase I study of samarium-153 lexidronam with docetaxel in castration-resistant metastatic prostate cancer.. 27. 2009
Dose-intensified compared with standard chemotherapy for nonmetastatic Ewing sarcoma family of tumors: a Children's Oncology Group Study.. 27. 2009
Effects of chemotherapy in AIDS-associated non-Hodgkin's lymphoma on Kaposi's sarcoma herpesvirus DNA in blood.. 27. 2009
The effects of a presurgical stress management intervention for men with prostate cancer undergoing radical prostatectomy.. 27. 2009
Feasibility trial of partial breast irradiation with concurrent dose-dense doxorubicin and cyclophosphamide in early-stage breast cancer.. 27. 2009
Newer antidepressants and gabapentin for hot flashes: an individual patient pooled analysis.. 27. 2009
DPC4 gene status of the primary carcinoma correlates with patterns of failure in patients with pancreatic cancer.. 27. 2009
Microsatellite instability predicts improved response to adjuvant therapy with irinotecan, fluorouracil, and leucovorin in stage III colon cancer: Cancer and Leukemia Group B Protocol 89803.. 27. 2009
Randomized phase II trial evaluating two paclitaxel and cisplatin-containing chemoradiation regimens as adjuvant therapy in resected gastric cancer (RTOG-0114).. 27. 2009
Multi-institutional phase I/II trial of stereotactic body radiation therapy for liver metastases.. 27. 2009
Multi-institutional phase I/II trial of stereotactic body radiation therapy for lung metastases.. 27. 2009
Phase I and pharmacokinetic study of sorafenib in patients with hepatic or renal dysfunction: CALGB 60301.. 27. 2009
Stage-specific outcomes of patients with uterine leiomyosarcoma: a comparison of the international Federation of gynecology and obstetrics and american joint committee on cancer staging systems.. 27. 2009
Follicular lymphoma in the United States: first report of the national LymphoCare study.. 27. 2009
Outcome of deferred initial therapy in mantle-cell lymphoma.. 27. 2009
Sensitivity of surveillance studies for detecting asymptomatic and unsuspected relapse of high-risk neuroblastoma.. 27. 2009
Gene expression profiling reveals a new classification of adrenocortical tumors and identifies molecular predictors of malignancy and survival.. 27. 2009
Phase II trial of single-agent bevacizumab followed by bevacizumab plus irinotecan at tumor progression in recurrent glioblastoma.. 27. 2008
Clinical cancer advances 2008: major research advances in cancer treatment, prevention, and screening--a report from the American Society of Clinical Oncology.. 27. 2008
Lymphovascular invasion predicts clinical outcomes in patients with node-negative upper tract urothelial carcinoma.. 27. 2008
Sequential therapy with fludarabine, high-dose cyclophosphamide, and rituximab in previously untreated patients with chronic lymphocytic leukemia produces high-quality responses: molecular remissions predict for durable complete responses.. 27. 2008
BRCA germline mutations in Jewish patients with pancreatic adenocarcinoma.. 27. 2008
Randomized phase II study of pulse erlotinib before or after carboplatin and paclitaxel in current or former smokers with advanced non-small-cell lung cancer.. 27. 2008
Unresolved grief in a national sample of bereaved parents: impaired mental and physical health 4 to 9 years later.. 26. 2008
American Society of Clinical Oncology 2008 clinical practice guideline update: use of chemotherapy and radiation therapy protectants.. 27. 2008
Estrogen receptor genotypes influence hot flash prevalence and composite score before and after tamoxifen therapy.. 26. 2008
Impact of molecular staging methods in primary melanoma: reverse-transcriptase polymerase chain reaction (RT-PCR) of ultrasound-guided aspirate of the sentinel node does not improve diagnostic accuracy, but RT-PCR of peripheral blood does predict survival.. 26. 2008
Cohort study of fatty acid synthase expression and patient survival in colon cancer.. 26. 2008
Phase I study of ON 01910.Na, a novel modulator of the Polo-like kinase 1 pathway, in adult patients with solid tumors.. 26. 2008
Primary and secondary kinase genotypes correlate with the biological and clinical activity of sunitinib in imatinib-resistant gastrointestinal stromal tumor.. 26. 2008
Clinical outcome and predictors of survival in late relapse of germ cell tumor.. 26. 2008
Prevalence of lymphedema in women with breast cancer 5 years after sentinel lymph node biopsy or axillary dissection: objective measurements.. 26. 2008
Prevalence of lymphedema in women with breast cancer 5 years after sentinel lymph node biopsy or axillary dissection: patient perceptions and precautionary behaviors.. 26. 2008
Longitudinal changes in obesity and body mass index among adult survivors of childhood acute lymphoblastic leukemia: a report from the Childhood Cancer Survivor Study.. 26. 2008
Long-term effects of high-dose chemotherapy and radiation for relapsed and refractory Hodgkin's lymphoma.. 26. 2008
Randomized trial of a hypnosis intervention for treatment of hot flashes among breast cancer survivors.. 26. 2008
Comparison of referring and final pathology for patients with non-Hodgkin's lymphoma in the National Comprehensive Cancer Network.. 26. 2008
Impact of body mass index and weight change after treatment on cancer recurrence and survival in patients with stage III colon cancer: findings from Cancer and Leukemia Group B 89803.. 26. 2008
Pharmacodynamic-guided modified continuous reassessment method-based, dose-finding study of rapamycin in adult patients with solid tumors.. 26. 2008
Racial and ethnic differences in advance care planning among patients with cancer: impact of terminal illness acknowledgment, religiousness, and treatment preferences.. 26. 2008
Economic evaluation of sunitinib malate for the first-line treatment of metastatic renal cell carcinoma.. 26. 2008
Systems pathology approach for the prediction of prostate cancer progression after radical prostatectomy.. 26. 2008
Urgent need for a new staging system in advanced colorectal cancer.. 26. 2008
Quality of life in patients with metastatic renal cell carcinoma treated with sunitinib or interferon alfa: results from a phase III randomized trial.. 26. 2008
Del(6)(q22) and BCL6 rearrangements in primary CNS lymphoma are indicators of an aggressive clinical course.. 26. 2008
Analysis of fluorouracil-based adjuvant chemotherapy and radiation after pancreaticoduodenectomy for ductal adenocarcinoma of the pancreas: results of a large, prospectively collected database at the Johns Hopkins Hospital.. 26. 2008
DNA damage and repair capacity in patients with lung cancer: prediction of multiple primary tumors.. 26. 2008
Effect of esthetic outcome after breast-conserving surgery on psychosocial functioning and quality of life.. 26. 2008
Impact of intensity-modulated radiation therapy on local control in primary soft-tissue sarcoma of the extremity.. 26. 2008
Novel intraoperative molecular test for sentinel lymph node metastases in patients with early-stage breast cancer.. 26. 2008
Phase II randomized trial of two nonoperative regimens of induction chemotherapy followed by chemoradiation in patients with localized carcinoma of the esophagus: RTOG 0113.. 26. 2008
Osteonecrosis in adult survivors of childhood cancer: a report from the childhood cancer survivor study.. 26. 2008
Phase I/II study of biweekly paclitaxel and radiation in androgen-ablated locally advanced prostate cancer.. 26. 2008
Phase II trial evaluating the clinical and biologic effects of bevacizumab in unresectable hepatocellular carcinoma.. 26. 2008
Phase II trial of docetaxel with rapid androgen cycling for progressive noncastrate prostate cancer.. 26. 2008
Axitinib is an active treatment for all histologic subtypes of advanced thyroid cancer: results from a phase II study.. 26. 2008
Intermittent target inhibition with dasatinib 100 mg once daily preserves efficacy and improves tolerability in imatinib-resistant and -intolerant chronic-phase chronic myeloid leukemia.. 26. 2008
Racial differences in clinical outcomes from metastatic breast cancer: a pooled analysis of CALGB 9342 and 9840--Cancer and Leukemia Group B.. 26. 2008
Phase II study of extended-dose temozolomide in patients with melanoma.. 26. 2008
Utilization and outcomes of minimally invasive radical prostatectomy.. 26. 2008
Potential regional differences for the tolerability profiles of fluoropyrimidines.. 26. 2008
Bevacizumab in combination with oxaliplatin-based chemotherapy as first-line therapy in metastatic colorectal cancer: a randomized phase III study.. 26. 2008
Randomized phase III study of capecitabine plus oxaliplatin compared with fluorouracil/folinic acid plus oxaliplatin as first-line therapy for metastatic colorectal cancer.. 26. 2008
Ten-year follow-up of radiation therapy oncology group protocol 92-02: a phase III trial of the duration of elective androgen deprivation in locally advanced prostate cancer.. 26. 2008
Effect of molecular therapeutics on liver regeneration in a murine model.. 26. 2008
Phase I study of a novel capecitabine schedule based on the Norton-Simon mathematical model in patients with metastatic breast cancer.. 26. 2008
Influence of activation state of ErbB-2 (HER-2) on response to adjuvant cyclophosphamide, doxorubicin, and fluorouracil for stage II, node-positive breast cancer: study 8541 from the Cancer and Leukemia Group B.. 26. 2008
Randomized phase III trial of weekly compared with every-3-weeks paclitaxel for metastatic breast cancer, with trastuzumab for all HER-2 overexpressors and random assignment to trastuzumab or not in HER-2 nonoverexpressors: final results of Cancer and Leukemia Group B protocol 9840.. 26. 2008
Phase I trial of the prostate-specific membrane antigen-directed immunoconjugate MLN2704 in patients with progressive metastatic castration-resistant prostate cancer.. 26. 2008
Prognostic implications of the distribution of lymph node metastases in rectal cancer after neoadjuvant chemoradiotherapy.. 26. 2008
External validation of a biomarker-based preoperative nomogram predicts biochemical recurrence after radical prostatectomy.. 26. 2008
Molecular characteristics of bronchioloalveolar carcinoma and adenocarcinoma, bronchioloalveolar carcinoma subtype, predict response to erlotinib.. 26. 2008
Involved-field radiotherapy before high-dose therapy and autologous stem-cell rescue in diffuse large-cell lymphoma: long-term disease control and toxicity.. 26. 2008
Late extended adjuvant treatment with letrozole improves outcome in women with early-stage breast cancer who complete 5 years of tamoxifen.. 26. 2008
Occult axillary node metastases in breast cancer are prognostically significant: results in 368 node-negative patients with 20-year follow-up.. 26. 2008
The safety of dose-dense doxorubicin and cyclophosphamide followed by paclitaxel with trastuzumab in HER-2/neu overexpressed/amplified breast cancer.. 26. 2008
Endocrine outcomes for children with embryonal brain tumors after risk-adapted craniospinal and conformal primary-site irradiation and high-dose chemotherapy with stem-cell rescue on the SJMB-96 trial.. 26. 2008
Pharmacogenomic and pharmacokinetic determinants of erlotinib toxicity.. 26. 2008
Long-term prediction of prostate cancer: prostate-specific antigen (PSA) velocity is predictive but does not improve the predictive accuracy of a single PSA measurement 15 years or more before cancer diagnosis in a large, representative, unscreened population.. 26. 2008
Randomized phase II Study of carboplatin and etoposide with or without the bcl-2 antisense oligonucleotide oblimersen for extensive-stage small-cell lung cancer: CALGB 30103.. 26. 2008
Risk-reducing salpingo-oophorectomy for the prevention of BRCA1- and BRCA2-associated breast and gynecologic cancer: a multicenter, prospective study.. 26. 2008
Response to neoadjuvant therapy and long-term survival in patients with triple-negative breast cancer.. 26. 2008
Osteosarcoma: the addition of muramyl tripeptide to chemotherapy improves overall survival--a report from the Children's Oncology Group.. 26. 2008
Phase I and pharmacokinetic study of imatinib mesylate in patients with advanced malignancies and varying degrees of renal dysfunction: a study by the National Cancer Institute Organ Dysfunction Working Group.. 26. 2008
Phase I/II trial of weekly intravenous 130-nm albumin-bound paclitaxel as initial chemotherapy in patients with stage IV non-small-cell lung cancer.. 26. 2008
Phase III randomized, intergroup trial assessing imatinib mesylate at two dose levels in patients with unresectable or metastatic gastrointestinal stromal tumors expressing the kit receptor tyrosine kinase: S0033.. 26. 2008
Individualized prediction of colon cancer recurrence using a nomogram.. 26. 2008
Lymph node density is superior to TNM nodal status in predicting disease-specific survival after radical cystectomy for bladder cancer: analysis of pooled data from MDACC and MSKCC.. 26. 2008
Is failure to meet spiritual needs associated with cancer patients' perceptions of quality of care and their satisfaction with care?. 25. 2007
Determining prognosis in patients with pancreatic endocrine neoplasms: can the WHO classification system be simplified?. 25. 2007
Nonrandomized comparison of primary chemotherapy and retroperitoneal lymph node dissection for clinical stage IIA and IIB nonseminomatous germ cell testicular cancer.. 25. 2007
Randomized, controlled trial of acupuncture for the treatment of hot flashes in breast cancer patients.. 25. 2007
Combination of trastuzumab and tanespimycin (17-AAG, KOS-953) is safe and active in trastuzumab-refractory HER-2 overexpressing breast cancer: a phase I dose-escalation study.. 25. 2007
Long-term toxicity monitoring via electronic patient-reported outcomes in patients receiving chemotherapy.. 25. 2007
Phase I study of targeted radioimmunotherapy for leptomeningeal cancers using intra-Ommaya 131-I-3F8.. 25. 2007
Phase II study of uracil-tegafur with leucovorin in elderly (> or = 75 years old) patients with colorectal cancer: ECOG 1299.. 25. 2007
Randomized double-blind trial of prophylactic oral minocycline and topical tazarotene for cetuximab-associated acne-like eruption.. 25. 2007
Randomized trial of high-dose chemotherapy with autologous peripheral-blood stem-cell support compared with standard-dose chemotherapy in women with metastatic breast cancer: NCIC MA.16.. 26. 2007
Improved clinical outcome in recent years for men with metastatic nonseminomatous germ cell tumors.. 25. 2007
Prospective study of the correlation between postoperative computed tomography scan and primary surgeon assessment in patients with advanced ovarian, tubal, and peritoneal carcinoma reported to have undergone primary surgical cytoreduction to residual disease 1 cm or less.. 25. 2007
Combined immunochemotherapy with reduced whole-brain radiotherapy for newly diagnosed primary CNS lymphoma.. 25. 2007
Phase II trial of sunitinib in patients with metastatic colorectal cancer after failure of standard therapy.. 25. 2007
Actual 10-year survival after resection of colorectal liver metastases defines cure.. 25. 2007
Global histone modifications predict prognosis of resected non small-cell lung cancer.. 25. 2007
Incidence of metastatic nonseminomatous germ cell tumor outside the boundaries of a modified postchemotherapy retroperitoneal lymph node dissection.. 25. 2007
Randomized phase II trial of cetuximab, bevacizumab, and irinotecan compared with cetuximab and bevacizumab alone in irinotecan-refractory colorectal cancer: the BOND-2 study.. 25. 2007
Phase I/II trial of temsirolimus combined with interferon alfa for advanced renal cell carcinoma.. 25. 2007
A nomogram predicting 10-year life expectancy in candidates for radical prostatectomy or radiotherapy for prostate cancer.. 25. 2007
Long-term results of RTOG trial 8911 (USA Intergroup 113): a random assignment trial comparison of chemotherapy followed by surgery compared with surgery alone for esophageal cancer.. 25. 2007
Toxicity of older and younger patients treated with adjuvant chemotherapy for node-positive breast cancer: the Cancer and Leukemia Group B Experience.. 25. 2007
Irinotecan fluorouracil plus leucovorin is not superior to fluorouracil plus leucovorin alone as adjuvant treatment for stage III colon cancer: results of CALGB 89803.. 25. 2007
Expression of epiregulin and amphiregulin and K-ras mutation status predict disease control in metastatic colorectal cancer patients treated with cetuximab.. 25. 2007
Doctor, what are my chances of having a positive sentinel node? A validated nomogram for risk estimation.. 25. 2007
Patient satisfaction with treatment of breast cancer: does surgeon specialization matter?. 25. 2007
Phase II clinical trial of ixabepilone (BMS-247550), an epothilone B analog, in patients with taxane-resistant metastatic breast cancer.. 25. 2007
Bevacizumab 5 mg/kg can be infused safely over 10 minutes.. 25. 2007
Randomized phase II study of gemcitabine and docetaxel compared with gemcitabine alone in patients with metastatic soft tissue sarcomas: results of sarcoma alliance for research through collaboration study 002 [corrected].. 25. 2007
Superiority of fluorodeoxyglucose positron emission tomography to other functional imaging techniques in the evaluation of metastatic SDHB-associated pheochromocytoma and paraganglioma.. 25. 2007
Trastuzumab, paclitaxel, carboplatin, and gemcitabine in advanced human epidermal growth factor receptor-2/neu-positive urothelial carcinoma: results of a multicenter phase II National Cancer Institute trial.. 25. 2007
Phase I/II study of an anti-CD30 monoclonal antibody (MDX-060) in Hodgkin's lymphoma and anaplastic large-cell lymphoma.. 25. 2007
Multiple drug resistance in osteogenic sarcoma: INT0133 from the Children's Oncology Group.. 25. 2007
Predicting the outcome of salvage radiation therapy for recurrent prostate cancer after radical prostatectomy.. 25. 2007
Phase I-II trial of prone accelerated intensity modulated radiation therapy to the breast to optimally spare normal tissue.. 25. 2007
Efficacy of letrozole extended adjuvant therapy according to estrogen receptor and progesterone receptor status of the primary tumor: National Cancer Institute of Canada Clinical Trials Group MA.17.. 25. 2007
Identification of angiogenesis/metastases genes predicting chemoradiotherapy response in patients with laryngopharyngeal carcinoma.. 25. 2007
Direct intracerebral delivery of cintredekin besudotox (IL13-PE38QQR) in recurrent malignant glioma: a report by the Cintredekin Besudotox Intraparenchymal Study Group.. 25. 2007
Tumor-infiltrating lymphocytes predict sentinel lymph node positivity in patients with cutaneous melanoma.. 25. 2007
Efficacy and safety of single-agent pertuzumab (rhuMAb 2C4), a human epidermal growth factor receptor dimerization inhibitor, in castration-resistant prostate cancer after progression from taxane-based therapy.. 25. 2007
American Joint Committee on Cancer staging system does not accurately predict survival in patients receiving multimodality therapy for esophageal adenocarcinoma.. 25. 2007
Religiousness and spiritual support among advanced cancer patients and associations with end-of-life treatment preferences and quality of life.. 25. 2007
Vascular targeted therapy with anti-prostate-specific membrane antigen monoclonal antibody J591 in advanced solid tumors.. 25. 2007
Association of the circulating levels of the urokinase system of plasminogen activation with the presence of prostate cancer and invasion, progression, and metastasis.. 25. 2007
Long-term prediction of prostate cancer up to 25 years before diagnosis of prostate cancer using prostate kallikreins measured at age 44 to 50 years.. 25. 2007
Long-term clinical outcome after postchemotherapy retroperitoneal lymph node dissection in men with residual teratoma.. 25. 2007
Phase I study of the novel epothilone analog ixabepilone (BMS-247550) in patients with advanced solid tumors and lymphomas.. 25. 2007
Induction chemoradiation and surgical resection for superior sulcus non-small-cell lung carcinomas: long-term results of Southwest Oncology Group Trial 9416 (Intergroup Trial 0160).. 25. 2007
Open-label phase II study evaluating the efficacy and safety of two doses of pertuzumab in castrate chemotherapy-naive patients with hormone-refractory prostate cancer.. 25. 2007
Patterns and correlates of patient referral to surgeons for treatment of breast cancer.. 25. 2007
Phase III randomized trial of conventional-dose chemotherapy with or without high-dose chemotherapy and autologous hematopoietic stem-cell rescue as first-line treatment for patients with poor-prognosis metastatic germ cell tumors.. 25. 2007
Phase II clinical trial of chemotherapy-naive patients > or = 70 years of age treated with erlotinib for advanced non-small-cell lung cancer.. 25. 2007
Paclitaxel plus Ifosfamide followed by high-dose carboplatin plus etoposide in previously treated germ cell tumors.. 25. 2007
Phase II study of neoadjuvant androgen deprivation followed by external-beam radiotherapy with 9 months of androgen deprivation for intermediate- to high-risk localized prostate cancer.. 25. 2007
Early invasive cervical cancer: tumor delineation by magnetic resonance imaging, computed tomography, and clinical examination, verified by pathologic results, in the ACRIN 6651/GOG 183 Intergroup Study.. 24. 2006
Clinical cancer advances 2006: major research advances in cancer treatment, prevention, and screening--a report from the American Society of Clinical Oncology.. 25. 2006
Cloretazine (VNP40101M), a novel sulfonylhydrazine alkylating agent, in patients age 60 years or older with previously untreated acute myeloid leukemia.. 25. 2006
Phase I/II study of continuous-infusion troxacitabine in refractory acute myeloid leukemia.. 25. 2006
Irinotecan plus temozolomide for relapsed or refractory neuroblastoma.. 24. 2006
Multicenter phase II study of irinotecan, cisplatin, and bevacizumab in patients with metastatic gastric or gastroesophageal junction adenocarcinoma.. 24. 2006
Primary central nervous system lymphoma: the Memorial Sloan-Kettering Cancer Center prognostic model.. 24. 2006
Molecular on/off switch.. 24. 2006
Randomized phase II trial of docetaxel/irinotecan and gemcitabine/irinotecan with or without celecoxib in the second-line treatment of non-small-cell lung cancer.. 24. 2006
Long-term follow-up of high-dose methotrexate-based therapy with and without whole brain irradiation for newly diagnosed primary CNS lymphoma.. 24. 2006
Multicenter phase II study of bortezomib in patients with relapsed or refractory mantle cell lymphoma.. 24. 2006
Randomized phase III study of exatecan and gemcitabine compared with gemcitabine alone in untreated advanced pancreatic cancer.. 24. 2006
Bcl-2 antisense (oblimersen sodium) plus dacarbazine in patients with advanced melanoma: the Oblimersen Melanoma Study Group.. 24. 2006
Predictors of recurrence in patients with T2 and early T3, N0 adenocarcinoma of the rectum treated by surgery alone.. 24. 2006
Defining biochemical recurrence of prostate cancer after radical prostatectomy: a proposal for a standardized definition.. 24. 2006
Phase II study of sorafenib in patients with advanced hepatocellular carcinoma.. 24. 2006
Somatic activation of KIT in distinct subtypes of melanoma.. 24. 2006
Clinical activity of pertuzumab (rhuMAb 2C4), a HER dimerization inhibitor, in advanced ovarian cancer: potential predictive relationship with tumor HER2 activation status.. 24. 2006
Phase II trial of tipifarnib in patients with recurrent malignant glioma either receiving or not receiving enzyme-inducing antiepileptic drugs: a North American Brain Tumor Consortium Study.. 24. 2006
Postoperative nomogram predicting risk of recurrence after radical cystectomy for bladder cancer.. 24. 2006
Impact of physical activity on cancer recurrence and survival in patients with stage III colon cancer: findings from CALGB 89803.. 24. 2006
Formulas calculating creatinine clearance are inadequate for determining eligibility for Cisplatin-based chemotherapy in bladder cancer.. 24. 2006
Renal cell carcinoma recurrence after nephrectomy for localized disease: predicting survival from time of recurrence.. 24. 2006
Phase II trial of intravesical gemcitabine in bacille Calmette-Guérin-refractory transitional cell carcinoma of the bladder.. 24. 2006
Phase II trial of idiotype vaccination in previously treated patients with indolent non-Hodgkin's lymphoma resulting in durable clinical responses.. 24. 2006
Identifying individuals at high risk of melanoma: a practical predictor of absolute risk.. 24. 2006
Phase I study of EKB-569, an irreversible inhibitor of the epidermal growth factor receptor, in patients with advanced solid tumors.. 24. 2006
The role of prevention in oncology practice: results from a 2004 survey of American Society of Clinical Oncology members.. 24. 2006
FCGR2A polymorphism is correlated with clinical outcome after immunotherapy of neuroblastoma with anti-GD2 antibody and granulocyte macrophage colony-stimulating factor.. 24. 2006
Phase II study of clofarabine in pediatric patients with refractory or relapsed acute lymphoblastic leukemia.. 24. 2006
Predictive factors for outcome in a phase II study of gefitinib in second-line treatment of advanced esophageal cancer patients.. 24. 2006
Translocation carcinomas of the kidney after chemotherapy in childhood.. 24. 2006
Pentostatin, cyclophosphamide, and rituximab is an active, well-tolerated regimen for patients with previously treated chronic lymphocytic leukemia.. 24. 2006
Concurrent cetuximab, cisplatin, and concomitant boost radiotherapy for locoregionally advanced, squamous cell head and neck cancer: a pilot phase II study of a new combined-modality paradigm.. 24. 2006
Differential cell cycle-regulatory protein expression in biliary tract adenocarcinoma: correlation with anatomic site, pathologic variables, and clinical outcome.. 24. 2006
Prognostic value of pathologic complete response after primary chemotherapy in relation to hormone receptor status and other factors.. 24. 2006
Hepatic arterial infusion versus systemic therapy for hepatic metastases from colorectal cancer: a randomized trial of efficacy, quality of life, and molecular markers (CALGB 9481).. 24. 2006
Use of cigarette-smoking history to estimate the likelihood of mutations in epidermal growth factor receptor gene exons 19 and 21 in lung adenocarcinomas.. 24. 2006
Short-term treatment-related symptoms and quality of life: results from an international randomized phase III study of cisplatin with or without raltitrexed in patients with malignant pleural mesothelioma: an EORTC Lung-Cancer Group and National Cancer Institute, Canada, Intergroup Study.. 24. 2006
Comparable long-term survival after unrelated and HLA-matched sibling donor hematopoietic stem cell transplantations for acute leukemia in children younger than 18 months.. 24. 2006
Intensive therapy with growth factor support for patients with Ewing tumor metastatic at diagnosis: Pediatric Oncology Group/Children's Cancer Group Phase II Study 9457--a report from the Children's Oncology Group.. 24. 2006
Preoperative serum tissue factor levels are an independent prognostic factor in patients with ovarian carcinoma.. 24. 2005
Etoposide and cisplatin chemotherapy for metastatic good-risk germ cell tumors.. 23. 2005
Risk of epithelial ovarian cancer recurrence in patients with rising serum CA-125 levels within the normal range.. 23. 2005
Role of imaging in pretreatment evaluation of early invasive cervical cancer: results of the intergroup study American College of Radiology Imaging Network 6651-Gynecologic Oncology Group 183.. 23. 2005
Activity of SU11248, a multitargeted inhibitor of vascular endothelial growth factor receptor and platelet-derived growth factor receptor, in patients with metastatic renal cell carcinoma.. 24. 2005
Clinical experience with intravenous and oral formulations of the novel histone deacetylase inhibitor suberoylanilide hydroxamic acid in patients with advanced hematologic malignancies.. 24. 2005
Evaluation of two phosphorylation sites improves the prognostic significance of Akt activation in non-small-cell lung cancer tumors.. 24. 2005
Phase II trial of radiosurgery for one to three newly diagnosed brain metastases from renal cell carcinoma, melanoma, and sarcoma: an Eastern Cooperative Oncology Group study (E 6397).. 23. 2005
Recent chemotherapy reduces the sensitivity of [18F]fluorodeoxyglucose positron emission tomography in the detection of colorectal metastases.. 23. 2005
Response of retinoblastoma with vitreous tumor seeding to adenovirus-mediated delivery of thymidine kinase followed by ganciclovir.. 23. 2005
Variates of survival in metastatic uveal melanoma.. 23. 2005
Colorectal cancer surveillance: 2005 update of an American Society of Clinical Oncology practice guideline.. 23. 2005
Breast cancer risk following bilateral oophorectomy in BRCA1 and BRCA2 mutation carriers: an international case-control study.. 23. 2005
Multiagent chemotherapy and deferred radiotherapy in infants with malignant brain tumors: a report from the Children's Cancer Group.. 23. 2005
Utilization of diagnostic studies in the pretreatment evaluation of invasive cervical cancer in the United States: results of intergroup protocol ACRIN 6651/GOG 183.. 23. 2005
Validation of a postresection pancreatic adenocarcinoma nomogram for disease-specific survival.. 23. 2005
Epidermal growth factor receptor mutations and gene amplification in non-small-cell lung cancer: molecular analysis of the IDEAL/INTACT gefitinib trials.. 23. 2005
Re-treatment with I-131 tositumomab in patients with non-Hodgkin's lymphoma who had previously responded to I-131 tositumomab.. 23. 2005
Incidence of late-relapse germ cell tumor and outcome to salvage chemotherapy.. 23. 2005
Paroxetine is an effective treatment for hot flashes: results from a prospective randomized clinical trial.. 23. 2005
Phase II study of doxorubicin and bevacizumab for patients with metastatic soft-tissue sarcomas.. 23. 2005
Phase III study of adjuvant vaccination with Bec2/bacille Calmette-Guerin in responding patients with limited-disease small-cell lung cancer (European Organisation for Research and Treatment of Cancer 08971-08971B; Silva Study).. 23. 2005
Postoperative nomogram predicting the 10-year probability of prostate cancer recurrence after radical prostatectomy.. 23. 2005
Randomized phase III study of cisplatin with or without raltitrexed in patients with malignant pleural mesothelioma: an intergroup study of the European Organisation for Research and Treatment of Cancer Lung Cancer Group and the National Cancer Institute of Canada.. 23. 2005
Tositumomab and iodine-131 tositumomab produces durable complete remissions in a subset of heavily pretreated patients with low-grade and transformed non-Hodgkin's lymphomas.. 23. 2005
Combination of paclitaxel, ifosfamide, and cisplatin is an effective second-line therapy for patients with relapsed testicular germ cell tumors.. 23. 2005
Phase I trial of tipifarnib in patients with recurrent malignant glioma taking enzyme-inducing antiepileptic drugs: a North American Brain Tumor Consortium Study.. 23. 2005
Prostate-specific antigen nadir and cancer-specific mortality following hormonal therapy for prostate-specific antigen failure.. 23. 2005
Phase I study of gefitinib plus celecoxib in recurrent or metastatic squamous cell carcinoma of the head and neck.. 23. 2005
Phase I trial of bortezomib and carboplatin in recurrent ovarian or primary peritoneal cancer.. 23. 2005
Proteasome inhibition with bortezomib (PS-341): a phase I study with pharmacodynamic end points using a day 1 and day 4 schedule in a 14-day cycle.. 23. 2005
Survival in patients operated on for pathologic fracture: implications for end-of-life orthopedic care.. 23. 2005
Psychiatric disorders and mental health service use among caregivers of advanced cancer patients.. 23. 2005
Lymphovascular invasion is independently associated with overall survival, cause-specific survival, and local and distant recurrence in patients with negative lymph nodes at radical cystectomy.. 23. 2005
Abbreviated chemotherapy with fludarabine followed by tositumomab and iodine I 131 tositumomab for untreated follicular lymphoma.. 23. 2005
Patient involvement in surgery treatment decisions for breast cancer.. 23. 2005
Weekly paclitaxel improves pathologic complete remission in operable breast cancer when compared with paclitaxel once every 3 weeks.. 23. 2005
Distal cT2N0 rectal cancer: is there an alternative to abdominoperineal resection?. 23. 2005
TRIBUTE: a phase III trial of erlotinib hydrochloride (OSI-774) combined with carboplatin and paclitaxel chemotherapy in advanced non-small-cell lung cancer.. 23. 2005
Unrelated donor marrow transplantation for B-cell chronic lymphocytic leukemia after using myeloablative conditioning: results from the Center for International Blood and Marrow Transplant research.. 23. 2005
Fludarabine, melphalan, and alemtuzumab conditioning in adults with standard-risk advanced acute myeloid leukemia and myelodysplastic syndrome.. 23. 2005
Phase I trial of systemic oxaliplatin combination chemotherapy with hepatic arterial infusion in patients with unresectable liver metastases from colorectal cancer.. 23. 2005
Phase II trial of temsirolimus (CCI-779) in recurrent glioblastoma multiforme: a North Central Cancer Treatment Group Study.. 23. 2005
Comparison of HER2 status by fluorescence in situ hybridization and immunohistochemistry to predict benefit from dose escalation of adjuvant doxorubicin-based therapy in node-positive breast cancer patients.. 23. 2005
Phase I/II study of galiximab, an anti-CD80 antibody, for relapsed or refractory follicular lymphoma.. 23. 2005
Quality of life of long-term survivors of breast cancer and lymphoma treated with standard-dose chemotherapy or local therapy.. 23. 2005
Achieving optimal outcomes after radical prostatectomy.. 23. 2005
Phase III randomized multicenter study of a humanized anti-CD33 monoclonal antibody, lintuzumab, in combination with chemotherapy, versus chemotherapy alone in patients with refractory or first-relapsed acute myeloid leukemia.. 23. 2005
Combination antibody therapy with epratuzumab and rituximab in relapsed or refractory non-Hodgkin's lymphoma.. 23. 2005
Phase I and pharmacokinetic study of LY293111, an orally bioavailable LTB4 receptor antagonist, in patients with advanced solid tumors.. 23. 2005
Gastric mucosa-associated lymphoid tissue lymphoma detected by clonotypic polymerase chain reaction despite continuous pathologic remission induced by involved-field radiotherapy.. 23. 2005
Clinical examination following preoperative chemoradiation for rectal cancer is not a reliable surrogate end point.. 23. 2005
Patient online self-reporting of toxicity symptoms during chemotherapy.. 23. 2005
Phase I study of an oral histone deacetylase inhibitor, suberoylanilide hydroxamic acid, in patients with advanced cancer.. 23. 2005
Patterns and correlates of local therapy for women with ductal carcinoma-in-situ.. 23. 2005
Retroperitoneal lymph node dissection for nonseminomatous germ cell testicular cancer: impact of patient selection factors on outcome.. 23. 2005
Intensity of 18fluorodeoxyglucose uptake in positron emission tomography distinguishes between indolent and aggressive non-Hodgkin's lymphoma.. 23. 2005
Phase I trial of 177lutetium-labeled J591, a monoclonal antibody to prostate-specific membrane antigen, in patients with androgen-independent prostate cancer.. 23. 2005
Fertility preservation in breast cancer patients: a prospective controlled comparison of ovarian stimulation with tamoxifen and letrozole for embryo cryopreservation.. 23. 2005
Concurrent administration of high-dose rituximab before and after autologous stem-cell transplantation for relapsed aggressive B-cell non-Hodgkin's lymphomas.. 23. 2005
Merkel cell carcinoma: prognosis and treatment of patients from a single institution.. 23. 2005
Risk of new cancers after radiotherapy in long-term survivors of retinoblastoma: an extended follow-up.. 23. 2005
Osteosarcoma: a randomized, prospective trial of the addition of ifosfamide and/or muramyl tripeptide to cisplatin, doxorubicin, and high-dose methotrexate.. 23. 2005
Pattern of prostate-specific antigen (PSA) failure dictates the probability of a positive bone scan in patients with an increasing PSA after radical prostatectomy.. 23. 2005
Prospective, randomized comparison of high-dose chemotherapy with stem-cell support versus intermediate-dose chemotherapy after surgery and adjuvant chemotherapy in women with high-risk primary breast cancer: a report of CALGB 9082, SWOG 9114, and NCIC MA-13.. 23. 2005
Circulating tumor cells: a novel prognostic factor for newly diagnosed metastatic breast cancer.. 23. 2005
Multi-institutional randomized phase II trial of the epothilone B analog ixabepilone (BMS-247550) with or without estramustine phosphate in patients with progressive castrate metastatic prostate cancer.. 23. 2005
TP53 mutations and outcome in osteosarcoma: a prospective, multicenter study.. 23. 2005
Significantly higher pathologic complete remission rate after neoadjuvant therapy with trastuzumab, paclitaxel, and epirubicin chemotherapy: results of a randomized trial in human epidermal growth factor receptor 2-positive operable breast cancer.. 23. 2005
ACCO: ASCO core curriculum outline.. 23. 2005
Molecular staging in stage II and III melanoma patients and its effect on long-term survival.. 23. 2005
Clinically meaningful improvement in symptoms and quality of life for patients with non-small-cell lung cancer receiving gefitinib in a randomized controlled trial.. 23. 2005
Phase I trial of the cyclin-dependent kinase inhibitor and protein kinase C inhibitor 7-hydroxystaurosporine in combination with Fluorouracil in patients with advanced solid tumors.. 23. 2005
Outcome predictors for the increasing PSA state after definitive external-beam radiotherapy for prostate cancer.. 23. 2005
Cetuximab shows activity in colorectal cancer patients with tumors that do not express the epidermal growth factor receptor by immunohistochemistry.. 23. 2005
Ewing sarcomas with p53 mutation or p16/p14ARF homozygous deletion: a highly lethal subset associated with poor chemoresponse.. 23. 2005
Prognostic implications of multiple lymphatic basin drainage in patients with truncal melanoma.. 23. 2005
Invasive lobular carcinoma classic type: response to primary chemotherapy and survival outcomes.. 23. 2005
Phase II clinical experience with the novel proteasome inhibitor bortezomib in patients with indolent non-Hodgkin's lymphoma and mantle cell lymphoma.. 23. 2004
Reduction from seven to five cycles of intensive induction chemotherapy in children with high-risk neuroblastoma.. 22. 2004
Angiogenesis inhibitor IM862 is ineffective against AIDS-Kaposi's sarcoma in a phase III trial, but demonstrates sustained, potent effect of highly active antiretroviral therapy: from the AIDS Malignancy Consortium and IM862 Study Team.. 23. 2004
Randomized multicenter phase II trial of bolus plus infusional fluorouracil/leucovorin compared with fluorouracil/leucovorin plus oxaliplatin as third-line treatment of patients with advanced colorectal cancer.. 22. 2004
Effect of addition of adjuvant paclitaxel on radiotherapy delivery and locoregional control of node-positive breast cancer: cancer and leukemia group B 9344.. 23. 2004
Phase II study of CT-2103 in patients with recurrent epithelial ovarian, fallopian tube, or primary peritoneal carcinoma.. 22. 2004
Identification of novel prognosticators of outcome in squamous cell carcinoma of the head and neck.. 22. 2004
Serial follow-up and the prognostic significance of reverse transcriptase-polymerase chain reaction--staged sentinel lymph nodes from melanoma patients.. 22. 2004
Phase II trial of bortezomib for patients with advanced renal cell carcinoma.. 22. 2004
Genetic variation in the leptin receptor gene and obesity in survivors of childhood acute lymphoblastic leukemia: a report from the Childhood Cancer Survivor Study.. 22. 2004
Use of surgery among elderly patients with stage IV colorectal cancer.. 22. 2004
Early detection and prognosis of ovarian cancer using serum YKL-40.. 22. 2004
Phase I and pharmacokinetic study of the novel oral cell-cycle inhibitor Ro 31-7453 in patients with advanced solid tumors.. 22. 2004
Evaluation of biologic end points and pharmacokinetics in patients with metastatic breast cancer after treatment with erlotinib, an epidermal growth factor receptor tyrosine kinase inhibitor.. 22. 2004
Treatment of metastatic Ewing's sarcoma or primitive neuroectodermal tumor of bone: evaluation of combination ifosfamide and etoposide--a Children's Cancer Group and Pediatric Oncology Group study.. 22. 2004
Cost minimization study of image-guided core biopsy versus surgical excisional biopsy for women with abnormal mammograms.. 22. 2004
Nonmyeloablative allogeneic hematopoietic transplantation: a promising salvage therapy for patients with non-Hodgkin's lymphoma whose disease has failed a prior autologous transplantation.. 22. 2004
Surgical factors influence bladder cancer outcomes: a cooperative group report.. 22. 2004
Failure of higher-dose paclitaxel to improve outcome in patients with metastatic breast cancer: cancer and leukemia group B trial 9342.. 22. 2004
Phase I trial of yttrium-90-labeled anti-prostate-specific membrane antigen monoclonal antibody J591 for androgen-independent prostate cancer.. 22. 2004
Thiotepa-based high-dose chemotherapy with autologous stem-cell rescue in patients with recurrent or progressive CNS germ cell tumors.. 22. 2004
Acupuncture for postchemotherapy fatigue: a phase II study.. 22. 2004
Association of preoperative plasma levels of vascular endothelial growth factor and soluble vascular cell adhesion molecule-1 with lymph node status and biochemical progression after radical prostatectomy.. 22. 2004
Phase II and pharmacokinetic study of ecteinascidin 743 in patients with progressive sarcomas of soft tissues refractory to chemotherapy.. 22. 2004
Using patients as their own controls for cost evaluation of phase I clinical trials.. 22. 2004
Phase I study of G3139, a bcl-2 antisense oligonucleotide, combined with carboplatin and etoposide in patients with small-cell lung cancer.. 22. 2004
Genetic variants in the UDP-glucuronosyltransferase 1A1 gene predict the risk of severe neutropenia of irinotecan.. 22. 2004
Gefitinib in combination with gemcitabine and cisplatin in advanced non-small-cell lung cancer: a phase III trial--INTACT 1.. 22. 2004
Gefitinib in combination with paclitaxel and carboplatin in advanced non-small-cell lung cancer: a phase III trial--INTACT 2.. 22. 2004
Pharmacokinetics and pharmacodynamics of imatinib in a phase I trial with chronic myeloid leukemia patients.. 22. 2004
Phase II trial of cetuximab in patients with refractory colorectal cancer that expresses the epidermal growth factor receptor.. 22. 2004
Primary chemotherapy for intracranial nongerminomatous germ cell tumors: results of the second international CNS germ cell study group protocol.. 22. 2004
Randomized phase II study of multiple dose levels of CCI-779, a novel mammalian target of rapamycin kinase inhibitor, in patients with advanced refractory renal cell carcinoma.. 22. 2004
p53, p21, pRB, and p16 expression predict clinical outcome in cystectomy with bladder cancer.. 22. 2004
Prognostic factors for survival in previously treated patients with metastatic renal cell carcinoma.. 22. 2004
Relapse-free and overall survival in patients with pathologic stage II nonseminomatous germ cell cancer treated with etoposide and cisplatin adjuvant chemotherapy.. 22. 2004
Selective CD4+ lymphopenia in melanoma patients treated with temozolomide: a toxicity with therapeutic implications.. 22. 2004
Multicenter phase II study of erlotinib, an oral epidermal growth factor receptor tyrosine kinase inhibitor, in patients with recurrent or metastatic squamous cell cancer of the head and neck.. 22. 2004
Phase I trial of combined-modality therapy for localized esophageal cancer: escalating doses of continuous-infusion paclitaxel with cisplatin and concurrent radiation therapy.. 22. 2004
Interaction of splenectomy and perioperative blood transfusions on prognosis of patients with proximal gastric and gastroesophageal junction cancer.. 21. 2003
Pretreatment nomogram that predicts 5-year probability of metastasis following three-dimensional conformal radiation therapy for localized prostate cancer.. 21. 2003
Chemotherapy for teratoma with malignant transformation.. 21. 2003
Fully synthetic carbohydrate-based vaccines in biochemically relapsed prostate cancer: clinical trial results with alpha-N-acetylgalactosamine-O-serine/threonine conjugate vaccine.. 21. 2003
Kinase mutations and imatinib response in patients with metastatic gastrointestinal stromal tumor.. 21. 2003
Intensive methotrexate and cytarabine followed by high-dose chemotherapy with autologous stem-cell rescue in patients with newly diagnosed primary CNS lymphoma: an intent-to-treat analysis.. 21. 2003
An attenuated adenovirus, ONYX-015, as mouthwash therapy for premalignant oral dysplasia.. 21. 2003
Phase III trial of long-term adjuvant androgen deprivation after neoadjuvant hormonal cytoreduction and radiotherapy in locally advanced carcinoma of the prostate: the Radiation Therapy Oncology Group Protocol 92-02.. 21. 2003
Three-arm randomized study of two cisplatin-based regimens and paclitaxel plus gemcitabine in advanced non-small-cell lung cancer: a phase III trial of the European Organization for Research and Treatment of Cancer Lung Cancer Group--EORTC 08975.. 21. 2003
Early molecular response of marrow disease to biologic therapy is highly prognostic in neuroblastoma.. 21. 2003
Postoperative nomogram for disease-specific survival after an R0 resection for gastric carcinoma.. 21. 2003
Long-term event-free survival after intensive chemotherapy for Ewing's family of tumors in children and young adults.. 21. 2003
Syngeneic hematopoietic stem-cell transplantation for non-Hodgkin's lymphoma: a comparison with allogeneic and autologous transplantation--The Lymphoma Working Committee of the International Bone Marrow Transplant Registry and the European Group for Blood and Marrow Transplantation.. 21. 2003
Long-term neurologic and neurosensory sequelae in adult survivors of a childhood brain tumor: childhood cancer survivor study.. 21. 2003
Phase I/II study of hepatic arterial therapy with floxuridine and dexamethasone in combination with intravenous irinotecan as adjuvant treatment after resection of hepatic metastases from colorectal cancer.. 21. 2003
Phase II study of temozolomide plus thalidomide for the treatment of metastatic melanoma.. 21. 2003
Vaccination with irradiated, autologous melanoma cells engineered to secrete granulocyte-macrophage colony-stimulating factor by adenoviral-mediated gene transfer augments antitumor immunity in patients with metastatic melanoma.. 21. 2003
Automated, multiplex assay for high-frequency microsatellite instability in colorectal cancer.. 21. 2003
Patterns of failure using a conformal radiation therapy tumor bed boost for medulloblastoma.. 21. 2003
The addition of interleukin-6 soluble receptor and transforming growth factor beta1 improves a preoperative nomogram for predicting biochemical progression in patients with clinically localized prostate cancer.. 21. 2003
Phase I trial of escalating-dose irinotecan given weekly with cisplatin and concurrent radiotherapy in locally advanced esophageal cancer.. 21. 2003
Safety and toxicity analysis of oxaliplatin combined with fluorouracil or as a single agent in patients with previously treated advanced colorectal cancer.. 21. 2003
Celecoxib, a selective cyclo-oxygenase-2 inhibitor, enhances the response to preoperative paclitaxel and carboplatin in early-stage non-small-cell lung cancer.. 21. 2003
Cluster analysis of p53 and Ki67 expression, apoptosis, alpha-fetoprotein, and human chorionic gonadotrophin indicates a favorable prognostic subgroup within the embryonal carcinoma germ cell tumor.. 21. 2003
Localized extremity soft tissue sarcoma: improved knowledge with unchanged survival over time.. 21. 2003
Phase III trial of carboplatin and paclitaxel compared with cisplatin and paclitaxel in patients with optimally resected stage III ovarian cancer: a Gynecologic Oncology Group study.. 21. 2003
Phase I/II trial of epratuzumab (humanized anti-CD22 antibody) in indolent non-Hodgkin's lymphoma.. 21. 2003
Phase II evaluation of temozolomide and 13-cis-retinoic acid for the treatment of recurrent and progressive malignant glioma: a North American Brain Tumor Consortium study.. 21. 2003
Phase II trial of thalidomide and carmustine for patients with recurrent high-grade gliomas.. 21. 2003
Pilot trial of the epidermal growth factor receptor tyrosine kinase inhibitor gefitinib plus carboplatin and paclitaxel in patients with stage IIIB or IV non-small-cell lung cancer.. 21. 2003
Quality of life in patients with newly diagnosed chronic phase chronic myeloid leukemia on imatinib versus interferon alfa plus low-dose cytarabine: results from the IRIS Study.. 21. 2003
Multi-institutional randomized phase II trial of gefitinib for previously treated patients with advanced non-small-cell lung cancer (The IDEAL 1 Trial) [corrected].. 21. 2003
Classification of clear-cell sarcoma as a subtype of melanoma by genomic profiling.. 21. 2003
Natural history of more than 20 years of node-positive primary breast carcinoma treated with cyclophosphamide, methotrexate, and fluorouracil-based adjuvant chemotherapy: a study by the Cancer and Leukemia Group B.. 21. 2003
Phase III study of cyclophosphamide, doxorubicin, and fluorouracil (CAF) plus leucovorin versus CAF for metastatic breast cancer: Cancer and Leukemia Group B 9140.. 21. 2003
Randomized controlled trial of exercise training in postmenopausal breast cancer survivors: cardiopulmonary and quality of life outcomes.. 21. 2003
Resistance exercise in men receiving androgen deprivation therapy for prostate cancer.. 21. 2003
Human granulocyte colony-stimulating factor in children with high-risk acute lymphoblastic leukemia: a Children's Cancer Group Study.. 21. 2003
Detection of clinically significant, occult prostate cancer metastases in lymph nodes using a splice variant-specific rt-PCR assay for human glandular kallikrein.. 21. 2003
Obesity in adult survivors of childhood acute lymphoblastic leukemia: a report from the Childhood Cancer Survivor Study.. 21. 2003
Pentostatin and cyclophosphamide: an effective new regimen in previously treated patients with chronic lymphocytic leukemia.. 21. 2003
Impact of metaiodobenzylguanidine scintigraphy on assessing response of high-risk neuroblastoma to dose-intensive induction chemotherapy.. 21. 2003
Improved outcomes from adding sequential Paclitaxel but not from escalating Doxorubicin dose in an adjuvant chemotherapy regimen for patients with node-positive primary breast cancer.. 21. 2003
Quantitation of GD2 synthase mRNA by real-time reverse transcriptase polymerase chain reaction: clinical utility in evaluating adjuvant therapy in neuroblastoma.. 21. 2003
Preoperative twice-weekly paclitaxel with concurrent radiation therapy followed by surgery and postoperative doxorubicin-based chemotherapy in locally advanced breast cancer: a phase I/II trial.. 21. 2003
Randomized trial of dose-dense versus conventionally scheduled and sequential versus concurrent combination chemotherapy as postoperative adjuvant treatment of node-positive primary breast cancer: first report of Intergroup Trial C9741/Cancer and Leukemia Group B Trial 9741.. 21. 2003
Predictors of biochemical outcome with salvage conformal radiotherapy after radical prostatectomy for prostate cancer.. 21. 2003
Role of surgeon volume in radical prostatectomy outcomes.. 21. 2003
Thymidylate synthase expression in hepatic tumors is a predictor of survival and progression in patients with resectable metastatic colorectal cancer.. 21. 2003
Whole body 18FDG-PET and the response of esophageal cancer to induction therapy: results of a prospective trial.. 21. 2003
Metachronous skeletal osteosarcoma in patients treated with adjuvant and neoadjuvant chemotherapy for nonmetastatic osteosarcoma.. 21. 2003
Clinical characteristics and outcomes from an institutional series of acinar cell carcinoma of the pancreas and related tumors.. 20. 2002
Combination chemotherapy and radiotherapy for primary central nervous system lymphoma: Radiation Therapy Oncology Group Study 93-10.. 20. 2002
Prospective, randomized, double-blind, placebo-controlled trial of marimastat after response to first-line chemotherapy in patients with small-cell lung cancer: a trial of the National Cancer Institute of Canada-Clinical Trials Group and the European Organization for Research and Treatment of Cancer.. 20. 2002
Primary adult soft tissue sarcoma: time-dependent influence of prognostic variables.. 20. 2002
Diagnostic and prognostic value of [(18)F]fluorodeoxyglucose positron emission tomography for recurrent head and neck squamous cell carcinoma.. 20. 2002
Adjuvant chemotherapy use for Medicare beneficiaries with stage II colon cancer.. 20. 2002
Nomogram for overall survival of patients with progressive metastatic prostate cancer after castration.. 20. 2002
Standard versus intensified chemotherapy with granulocyte colony-stimulating factor support in small-cell lung cancer: a prospective European Organization for Research and Treatment of Cancer-Lung Cancer Group Phase III Trial-08923.. 20. 2002
Use of epoetin in patients with cancer: evidence-based clinical practice guidelines of the American Society of Clinical Oncology and the American Society of Hematology.. 20. 2002
Prognostic value of KIT mutation type, mitotic activity, and histologic subtype in gastrointestinal stromal tumors.. 20. 2002
Lack of effect of a low-fat, high-fruit, -vegetable, and -fiber diet on serum prostate-specific antigen of men without prostate cancer: results from a randomized trial.. 20. 2002
Prospective exploratory analysis of the association between tumor response, quality of life, and expenditures among patients receiving paclitaxel monotherapy for refractory metastatic breast cancer.. 20. 2002
Revision of the American Joint Committee on Cancer staging system for breast cancer.. 20. 2002
Complication rates among cancer patients with peripherally inserted central catheters.. 20. 2002
International validation of a preoperative nomogram for prostate cancer recurrence after radical prostatectomy.. 20. 2002
Phase I trial of intravesical gemcitabine in bacillus Calmette-Guérin-refractory transitional-cell carcinoma of the bladder.. 20. 2002
Alteration of p53 pathway in squamous cell carcinoma of the head and neck: impact on treatment outcome in patients treated with larynx preservation intent.. 20. 2002
Gemcitabine and docetaxel in patients with unresectable leiomyosarcoma: results of a phase II trial.. 20. 2002
Prognostic factors in pancreatic endocrine neoplasms: an analysis of 136 cases with a proposal for low-grade and intermediate-grade groups.. 20. 2002
Temozolomide plus thalidomide in patients with advanced melanoma: results of a dose-finding trial.. 20. 2002
Assessment of molecular markers of clinical sensitivity to single-agent taxane therapy for metastatic breast cancer.. 20. 2002
Measuring health-related quality of life in patients with hepatobiliary cancers: the functional assessment of cancer therapy-hepatobiliary questionnaire.. 20. 2002
Temporal change in risk of metachronous contralateral renal cell carcinoma: influence of tumor characteristics and demographic factors.. 20. 2002
Treatment outcome and survival associated with metastatic renal cell carcinoma of non-clear-cell histology.. 20. 2002
ZD1839, a selective oral epidermal growth factor receptor-tyrosine kinase inhibitor, is well tolerated and active in patients with solid, malignant tumors: results of a phase I trial.. 20. 2002
Analysis of clinical stage T2 prostate cancer: do current subclassifications represent an improvement?. 20. 2002
Long-term results of combined-modality therapy in resectable non-small-cell lung cancer.. 20. 2002
Phase I study of the cyclin-dependent kinase inhibitor flavopiridol in combination with paclitaxel in patients with advanced solid tumors.. 20. 2002
Phase II study of weekly docetaxel and trastuzumab for patients with HER-2-overexpressing metastatic breast cancer.. 20. 2002
Safe and cost effective use of alteplase for the clearance of occluded central venous access devices.. 20. 2002
Adjuvant radiation for stage II-B soft tissue sarcoma of the extremity.. 20. 2002
Dose-finding and pharmacokinetic study of cisplatin, gemcitabine, and SU5416 in patients with solid tumors.. 20. 2002
Cardiac dysfunction in the trastuzumab clinical trials experience.. 20. 2002
Clinical factors associated with cancer-related fatigue in patients being treated for leukemia and non-Hodgkin's lymphoma.. 20. 2002
INT 0123 (Radiation Therapy Oncology Group 94-05) phase III trial of combined-modality therapy for esophageal cancer: high-dose versus standard-dose radiation therapy.. 20. 2002
Outcome of preventive surgery and screening for breast and ovarian cancer in BRCA mutation carriers.. 20. 2002
Retrospective analysis of carboplatin and paclitaxel as initial second-line therapy for recurrent epithelial ovarian carcinoma: application toward a dynamic disease state model of ovarian cancer.. 20. 2002
Adrenocortical carcinoma: clinical, morphologic, and molecular characterization.. 20. 2002
Validation study of the accuracy of a postoperative nomogram for recurrence after radical prostatectomy for localized prostate cancer.. 20. 2002
Association of angiogenesis and disease outcome in node-positive breast cancer patients treated with adjuvant cyclophosphamide, doxorubicin, and fluorouracil: a Cancer and Leukemia Group B correlative science study from protocols 8541/8869.. 20. 2002
Association of preoperative plasma levels of insulin-like growth factor I and insulin-like growth factor binding proteins-2 and -3 with prostate cancer invasion, progression, and metastasis.. 20. 2002
Does menopausal hormone replacement therapy interact with known factors to increase risk of breast cancer?. 20. 2002
High-dose versus standard chemotherapy in metastatic breast cancer: comparison of Cancer and Leukemia Group B trials with data from the Autologous Blood and Marrow Transplant Registry.. 20. 2002
Intraperitoneal chemotherapy for ovarian carcinoma: results of long-term follow-up.. 20. 2002
Postoperative nomogram for 12-year sarcoma-specific death.. 20. 2002
Neuropsychologic impact of standard-dose systemic chemotherapy in long-term survivors of breast cancer and lymphoma.. 20. 2002
Prospective trial of chemotherapy and donor leukocyte infusions for relapse of advanced myeloid malignancies after allogeneic stem-cell transplantation.. 20. 2002
Interferon-alfa as a comparative treatment for clinical trials of new therapies against advanced renal cell carcinoma.. 20. 2002
Phase II trial of thalidomide for patients with advanced renal cell carcinoma.. 20. 2002
Salvage chemotherapy for patients with advanced pure seminoma.. 20. 2002
Troxacitabine, an L-stereoisomeric nucleoside analog, on a five-times-daily schedule: a phase I and pharmacokinetic study in patients with advanced solid malignancies.. 20. 2002
Phase II trial of the anti-G(D2) monoclonal antibody 3F8 and granulocyte-macrophage colony-stimulating factor for neuroblastoma.. 19. 2001
Pivotal study of iodine I 131 tositumomab for chemotherapy-refractory low-grade or transformed low-grade B-cell non-Hodgkin's lymphomas.. 19. 2001
United States multicenter study of arsenic trioxide in relapsed acute promyelocytic leukemia.. 19. 2001
Impact of high-dose chemotherapy on peripheral T-cell lymphomas.. 19. 2001
Who gets adjuvant treatment for stage II and III rectal cancer? Insight from surveillance, epidemiology, and end results--Medicare.. 19. 2001
Immunomagnetic purging of Ewing's sarcoma from blood and bone marrow: quantitation by real-time polymerase chain reaction.. 19. 2001
Prognostic factors analysis of 17,600 melanoma patients: validation of the American Joint Committee on Cancer melanoma staging system.. 19. 2001
Cancer-related fatigue: prevalence of proposed diagnostic criteria in a United States sample of cancer survivors.. 19. 2001
Extending positron emission tomography scan utility to high-risk neuroblastoma: fluorine-18 fluorodeoxyglucose positron emission tomography as sole imaging modality in follow-up of patients.. 19. 2001
Phase I and pharmacologic study of OSI-774, an epidermal growth factor receptor tyrosine kinase inhibitor, in patients with advanced solid malignancies.. 19. 2001
High-dose melphalan, etoposide, total-body irradiation, and autologous stem-cell reconstitution as consolidation therapy for high-risk Ewing's sarcoma does not improve prognosis.. 19. 2001
Hyperfractionated low-dose radiotherapy for high-risk neuroblastoma after intensive chemotherapy and surgery.. 19. 2001
Phase I and pharmacokinetic study of NSC 655649, a rebeccamycin analog with topoisomerase inhibitory properties.. 19. 2001
Preoperative plasma levels of transforming growth factor beta(1) (TGF-beta(1)) strongly predict progression in patients undergoing radical prostatectomy.. 19. 2001
Hürthle cell carcinoma: a critical histopathologic appraisal.. 19. 2001
Phase I study of hepatic arterial infusion of floxuridine and dexamethasone with systemic irinotecan for unresectable hepatic metastases from colorectal cancer.. 19. 2001
Randomized phase III trial of high-dose-intensity methotrexate, vinblastine, doxorubicin, and cisplatin (MVAC) chemotherapy and recombinant human granulocyte colony-stimulating factor versus classic MVAC in advanced urothelial tract tumors: European Organization for Research and Treatment of Cancer Protocol no. 30924.. 19. 2001
Randomized trial of black cohosh for the treatment of hot flashes among women with a history of breast cancer.. 19. 2001
Weekly trastuzumab and paclitaxel therapy for metastatic breast cancer with analysis of efficacy by HER2 immunophenotype and gene amplification.. 19. 2001
Phase I and pharmacokinetic study of BMS-184476, a taxane with greater potency and solubility than paclitaxel.. 19. 2001
Predicting outcome to chemotherapy in patients with germ cell tumors: the value of the rate of decline of human chorionic gonadotrophin and alpha-fetoprotein during therapy.. 19. 2001
Factors predicting the use of breast-conserving therapy in stage I and II breast carcinoma.. 19. 2001
Impact of systemic treatment on local control for patients with lymph node-negative breast cancer treated with breast-conservation therapy.. 19. 2001
Duration of hospitalization as a measure of cost on Children's Cancer Group acute lymphoblastic leukemia studies.. 19. 2001
Low-volume nodal metastases detected at retroperitoneal lymphadenectomy for testicular cancer: pattern and prognostic factors for relapse.. 19. 2001
Phase I study of a third-generation selective estrogen receptor modulator, LY353381.HCL, in metastatic breast cancer.. 19. 2001
Phase II study of the cyclin-dependent kinase inhibitor flavopiridol administered to patients with advanced gastric carcinoma.. 19. 2001
High-dose interferon alfa-2b does not diminish antibody response to GM2 vaccination in patients with resected melanoma: results of the Multicenter Eastern Cooperative Oncology Group Phase II Trial E2696.. 19. 2001
Phase I trial of 40-kd branched pegylated interferon alfa-2a for patients with advanced renal cell carcinoma.. 19. 2001
Accelerated concomitant boost radiotherapy and chemotherapy for advanced nasopharyngeal carcinoma.. 19. 2001
Prediction of response to salvage radiation therapy in patients with prostate cancer recurrence after radical prostatectomy.. 19. 2001
Pilot trial of interleukin-2 with granulocyte colony-stimulating factor for the mobilization of progenitor cells in advanced breast cancer patients undergoing high-dose chemotherapy: expansion of immune effectors within the stem-cell graft and post-stem-cell infusion.. 19. 2001
Radical cystectomy in the treatment of invasive bladder cancer: long-term results in 1,054 patients.. 19. 2001
Role of postchemotherapy adjunctive surgery in the management of patients with nonseminoma arising from the mediastinum.. 19. 2001
Autologous transplantation for diffuse aggressive non-Hodgkin's lymphoma in patients never achieving remission: a report from the Autologous Blood and Marrow Transplant Registry.. 19. 2001
Paclitaxel, estramustine phosphate, and carboplatin in patients with advanced prostate cancer.. 19. 2001
Transurethral resection of muscle-invasive bladder cancer: 10-year outcome.. 19. 2001
Upper-tract tumors after an initial diagnosis of bladder cancer: argument for long-term surveillance.. 19. 2001
Phase I and pharmacokinetic study of irofulven, a novel mushroom-derived cytotoxin, administered for five consecutive days every four weeks in patients with advanced solid malignancies.. 18. 2000
Phase I and pharmacokinetic study of the differentiating agent vesnarinone in combination with gemcitabine in patients with advanced cancer.. 18. 2000
Abnormalities of chromosome bands 13q12 to 13q14 in childhood acute lymphoblastic leukemia.. 18. 2000
HER-2/neu and p53 expression versus tamoxifen resistance in estrogen receptor-positive, node-positive breast cancer.. 18. 2000
Sentinel lymph node biopsy is accurate after neoadjuvant chemotherapy for breast cancer.. 18. 2000
Pretreatment nomogram for predicting the outcome of three-dimensional conformal radiotherapy in prostate cancer.. 18. 2000
Treatment of brain metastases of small-cell lung cancer: comparing teniposide and teniposide with whole-brain radiotherapy--a phase III study of the European Organization for the Research and Treatment of Cancer Lung Cancer Cooperative Group.. 18. 2000
Treatment for primary CNS lymphoma: the next step.. 18. 2000
Phase III trial of interferon alfa-2a with or without 13-cis-retinoic acid for patients with advanced renal cell carcinoma.. 18. 2000
Gemcitabine and cisplatin as induction regimen for patients with biopsy-proven stage IIIA N2 non-small-cell lung cancer: a phase II study of the European Organization for Research and Treatment of Cancer Lung Cancer Cooperative Group (EORTC 08955).. 18. 2000
Leukocytosis and the retinoic acid syndrome in patients with acute promyelocytic leukemia treated with arsenic trioxide.. 18. 2000
MDR1 gene expression and outcome in osteosarcoma: a prospective, multicenter study.. 18. 2000
Phase I clinical and pharmacokinetic study of oral S-1 in patients with advanced solid tumors.. 18. 2000
Southwest Oncology Group Study of paclitaxel and carboplatin for advanced transitional-cell carcinoma: the importance of survival as a clinical trial end point.. 18. 2000
Paclitaxel, ifosfamide, and cisplatin second-line therapy for patients with relapsed testicular germ cell cancer.. 18. 2000
Randomized phase III trial of docetaxel versus vinorelbine or ifosfamide in patients with advanced non-small-cell lung cancer previously treated with platinum-containing chemotherapy regimens. The TAX 320 Non-Small Cell Lung Cancer Study Group.. 18. 2000
Early detection of relapse by hypermetaphase fluorescence in situ hybridization after allogeneic bone marrow transplantation for chronic myeloid leukemia.. 18. 2000
Effect of cytokine therapy on survival for patients with advanced renal cell carcinoma.. 18. 2000
Evaluation of tumor measurements in oncology: use of film-based and electronic techniques.. 18. 2000
Prognostic impact of trisomies of chromosomes 10, 17, and 5 among children with acute lymphoblastic leukemia and high hyperdiploidy (> 50 chromosomes).. 18. 2000
Results of a phase II study using estramustine phosphate and vinblastine in combination with high-dose three-dimensional conformal radiotherapy for patients with locally advanced prostate cancer.. 18. 2000
Rifampin does not improve the efficacy of quinolone antibacterial prophylaxis in neutropenic cancer patients: results of a randomized clinical trial.. 18. 2000
Synovial sarcoma: a multivariate analysis of prognostic factors in 112 patients with primary localized tumors of the extremity.. 18. 2000
Influence of biologic factors and anatomic site in completely resected liposarcoma.. 18. 2000
Multicenter phase II study of iodine-131 tositumomab for chemotherapy-relapsed/refractory low-grade and transformed low-grade B-cell non-Hodgkin's lymphomas.. 18. 2000
Phase II trial of docetaxel and vinorelbine in patients with advanced non-small-cell lung cancer.. 18. 2000
Prospective analysis of Staphylococcus aureus bacteremia in nonneutropenic adults with malignancy.. 18. 2000
Risk factors for severe neuropsychiatric toxicity in patients receiving interferon alfa-2b and low-dose cytarabine for chronic myelogenous leukemia: analysis of Cancer and Leukemia Group B 9013.. 18. 2000
Sequential dose-intensive paclitaxel, ifosfamide, carboplatin, and etoposide salvage therapy for germ cell tumor patients.. 18. 2000
Phase I evaluation of sequential doxorubicin gemcitabine then ifosfamide paclitaxel cisplatin for patients with unresectable or metastatic transitional-cell carcinoma of the urothelial tract.. 18. 2000
Phase I studies of anti-epidermal growth factor receptor chimeric antibody C225 alone and in combination with cisplatin.. 18. 2000
Phase II evaluation of preoperative chemoradiation and postoperative adjuvant chemotherapy for squamous cell and adenocarcinoma of the esophagus.. 18. 2000
Phase II trial of the antiangiogenic agent thalidomide in patients with recurrent high-grade gliomas.. 18. 2000
Comparison of preparative regimens in transplants for children with acute lymphoblastic leukemia.. 18. 2000
New malignant diseases after allogeneic marrow transplantation for childhood acute leukemia.. 18. 2000
Phase I and pharmacologic study of PN401 and fluorouracil in patients with advanced solid malignancies.. 18. 2000
Phase I and pharmacologic study of the specific matrix metalloproteinase inhibitor BAY 12-9566 on a protracted oral daily dosing schedule in patients with solid malignancies.. 18. 2000
Expression of aberrantly spliced oncogenic ikaros isoforms in childhood acute lymphoblastic leukemia.. 17. 1999
Ifosfamide, carboplatin, and etoposide: a highly effective cytoreduction and peripheral-blood progenitor-cell mobilization regimen for transplant-eligible patients with non-Hodgkin's lymphoma.. 17. 1999
Eligibility and response guidelines for phase II clinical trials in androgen-independent prostate cancer: recommendations from the Prostate-Specific Antigen Working Group.. 17. 1999
Biologic markers as predictors of clinical outcome from systemic therapy for primary operable breast cancer.. 17. 1999
Long-term outcomes after function-sparing surgery without radiotherapy for soft tissue sarcoma of the extremities and trunk.. 17. 1999
Long-term survival in metastatic transitional-cell carcinoma and prognostic factors predicting outcome of therapy.. 17. 1999
Oral etoposide for refractory and relapsed neuroblastoma.. 17. 1999
Phase II trial of weekly irinotecan plus cisplatin in advanced esophageal cancer.. 17. 1999
Expression of HER2/erbB-2 correlates with survival in osteosarcoma.. 17. 1999
Phase III multicenter randomized trial of the Dartmouth regimen versus dacarbazine in patients with metastatic melanoma.. 17. 1999
Outcome of postchemotherapy surgery after treatment with methotrexate, vinblastine, doxorubicin, and cisplatin in patients with unresectable or metastatic transitional cell carcinoma.. 17. 1999
Survival and prognostic stratification of 670 patients with advanced renal cell carcinoma.. 17. 1999
Gemcitabine and paclitaxel: pharmacokinetic and pharmacodynamic interactions in patients with non-small-cell lung cancer.. 17. 1999
Quality-adjusted survival after treatment for acute myeloid leukemia in childhood: A Q-TWiST analysis of the Pediatric Oncology Group Study 8821.. 17. 1999
Postoperative nomogram for disease recurrence after radical prostatectomy for prostate cancer.. 17. 1999
Safety and efficacy of using a single agent or a phase II agent before instituting standard combination chemotherapy in previously untreated metastatic breast cancer patients: report of a randomized study--Cancer and Leukemia Group B 8642.. 17. 1999
5-year results of dose-intensive sequential adjuvant chemotherapy for women with high-risk node-positive breast cancer: A phase II study.. 17. 1999
Outcome for cancer patients requiring mechanical ventilation.. 17. 1999
Prognostic significance of extent of disease in bone in patients with androgen-independent prostate cancer.. 17. 1999
Autotransplants for Hodgkin's disease in patients never achieving remission: a report from the Autologous Blood and Marrow Transplant Registry.. 17. 1999
Clinical course of breast cancer patients with complete pathologic primary tumor and axillary lymph node response to doxorubicin-based neoadjuvant chemotherapy.. 17. 1999
Comparison of the 5-year outcome and morbidity of three-dimensional conformal radiotherapy versus transperineal permanent iodine-125 implantation for early-stage prostatic cancer.. 17. 1999
Octreotide acetate long-acting formulation versus open-label subcutaneous octreotide acetate in malignant carcinoid syndrome.. 17. 1999
Phase I-II study of gemcitabine and fluorouracil as a continuous infusion in patients with pancreatic cancer.. 17. 1999
Treatment outcome and prognostic factors for infants with acute lymphoblastic leukemia treated on two consecutive trials of the Children's Cancer Group.. 17. 1999
Allogeneic bone marrow transplantation versus chemotherapy for the treatment of childhood acute lymphoblastic leukemia in second remission: a single-institution study.. 17. 1999
Dose-response trial of megestrol acetate in advanced breast cancer: cancer and leukemia group B phase III study 8741.. 17. 1999
Sequential dose-dense doxorubicin, paclitaxel, and cyclophosphamide for resectable high-risk breast cancer: feasibility and efficacy.. 17. 1999
Treatment of Philadelphia chromosome-positive early chronic phase chronic myelogenous leukemia with daily doses of interferon alpha and low-dose cytarabine.. 17. 1999
Hyper-CVAD and high-dose methotrexate/cytarabine followed by stem-cell transplantation: an active regimen for aggressive mantle-cell lymphoma.. 16. 1998
Phase I clinical and pharmacologic study of weekly cisplatin combined with weekly irinotecan in patients with advanced solid tumors.. 16. 1998
Predictors of improved outcome for patients with localized prostate cancer treated with neoadjuvant androgen ablation therapy and three-dimensional conformal radiotherapy.. 16. 1998
Quality-of-life benefit in chemotherapy patients treated with epoetin alfa is independent of disease response or tumor type: results from a prospective community oncology study. Procrit Study Group.. 16. 1998
Anti-G(D2) antibody treatment of minimal residual stage 4 neuroblastoma diagnosed at more than 1 year of age.. 16. 1998
Clinical, pathologic, and molecular spectrum of tumors associated with t(11;22)(p13;q12): desmoplastic small round-cell tumor and its variants.. 16. 1998
High risk of leukemia after short-term dose-intensive chemotherapy in young patients with solid tumors.. 16. 1998
Postmastectomy radiotherapy: questions for the twenty-first century.. 16. 1998
Transplant-lite: induction of graft-versus-malignancy using fludarabine-based nonablative chemotherapy and allogeneic blood progenitor-cell transplantation as treatment for lymphoid malignancies.. 16. 1998
Treatment of patients with transitional-cell carcinoma of the urothelial tract with ifosfamide, paclitaxel, and cisplatin: a phase II trial.. 16. 1998
Intensification of preoperative chemotherapy for osteogenic sarcoma: results of the Memorial Sloan-Kettering (T12) protocol.. 16. 1998
Myeloablative chemotherapy with autologous bone marrow rescue in young children with recurrent malignant brain tumors.. 16. 1998
Sequence analysis of BRCA1 and BRCA2: correlation of mutations with family history and ovarian cancer risk.. 16. 1998
Prostate-specific antigen doubling times are similar in patients with recurrence after radical prostatectomy or radiotherapy: a novel analysis.. 16. 1998
Randomized study of paclitaxel-cisplatin versus cisplatin-teniposide in patients with advanced non-small-cell lung cancer. The European Organization for Research and Treatment of Cancer Lung Cancer Cooperative Group.. 16. 1998
Resection of metastatic renal cell carcinoma.. 16. 1998
Risk factors for treatment-related death in elderly patients with aggressive non-Hodgkin's lymphoma: results of a multivariate analysis.. 16. 1998
BRCA-associated breast cancer in young women.. 16. 1998
Diagnosis in oncology. Askin tumor.. 16. 1998
Emerging role of laparoscopy in the diagnosis of lymphoma.. 16. 1998
High-dose induction chemoradiotherapy followed by autologous bone marrow transplantation as consolidation therapy in rhabdomyosarcoma, extraosseous Ewing's sarcoma, and undifferentiated sarcoma.. 16. 1998
Phase II study of "dose-dense" high-dose chemotherapy treatment with peripheral-blood progenitor-cell support as primary treatment for patients with advanced ovarian cancer.. 16. 1998
Phase II trial of paclitaxel, fluorouracil, and cisplatin in patients with advanced carcinoma of the esophagus.. 16. 1998
Psychologic and neuropsychologic functioning of patients with limited small-cell lung cancer treated with chemotherapy and radiation therapy with or without warfarin: a study by the Cancer and Leukemia Group B.. 16. 1998
Treatment of mucosa-associated lymphoid tissue lymphoma of the stomach with radiation alone.. 16. 1998
EWS-FLI1 fusion transcript structure is an independent determinant of prognosis in Ewing's sarcoma.. 16. 1998
Frequency and clinical significance of cytogenetic abnormalities in pediatric T-lineage acute lymphoblastic leukemia: a report from the Children's Cancer Group.. 16. 1998
Higher levels of thymidylate synthase gene expression are observed in pulmonary as compared with hepatic metastases of colorectal adenocarcinoma.. 16. 1998
Neoadjuvant chemotherapy and bladder-sparing surgery for invasive bladder cancer: ten-year outcome.. 16. 1998
Allogeneic peripheral-blood progenitor-cell transplantation for poor-risk patients with metastatic breast cancer.. 16. 1998
Detection of thyroglobulin, thyroid peroxidase, and RET/PTC1 mRNA transcripts in the peripheral blood of patients with thyroid disease.. 16. 1998
Extravesical tumor relapse in patients with superficial bladder tumors.. 16. 1998
Long-term survival in primary CNS lymphoma.. 16. 1998
Assuring the optimal use of serotonin antagonist antiemetics: the process for development and implementation of institutional antiemetic guidelines at Memorial Sloan-Kettering Cancer Center.. 16. 1998
Clinical significance of translocation t(1;19) in childhood acute lymphoblastic leukemia in the context of contemporary therapies: a report from the Children's Cancer Group.. 16. 1998
Metastatic germ cell tumors: modeling for response to chemotherapy.. 16. 1998
Multicenter outcome study of cancer patients admitted to the intensive care unit: a probability of mortality model.. 16. 1998
Paternity in men with stage I testis tumors on surveillance.. 16. 1998
High-dose carboplatin, thiotepa, and etoposide with autologous stem-cell rescue for patients with recurrent medulloblastoma. Children's Cancer Group.. 16. 1998
High-dose chemotherapy for relapsed and refractory diffuse large B-cell lymphoma: mediastinal localization predicts for a favorable outcome.. 16. 1998
Intensive chemotherapy and bone marrow rescue for young children with newly diagnosed malignant brain tumors.. 16. 1998
Population pharmacokinetics/pharmacodynamics of docetaxel in phase II studies in patients with cancer.. 16. 1998
Use of octreotide in the symptomatic management of diarrhea induced by graft-versus-host disease in patients with hematologic malignancies.. 15. 1997
Fifteen-year survival and recurrence rates after radiotherapy for localized prostate cancer.. 15. 1997
Patient selection in high-dose chemotherapy trials: relevance in high-risk breast cancer.. 15. 1997
Bicalutamide for advanced prostate cancer: the natural versus treated history of disease.. 15. 1997
Detection of metastatic neuroblastoma in bone marrow: when is routine marrow histology insensitive?. 15. 1997
Prognostic factors associated with long-term survival for retroperitoneal sarcoma: implications for management.. 15. 1997
Randomized trial of alternating versus sequential radiotherapy/chemotherapy in limited-disease patients with small-cell lung cancer: a European Organization for Research and Treatment of Cancer Lung Cancer Cooperative Group Study.. 15. 1997
High-dose carboplatin, etoposide, and cyclophosphamide with autologous bone marrow transplantation in first-line therapy for patients with poor-risk germ cell tumors.. 15. 1997
Ifosfamide- and cisplatin-containing chemotherapy as first-line salvage therapy in germ cell tumors: response and survival.. 15. 1997
Long-term follow-up of patients with good-risk germ cell tumors treated with etoposide and cisplatin.. 15. 1997
Clinical features and treatment outcome of childhood T-lineage acute lymphoblastic leukemia according to the apparent maturational stage of T-lineage leukemic blasts: a Children's Cancer Group study.. 15. 1997
Cytotoxic therapy-induced D-xylose malabsorption and invasive infection during remission-induction therapy for acute myeloid leukemia in adults.. 15. 1997
Phase II randomized trial of gallium nitrate plus fluorouracil versus methotrexate, vinblastine, doxorubicin, and cisplatin in patients with advanced transitional-cell carcinoma.. 15. 1997
Prognostic value of the expression of p53, bcl-2, and bax oncoproteins, and neovascularization in patients with radically resected non-small-cell lung cancer.. 15. 1997
Endoscopic ultrasound in the evaluation of gastric small lymphocytic mucosa-associated lymphoid tumors.. 15. 1997
Phase I trial of dose-intense liposome-encapsulated doxorubicin in patients with advanced sarcoma.. 15. 1997
Phase II trial of docetaxel in patients with advanced or metastatic transitional-cell carcinoma.. 15. 1997
Prevention of acute emesis in cancer patients following high-dose cisplatin with the combination of oral dolasetron and dexamethasone.. 15. 1997
Topotecan, a new active drug in the second-line treatment of small-cell lung cancer: a phase II study in patients with refractory and sensitive disease. The European Organization for Research and Treatment of Cancer Early Clinical Studies Group and New Drug Development Office, and the Lung Cancer Cooperative Group.. 15. 1997
Fatty acid composition of adipose tissue, an indication of dietary fatty acids, and breast cancer prognosis.. 15. 1997
Phase I trial of PN401, an oral prodrug of uridine, to prevent toxicity from fluorouracil in patients with advanced cancer.. 15. 1997
Liver resection for colorectal metastases.. 15. 1997
Association of local recurrence with subsequent survival in extremity soft tissue sarcoma.. 15. 1997
Initial clinical trial of a selective retinoid X receptor ligand, LGD1069.. 15. 1997
Phase I trial of cyclosporine-induced autologous graft-versus-host disease in patients with multiple myeloma undergoing high-dose chemotherapy with autologous stem-cell rescue.. 15. 1997
Pharmacokinetics of paclitaxel and carboplatin in a dose-escalating and dose-sequencing study in patients with non-small-cell lung cancer. The European Cancer Centre.. 15. 1997
Phase I and pharmacologic study of paclitaxel administered weekly in patients with relapsed ovarian cancer.. 15. 1997
Phase I clinical and laboratory evaluation of topotecan and cytarabine in patients with acute leukemia.. 15. 1997
Value of molecular monitoring during the treatment of chronic myeloid leukemia: a Cancer and Leukemia Group B study.. 15. 1997
Chemotherapy without irradiation--a novel approach for newly diagnosed CNS germ cell tumors: results of an international cooperative trial. The First International Central Nervous System Germ Cell Tumor Study.. 14. 1996
Impact of preexisting CNS involvement on the outcome of bone marrow transplantation in adult hematologic malignancies.. 14. 1996
Phase I clinical and pharmacokinetic study of irinotecan, fluorouracil, and leucovorin in patients with advanced solid tumors.. 14. 1996
Overexpression of p53 protein in a high-risk population of patients with superficial bladder cancer before and after bacillus Calmette-Guérin therapy: correlation to clinical outcome.. 14. 1996
p53 nuclear protein overexpression in colorectal cancer: a dominant predictor of survival in patients with advanced hepatic metastases.. 14. 1996
Cytarabine with high-dose mitoxantrone induces rapid complete remissions in adult acute lymphoblastic leukemia without the use of vincristine or prednisone.. 14. 1996
Double-blind, randomized comparison of the antiemetic efficacy of intravenous dolasetron mesylate and intravenous ondansetron in the prevention of acute cisplatin-induced emesis in patients with cancer. Dolasetron Comparative Chemotherapy-induced Emesis Prevention Group.. 14. 1996
Carboxypeptidase G2 rescue after high-dose methotrexate.. 14. 1996
Influence of inflammatory bowel disease on the ability of patients to tolerate systemic fluorouracil-based chemotherapy.. 14. 1996
Neoadjuvant therapy of high-risk gastric cancer: a phase II trial of preoperative FAMTX and postoperative intraperitoneal fluorouracil-cisplatin plus intravenous fluorouracil.. 14. 1996
Ninety-six-hour paclitaxel infusion after progression during short taxane exposure: a phase II pharmacokinetic and pharmacodynamic study in metastatic breast cancer.. 14. 1996
Phase I trial of iodine 131-labeled COL-1 in patients with gastrointestinal malignancies: influence of serum carcinoembryonic antigen and tumor bulk on pharmacokinetics.. 14. 1996
Phase I/II study of iodine 125-labeled monoclonal antibody A33 in patients with advanced colon cancer.. 14. 1996
Simultaneous retroperitoneal, thoracic, and cervical resection of postchemotherapy residual masses in patients with metastatic nonseminomatous germ cell tumors of the testis.. 14. 1996
Tobacco control: reducing cancer incidence and saving lives. American Society of Clinical Oncology.. 14. 1996
Analysis of prognostic factors in 1,041 patients with localized soft tissue sarcomas of the extremities.. 14. 1996
Desmoplastic small round-cell tumor: prolonged progression-free survival with aggressive multimodality therapy.. 14. 1996
Doxorubicin and dose-escalated cyclophosphamide with granulocyte colony-stimulating factor for the treatment of hormone-resistant prostate cancer.. 14. 1996
Postsurgical adjuvant chemotherapy of stage II breast carcinoma with or without crossover to a non-cross-resistant regimen: a Cancer and Leukemia Group B study.. 14. 1996
Psychologic and neuropsychologic impact of autologous bone marrow transplantation.. 14. 1996
Effect of ABVD chemotherapy with and without mantle or mediastinal irradiation on pulmonary function and symptoms in early-stage Hodgkin's disease.. 14. 1996
High-dose carboplatin, etoposide, and cyclophosphamide for patients with refractory germ cell tumors: treatment results and prognostic factors for survival and toxicity.. 14. 1996
Synovial sarcoma: prognostic significance of tumor size, margin of resection, and mitotic activity for survival.. 14. 1996
Therapy of untreated acute myeloid leukemia in the elderly: remission-induction using a non-cytarabine-containing regimen of mitoxantrone plus etoposide.. 14. 1996
Cisplatin and etoposide combination chemotherapy for locally advanced or metastatic thymoma. A phase II study of the European Organization for Research and Treatment of Cancer Lung Cancer Cooperative Group.. 14. 1996
Fifteen-year results of breast-conserving surgery and definitive breast irradiation for the treatment of ductal carcinoma in situ of the breast.. 14. 1996
Irinotecan is an active agent in untreated patients with metastatic colorectal cancer.. 14. 1996
Long-term results of a prospective randomized trial of adjuvant brachytherapy in soft tissue sarcoma.. 14. 1996
Phase II study of weekly intravenous recombinant humanized anti-p185HER2 monoclonal antibody in patients with HER2/neu-overexpressing metastatic breast cancer.. 14. 1996
Cytoreduction and prognosis in acute lymphoblastic leukemia--the importance of early marrow response: report from the Childrens Cancer Group.. 14. 1996
Funding for clinical (patient-oriented) oncology research: current status and recommendations for improvement. American Society of Clinical Oncology.. 14. 1996
Management of residual mass in advanced seminoma: results and recommendations from the Memorial Sloan-Kettering Cancer Center.. 14. 1996
Prognostic significance of a positive microscopic margin in high-risk extremity soft tissue sarcoma: implications for management.. 14. 1996
Survival from locally invasive or widespread neuroblastoma without cytotoxic therapy.. 14. 1996
Neoadjuvant chemotherapy plus concurrent chemotherapy and high-dose radiation for squamous cell carcinoma of the esophagus: a preliminary analysis of the phase II intergroup trial 0122.. 14. 1996
Phase II and pharmacologic study of docetaxel as initial chemotherapy for metastatic breast cancer.. 14. 1996
Two schedules of teniposide with or without cisplatin in advanced non-small-cell lung cancer: a randomized study of the European Organization for Research and Treatment of Cancer Lung Cancer Cooperative Group.. 14. 1996
Does administration of chemotherapy before radiotherapy in breast cancer patients treated with conservative surgery negatively impact local control?. 13. 1995
Etoposide and cisplatin adjuvant therapy for patients with pathologic stage II germ cell tumors.. 13. 1995
Very-high-dose short-term chemotherapy for poor-risk peripheral primitive neuroectodermal tumors, including Ewing's sarcoma, in children and young adults.. 13. 1995
Phase II trial of paclitaxel by 3-hour infusion as initial and salvage chemotherapy for metastatic breast cancer.. 13. 1995
Prospective evaluation of hydrocortisone and suramin in patients with androgen-independent prostate cancer.. 13. 1995
Suramin and hydrocortisone: determining drug efficacy in androgen-independent prostate cancer.. 13. 1995
Adjusting the dose of intravenous ondansetron plus dexamethasone to the emetogenic potential of the chemotherapy regimen.. 13. 1995
Concurrent cisplatin/etoposide plus chest radiotherapy followed by surgery for stages IIIA (N2) and IIIB non-small-cell lung cancer: mature results of Southwest Oncology Group phase II study 8805.. 13. 1995
Interferon alfa-2a and 13-cis-retinoic acid in renal cell carcinoma: antitumor activity in a phase II trial and interactions in vitro.. 13. 1995
Phase I/II trial of dexverapamil plus vinblastine for patients with advanced renal cell carcinoma.. 13. 1995
Leukemogenic potential of adjuvant chemotherapy for early-stage breast cancer: the Eastern Cooperative Oncology Group experience.. 13. 1995
Combination chemotherapy for metastatic or recurrent carcinoma of the breast--a randomized phase III trial comparing CAF versus VATH versus VATH alternating with CMFVP: Cancer and Leukemia Group B Study 8281.. 13. 1995
Comparison of treatment regimens for pediatric lymphoblastic non-Hodgkin's lymphoma: a Childrens Cancer Group study.. 13. 1995
Intravesical bacillus Calmette-Guérin therapy prevents tumor progression and death from superficial bladder cancer: ten-year follow-up of a prospective randomized trial.. 13. 1995
Prognostic value of p53 nuclear overexpression in patients with invasive bladder cancer treated with neoadjuvant MVAC.. 13. 1995
Allogeneic bone marrow transplantation for refractory and recurrent low-grade lymphoma: the case for aggressive management.. 13. 1995
Detection of circulating tumor cells in patients with localized and metastatic prostatic carcinoma: clinical implications.. 13. 1995
Dose escalation of paclitaxel with high-dose cyclophosphamide, with analysis of progenitor-cell mobilization and hematologic support of advanced ovarian cancer patients receiving rapidly sequenced high-dose carboplatin/cyclophosphamide courses.. 13. 1995
Paclitaxel as second and subsequent therapy for metastatic breast cancer: activity independent of prior anthracycline response.. 13. 1995
Prediction of residual retroperitoneal mass histology after chemotherapy for metastatic nonseminomatous germ cell tumor: multivariate analysis of individual patient data from six study groups.. 13. 1995
p53 in node-negative breast carcinoma: an immunohistochemical study of epidemiologic risk factors, histologic features, and prognosis.. 13. 1995
Organ-function preservation in advanced oropharynx cancer: results with induction chemotherapy and radiation.. 13. 1995
Pain and depression in patients with newly diagnosed pancreas cancer.. 13. 1995
Teniposide for brain metastases of small-cell lung cancer: a phase II study. European Organization for Research and Treatment of Cancer Lung Cancer Cooperative Group.. 13. 1995
Significance of normal serum prostate-specific antigen in the follow-up period after definitive radiation therapy for prostatic cancer.. 13. 1995
Are axillary recurrence and overall survival affected by axillary extranodal tumor extension in breast cancer? Implications for radiation therapy.. 13. 1995
Molecular and cytogenetic studies in the diagnosis of patients with poorly differentiated carcinomas of unknown primary site.. 13. 1995
Recombinant human granulocyte-macrophage colony-stimulating factor as an adjunct to conventional-dose ifosfamide-based chemotherapy for patients with advanced or relapsed germ cell tumors: a randomized trial.. 13. 1995
Highly effective induction therapy for stage 4 neuroblastoma in children over 1 year of age.. 12. 1994
Neuropsychologic effects of cranial irradiation, intrathecal methotrexate, and systemic methotrexate in childhood cancer.. 12. 1994
Phase II study of hepatic arterial floxuridine, leucovorin, and dexamethasone for unresectable liver metastases from colorectal carcinoma.. 12. 1994
Phase II trial of paclitaxel shows antitumor activity in patients with previously treated germ cell tumors.. 12. 1994
Etoposide, cyclophosphamide, total-body irradiation, and allogeneic bone marrow transplantation for hematologic malignancies.. 12. 1994
Pharmacologic-guided trial of sequential methotrexate and thioguanine in children with advanced malignancies.. 12. 1994
Phase I/II study of iodine 131-labeled monoclonal antibody A33 in patients with advanced colon cancer.. 12. 1994
Neoadjuvant chemotherapy for invasive bladder cancer: prognostic factors for survival of patients treated with M-VAC with 5-year follow-up.. 12. 1994
A phase II trial of pleurectomy/decortication followed by intrapleural and systemic chemotherapy for malignant pleural mesothelioma.. 12. 1994
A prospective randomized trial of adjuvant brachytherapy in the management of low-grade soft tissue sarcomas of the extremity and superficial trunk.. 12. 1994
Antibody targeting in metastatic colon cancer: a phase I study of monoclonal antibody F19 against a cell-surface protein of reactive tumor stromal fibroblasts.. 12. 1994
Phase II trial of docetaxel in patients with stage III and IV non-small-cell lung cancer.. 12. 1994
Dose-ranging evaluation of the serotonin antagonist dolasetron mesylate in patients receiving high-dose cisplatin.. 12. 1994
Effects of topical tretinoin on dysplastic nevi.. 12. 1994
Neoadjuvant chemotherapy and partial cystectomy for invasive bladder cancer.. 12. 1994
Autologous and allogeneic bone marrow transplantation for chronic lymphocytic leukemia: preliminary results.. 12. 1994
Clinical and pharmacologic study of multidrug resistance reversal with vinblastine and bepridil.. 12. 1994
Trial of sequential trimetrexate, fluorouracil, and high-dose leucovorin in previously treated patients with gastrointestinal carcinoma.. 12. 1994
Advanced seminoma: treatment results, survival, and prognostic factors in 142 patients.. 12. 1994
Chemotherapy for induction of remission of childhood acute myeloid leukemia followed by marrow transplantation or multiagent chemotherapy: a report from the Childrens Cancer Group.. 12. 1994
Patterns of failure following surgical resection of renal cell carcinoma: implications for adjuvant local and systemic therapy.. 12. 1994
Low-dose gallium nitrate for prevention of osteolysis in myeloma: results of a pilot randomized study.. 11. 1993
Preoperative endoscopic ultrasound can predict the risk of recurrence after operation for gastric carcinoma.. 11. 1993
Effect of megestrol acetate on quality of life in a dose-response trial in women with advanced breast cancer. The Cancer and Leukemia Group B.. 11. 1993
Factors influencing prognosis in node-negative breast carcinoma: analysis of 767 T1N0M0/T2N0M0 patients with long-term follow-up.. 11. 1993
Improved therapy for children with acute lymphoblastic leukemia and unfavorable presenting features: a follow-up report of the Childrens Cancer Group Study CCG-106.. 11. 1993
Paclitaxel and recombinant human granulocyte colony-stimulating factor as initial chemotherapy for metastatic breast cancer.. 11. 1993
Phase I dose-escalation trial of iodine 131-labeled monoclonal antibody OKB7 in patients with non-Hodgkin's lymphoma.. 11. 1993
Pathologic complete response in advanced non-small-cell lung cancer following preoperative chemotherapy: implications for the design of future non-small-cell lung cancer combined modality trials.. 11. 1993
Phase II study of fluorouracil, leucovorin, and interferon alfa-2a in metastatic colorectal carcinoma.. 11. 1993
Flutamide withdrawal syndrome: its impact on clinical trials in hormone-refractory prostate cancer.. 11. 1993
Interferon alfa-2a in advanced renal cell carcinoma: treatment results and survival in 159 patients with long-term follow-up.. 11. 1993
Maintenance chemotherapy in small-cell lung cancer: long-term results of a randomized trial. European Organization for Research and Treatment of Cancer Lung Cancer Cooperative Group.. 11. 1993
Accelerated hyperfractionated total-lymphoid irradiation, high-dose chemotherapy, and autologous bone marrow transplantation for refractory and relapsing patients with Hodgkin's disease.. 11. 1993
Effect of prior interferon alfa therapy on the outcome of allogeneic bone marrow transplantation for chronic myelogenous leukemia.. 11. 1993
High-dose chemotherapy and autologous bone marrow support as consolidation after standard-dose adjuvant therapy for high-risk primary breast cancer.. 11. 1993
Rapid administration of multiple cycles of high-dose myelosuppressive chemotherapy in patients with metastatic breast cancer.. 11. 1993
Antibody localization in human renal cell carcinoma: a phase I study of monoclonal antibody G250.. 11. 1993
Prostate-specific antigen as a measure of disease outcome in metastatic hormone-refractory prostate cancer.. 11. 1993
Randomized trial of etoposide and cisplatin versus etoposide and carboplatin in patients with good-risk germ cell tumors: a multiinstitutional study.. 11. 1993
Dose-intensification of MVAC with recombinant granulocyte colony-stimulating factor as initial therapy in advanced urothelial cancer.. 11. 1993
Effect of relative cumulative dose-intensity on survival of patients with urothelial cancer treated with M-VAC.. 11. 1993
Osteogenic sarcoma with clinically detectable metastasis at initial presentation.. 11. 1993
Phase II trial of postoperative adjuvant intraperitoneal cisplatin and fluorouracil and systemic fluorouracil chemotherapy in patients with resected gastric cancer.. 11. 1993
Dose-escalation trial of M195 labeled with iodine 131 for cytoreduction and marrow ablation in relapsed or refractory myeloid leukemias.. 11. 1993
Randomized trial of hepatic arterial floxuridine, mitomycin, and carmustine versus floxuridine alone in previously treated patients with liver metastases from colorectal cancer.. 11. 1993
Breast cancer in patients irradiated for Hodgkin's disease: a clinical and pathologic analysis of 45 events in 37 patients.. 10. 1992
Impact on survival of surgically defined favorable responses to salvage intraperitoneal chemotherapy in small-volume residual ovarian cancer.. 10. 1992
Phase I trial of intraperitoneal taxol: a Gynecoloic Oncology Group study.. 10. 1992
Radiosurgery as part of the initial management of patients with malignant gliomas.. 10. 1992
Combined modality therapy of rectal cancer: decreased acute toxicity with the preoperative approach.. 10. 1992
Refinement of clinicopathologic staging for localized soft tissue sarcoma of the extremity: a study of 423 adults.. 10. 1992
A phase II trial of interleukin-2 and interferon alfa-2a in patients with advanced renal cell carcinoma.. 10. 1992
Intrapleural cisplatin and mitomycin for malignant mesothelioma following pleurectomy: pharmacokinetic studies.. 10. 1992
Treatment of patients with relapsed and resistant non-Hodgkin's lymphoma using total body irradiation, etoposide, and cyclophosphamide and autologous bone marrow transplantation.. 10. 1992
Biochemical modulation of bolus fluorouracil by PALA in patients with advanced colorectal cancer.. 10. 1992
Epirubicin in malignant mesothelioma: a phase II study of the European Organization for Research and Treatment of Cancer Lung Cancer Cooperative Group.. 10. 1992
Combined modality therapy for primary CNS lymphoma.. 10. 1992
FAMTX versus etoposide, doxorubicin, and cisplatin: a random assignment trial in gastric cancer.. 10. 1992
Ifosfamide and mesna in previously treated advanced epithelial ovarian cancer: activity in platinum-resistant disease.. 10. 1992
Interferon alfa-2a and fluorouracil in the treatment of patients with advanced esophageal cancer.. 10. 1992
Chemotherapy for nonmetastatic osteogenic sarcoma: the Memorial Sloan-Kettering experience.. 10. 1992
Enhancement of radiation-induced downstaging of rectal cancer by fluorouracil and high-dose leucovorin chemotherapy.. 10. 1992
Phase I/II trial and pharmacokinetics of intrathecal diaziquone in refractory meningeal malignancies.. 10. 1992
A study of infusional cisplatin and infusional fluorouracil for locally advanced or metastatic non-small-cell lung cancer: a Mid-Atlantic Oncology Program study.. 9. 1991
Impact of adjuvant radiation on the patterns and rate of relapse in advanced-stage Hodgkin's disease treated with alternating chemotherapy combinations.. 9. 1991
The effects of postinduction intensification treatment with cytarabine and daunorubicin in adult acute lymphocytic leukemia: a prospective randomized clinical trial by Cancer and Leukemia Group B.. 9. 1991
Responses to second-line cisplatin-based intraperitoneal therapy in ovarian cancer: influence of a prior response to intravenous cisplatin.. 9. 1991
A loading dose/continuous infusion schedule of fludarabine phosphate in chronic lymphocytic leukemia.. 9. 1991
Lack of efficacy of high-dose leucovorin and fluorouracil in patients with advanced pancreatic adenocarcinoma.. 9. 1991
Prediction of prognosis in primary breast cancer by detection of a high molecular weight mucin-like antigen using monoclonal antibodies DF3, F36/22, and CU18: a Cancer and Leukemia Group B study.. 9. 1991
A randomized clinical trial of alprazolam versus progressive muscle relaxation in cancer patients with anxiety and depressive symptoms.. 9. 1991
Phase II trial of weekly or biweekly intraperitoneal mitoxantrone in epithelial ovarian cancer.. 9. 1991
The prognosis of Hodgkin's disease in older adults.. 9. 1991
A phase I trial of monoclonal antibody M195 in acute myelogenous leukemia: specific bone marrow targeting and internalization of radionuclide.. 9. 1991
Second-line platinum therapy in patients with ovarian cancer previously treated with cisplatin.. 9. 1991
Intraperitoneal cisplatin and cytarabine in the treatment of refractory or recurrent ovarian carcinoma.. 9. 1991
Intrapleural cisplatin and cytarabine in the management of malignant pleural effusions: a Lung Cancer Study Group trial.. 9. 1991
Myeloablative combination chemotherapy without total body irradiation for neuroblastoma.. 9. 1991
Cardiopulmonary resuscitation and the patient with cancer.. 9. 1991
Effects of radiation on testicular function in long-term survivors of childhood acute lymphoblastic leukemia: a report from the Children Cancer Study Group.. 8. 1990
Quantitative analysis of antibody localization in human metastatic colon cancer: a phase I study of monoclonal antibody A33.. 8. 1990
Trimetrexate in prostatic cancer: preliminary observations on the use of prostate-specific antigen and acid phosphatase as a marker in measurable hormone-refractory disease.. 8. 1990
Adjunctive surgery after chemotherapy for nonseminomatous germ cell tumors: recommendations for patient selection.. 8. 1990
Preoperative therapy for esophageal cancer: a randomized comparison of chemotherapy versus radiation therapy.. 8. 1990
A phase I toxicity, pharmacology, and dosimetry trial of monoclonal antibody OKB7 in patients with non-Hodgkin's lymphoma: effects of tumor burden and antigen expression.. 8. 1990
The treatment of recurrent brain metastases with stereotactic radiosurgery.. 8. 1990
Toxicity, immunogenicity, and tumor radioimmunodetecting ability of two human monoclonal antibodies in patients with metastatic colorectal carcinoma.. 8. 1990
Randomized study of continuous infusion fluorouracil versus fluorouracil plus cisplatin in patients with metastatic colorectal cancer.. 8. 1990
High-dose ifosfamide with mesna uroprotection: a phase I study.. 8. 1990
Phase II trial of intraperitoneal mitoxantrone in the management of refractory ovarian cancer.. 8. 1990
Treatment results with an aggressive chemotherapeutic regimen (MACOP-B) for intermediate- and some high-grade non-Hodgkin's lymphomas.. 8. 1990
A phase II clinical trial of adoptive immunotherapy for advanced renal cell carcinoma using mitogen-activated autologous leukocytes and continuous infusion interleukin-2.. 7. 1989
Inability of computed tomography appearance of recurrent malignant astrocytoma to predict survival following reoperation.. 7. 1989
Intraperitoneal cisplatin and etoposide in the treatment of refractory/recurrent ovarian carcinoma.. 7. 1989
Flow cytometry as a predictive indicator in patients with operable gastric cancer.. 7. 1989
Dose-intensive chemotherapy in refractory germ cell cancer--a phase I/II trial of high-dose carboplatin and etoposide with autologous bone marrow transplantation.. 7. 1989
Should single agents be standard therapy for urothelial tract tumors?. 7. 1989
A phase I clinical and pharmacokinetic study of carboplatin and autologous bone marrow support.. 7. 1989
Phase I trial of intramuscularly administered tumor necrosis factor in patients with advanced cancer.. 7. 1989
Tumor localization of adoptively transferred indium-111 labeled tumor infiltrating lymphocytes in patients with metastatic melanoma.. 7. 1989
Cardiorespiratory effects of immunotherapy with interleukin-2.. 7. 1989
Controlling delayed vomiting: double-blind, randomized trial comparing placebo, dexamethasone alone, and metoclopramide plus dexamethasone in patients receiving cisplatin.. 7. 1989
Bacillus Calmette-Guérin therapy alters the progression of superficial bladder cancer.. 6. 1988
The effect of initial management of hyperleukocytosis on early complications and outcome of children with acute lymphoblastic leukemia.. 6. 1988
A randomized trial of etoposide + cisplatin versus vinblastine + bleomycin + cisplatin + cyclophosphamide + dactinomycin in patients with good-prognosis germ cell tumors.. 6. 1988
Autologous bone marrow transplantation for patients with poor-prognosis lymphoma.. 6. 1988
Teniposide in the treatment of small-cell lung cancer: the influence of prior chemotherapy.. 6. 1988
A cause-specific hazard rate analysis of prognostic factors among 199 adults with acute lymphoblastic leukemia: the Memorial Hospital experience since 1969.. 6. 1988
Comparison of criteria for assigning germ cell tumor patients to "good risk" and "poor risk" studies.. 6. 1988
Control of chemotherapy-induced diarrhea with the synthetic enkephalin BW942C: a randomized trial with placebo in patients receiving cisplatin.. 6. 1988
Dose-ranging evaluation of the serotonin antagonist GR-C507/75 (GR38032F) when used as an antiemetic in patients receiving anticancer chemotherapy.. 6. 1988
Chemotherapeutic and surgical induction of pathological complete remission and whole abdominal irradiation for consolidation does not enhance the cure of stage III ovarian carcinoma.. 6. 1988
High peripheral blast count in adult acute myelogenous leukemia is a primary risk factor for CNS leukemia.. 6. 1988
Phase II study of 10-ethyl-10-deaza-aminopterin in patients with stage III and IV non-small-cell lung cancer.. 6. 1988
Phase I trial of concurrent intraperitoneal and continuous intravenous infusion of fluorouracil in patients with refractory cancer.. 6. 1988
A controlled clinical trial of the addition of transdermal scopolamine to a standard metoclopramide and dexamethasone antiemetic regimen.. 5. 1987
Clinical pharmacology of recombinant human tumor necrosis factor in patients with advanced cancer.. 5. 1987
Coordinated use of sequentially escalated cyclophosphamide and cell-cycle-specific chemotherapy (N4SE protocol) for advanced neuroblastoma: experience with 100 patients.. 5. 1987
Tumor and liver drug uptake following hepatic artery and portal vein infusion.. 5. 1987
Phase I trial of escalating doses of cisplatin in hypertonic saline.. 5. 1987
Very-high-dose cisplatin with bleomycin infusion as initial treatment of advanced head and neck cancer.. 5. 1987
Ganglioside GD2 specific monoclonal antibody 3F8: a phase I study in patients with neuroblastoma and malignant melanoma.. 5. 1987
Residual mass: an indication for further therapy in patients with advanced seminoma following systemic chemotherapy.. 5. 1987
Eligibility and extrapolation in cancer clinical trials.. 5. 1987
Localized extremity soft tissue sarcoma: an analysis of factors affecting survival.. 5. 1987
A prospective randomized trial of maintenance versus nonmaintenance intravesical bacillus Calmette-Guérin therapy of superficial bladder cancer.. 5. 1987
Alternating cycles of etoposide plus cisplatin and VAB-6 in the treatment of poor-risk patients with germ cell tumors.. 5. 1987
Wound complications in the multimodality treatment of extremity and superficial truncal sarcomas.. 5. 1987
A phase I-II study of intensive-dose adriamycin for advanced breast cancer.. 5. 1987
Gallium nitrate inhibits accelerated bone turnover in patients with bone metastases.. 5. 1987
Semen cryopreservation and artificial insemination for Hodgkin's disease.. 5. 1987
Surgical treatment of spinal cord compression in kidney cancer.. 4. 1986
Frequency and prognostic importance of pretreatment clinical characteristics in patients with advanced non-small-cell lung cancer treated with combination chemotherapy.. 4. 1986
Increased plasma renin and aldosterone in patients treated with cisplatin-based chemotherapy for metastatic germ-cell tumors.. 4. 1986
Gonadal dysfunction in patients treated for metastatic germ-cell tumors.. 4. 1986
VAB-6: an effective chemotherapy regimen for patients with germ-cell tumors.. 4. 1986
Improved disease-free survival of children with acute lymphoblastic leukemia at high risk for early relapse with the New York regimen--a new intensive therapy protocol: a report from the Childrens Cancer Study Group.. 4. 1986
Prognostic significance of terminal deoxynucleotidyl transferase activity in acute nonlymphoblastic leukemia.. 4. 1986
Medical oncology manpower training: a position statement of the American Society of Clinical Oncology.. 4. 1986
Phase I trial of recombinant interferon gamma in cancer patients.. 4. 1986
Phase I and II study of fludarabine phosphate in leukemia: therapeutic efficacy with delayed central nervous system toxicity.. 4. 1986
Improvements in data collection through physician use of a computer-based chemotherapy treatment consultant.. 3. 1985
Incidence, course, and severity of delayed nausea and vomiting following the administration of high-dose cisplatin.. 3. 1985
Therapy of CNS leukemia with intraventricular chemotherapy and low-dose neuraxis radiotherapy.. 3. 1985
The results of chemotherapy for extragonadal germ-cell tumors in the cisplatin era: the Memorial Sloan-Kettering Cancer Center experience (1975 to 1982).. 3. 1985
13-cis-Retinoic acid does not increase the true remission rate and the duration of true remission (induced by cytotoxic chemotherapy) in patients with chronic phase chronic myelogenous leukemia.. 3. 1985
VAB-6 as initial treatment of patients with advanced seminoma.. 3. 1985
Chronic myelogenous leukemia: is aggressive treatment indicated?. 3. 1985
Methylglyoxal-bis(guanylhydrazone) in hormone-resistant adenocarcinoma of the prostate.. 3. 1985
Full dose versus attenuated dose daunorubicin, cytosine arabinoside, and 6-thioguanine in the treatment of acute nonlymphocytic leukemia in the elderly.. 2. 1984
The treatment of extragonadal seminoma.. 2. 1984
Hepatic artery pump infusion: toxicity and results in patients with metastatic colorectal carcinoma.. 2. 1984
A critical comparison of allogeneic bone marrow transplantation and conventional chemotherapy as treatment for acute nonlymphocytic leukemia.. 2. 1984
Activity of sequential low-dose methotrexate and fluorouracil in advanced colorectal carcinoma: attempt at correlation with tissue and blood levels of phosphoribosylpyrophosphate.. 2. 1984
Orchiectomy alone in the treatment of clinical stage I nonseminomatous germ cell tumor of the testis.. 2. 1984
Philadelphia chromosome and terminal transferase-positive acute leukemia: similarity of terminal phase of chronic myelogenous leukemia and de novo acute presentation.. 1. 1983
Marrow cytogenetic and cell-culture analyses of the myelodysplastic syndromes: insights to pathophysiology and prognosis.. 1. 1983
A technique to quantify cytoreduction in the bone marrow induced by cytotoxic chemotherapy.. 1. 1983
Four-drug combination chemotherapy (methotrexate, cyclophosphamide, hexamethylmelamine, and CCNU) for non-small cell bronchogenic carcinoma: a Cancer and Leukemia Group B study.. 1. 1983
Pazopanib in Locally Advanced or Metastatic Renal Cell Carcinoma: Results of a Randomized Phase III Trial.. 41. 2023
Response to Neoadjuvant Therapy and Long-Term Survival in Patients With Triple-Negative Breast Cancer.. 41. 2023
Reply to F. Tomao et al.. 37. 2019
Reply to C. Ren et al.. 36. 2018
Understanding Responses to Stereotactic Body Radiotherapy and Pembrolizumab.. 36. 2018
Stereotactic Body Radiation Therapy: Focusing on the Short Game.. 36. 2018
Learning All That We Can From MyPathway.. 36. 2018
Reply to E. Younger et al.. 36. 2018
Exercise Implementation in Oncology: One Size Does Not Fit All.. 36. 2018
Reply to M. Horiguchi et al.. 36. 2018
Reply to M. Mo et al.. 36. 2017
Reply to D.J. Beale.. 35. 2017
Reply to C.G. Rusthoven et al.. 35. 2017
Role of Cost-Sharing Subsidies on the Initiation of and Adherence to Tyrosine Kinase Inhibitor Therapy by Medicare Beneficiaries With Chronic Myeloid Leukemia.. 35. 2017
Reply to R.L. Nussbaum et al and J.S. Dolinsky et al.. 35. 2017
Reply to L.B. Marks et al.. 35. 2017
Reply to K. Kusaka et al.. 35. 2017
Reaffirming and Clarifying the American Society of Clinical Oncology's Policy Statement on the Critical Role of Phase I Trials in Cancer Research and Treatment.. 35. 2016
It Is Time to Stop Using Epirubicin to Treat Any Patient With Gastroesophageal Adenocarcinoma.. 35. 2016
Reply to M. Nishino.. 34. 2016
Reply to J. Jupp et al.. 34. 2016
Not All Androgen Deprivation Therapies Are Created Equal: Leuprolide and the Decreased Risk of Developing Alzheimer's Disease.. 34. 2016
Reply to N. Lowy et al and to J. Dhanda et al.. 34. 2016
Reply to O.O. Eren et al and S. Mikhail.. 34. 2016
Genetic Screening in All Young Patients With Colorectal Cancer?. 34. 2016
Re-Examining the Role of Radiation Therapy for Diffuse Large B-Cell Lymphoma in the Modern Era.. 34. 2016
Parsing the Etiology of Breast Cancer Disparities.. 34. 2016
Reply to A. Indini et al.. 34. 2016
Reply to M.P. Decatris et al.. 34. 2016
Reply to A. Addeo and A. Bahl.. 34. 2015
Reply to S.M. Sorscher and A.B. Hafeez Bhatti.. 33. 2015
Reply to A. Messori et al, R. Bordonaro et al, and G. Fasola et al.. 33. 2015
There Is Nothing New Under the Sun.. 33. 2015
Reply to K. Lu.. 33. 2015
Reply to D. Spiegel.. 33. 2015
Reply to A. Stenzinger et al.. 33. 2015
Reply to B. O'Sullivan et Al.. 33. 2015
Reply to D. Adkins et al.. 33. 2015
Reply to P. Stattin.. 33. 2015
National Cancer Institute-supported clinical trials networks.. 33. 2014
When overall survival fails to confirm event-free survival, should the latter be used to set the standard of care?. 32. 2014
Clinical trial evidence of the antitumor activity of topical imiquimod for breast cancer skin metastases.. 32. 2014
Reply to M. Voskoboynik et al.. 32. 2014
Minimal residual disease: what are the minimum requirements?. 32. 2014
Reply to P.G. Tsoutsou et al, o. Kaidar-Person et al, and A. Courdi et al.. 31. 2013
Role of expression profiling in carcinoma of unknown primary remains unknown.. 31. 2013
Reply to L. Moreno et al.. 31. 2013
Should cetuximab replace Cisplatin for definitive chemoradiotherapy in locally advanced head and neck cancer?. 31. 2012
Response to crizotinib in ROS1-rearranged non-small-cell lung cancer.. 30. 2012
Risk factors for the incidence of second cancers in survivors of retinoblastoma with a family history.. 30. 2012
HER2 mutations in non-small-cell lung cancer can be continually targeted.. 30. 2012
Neoadjuvant chemotherapy is rarely the easy way out.. 30. 2012
Targeting vascular endothelial growth factor in patients with squamous cell lung cancer.. 30. 2012
Misunderstanding regarding the carboplatin dose comparison in MRC TE19/EORTC 30982.. 29. 2011
Identifying circulating tumor stem cells that matter: the key to prognostication and therapeutic targeting.. 29. 2011
Interferon alfa in the treatment of Philadelphia-negative chronic myeloproliferative neoplasms.. 29. 2011
Do the data support the comorbidity hypothesis for the Prostate, Lung, Colorectal, and Ovarian Cancer Screening Trial results?. 29. 2011
High-dose methotrexate-induced renal dysfunction: is glucarpidase necessary for rescue?. 29. 2011
Thymoma-associated paraneoplastic polymyositis.. 28. 2010
Suggestions for regulatory agency approval of second-line systemic therapy for metastatic transitional cell carcinoma.. 28. 2010
Neurocutaneous melanocytosis: outcome not uniformly fatal.. 27. 2009
Effects of chemoradiation on tumor-host interactions: the immunologic side.. 26. 2008
Isn't there someone to blame?. 26. 2008
Bevacizumab: one treatment for all the seasons?. 26. 2008
End points in advanced colon cancer clinical trials: a review and proposal.. 25. 2007
Successful treatment of leptomeningeal disease in colorectal cancer with a regimen of bevacizumab, temozolomide, and irinotecan.. 25. 2007
New issues on cetuximab mechanism of action in epidermal growth factor receptor-negative colorectal cancer: the role of vascular endothelial growth factor.. 24. 2006
Medullary renal cell carcinoma and response to therapy with bortezomib.. 24. 2006
Thromboembolic events in gastric cancer: high incidence in patients receiving irinotecan- and bevacizumab-based therapy.. 23. 2005
Is immunohistochemistry for epidermal growth factor receptor expression a poor predictor of response to epidermal growth factor receptor-targeted therapy?. 23. 2005
Operate on my stomach cancer? Oh, no--not you, or not yet!. 22. 2004
Ototoxicity in patients with dose-intensive therapy for cisplatin-resistant germ cell tumors.. 22. 2004
TGFBR1*6A and cancer: a meta-analysis of 12 case-control studies.. 22. 2004
Fludarabine-related myeloid leukemia.. 21. 2003
Cardiac dysfunction in clinical trials of trastuzumab.. 20. 2002
Phase I trial of adoptive immunotherapy with cytolytic T lymphocytes immunized against a tyrosinase epitope.. 20. 2002
Endothelial dysfunction in antiangiogenesis-associated thrombosis.. 20. 2002
Role of symptom control and palliative care abstract presentations.. 20. 2002
Utilization of breast-conserving surgery in breast cancer.. 19. 2001
Fluorouracil (5FU) pharmacokinetics in 5FU prodrug formulations with a dihydropyrimidine dehydrogenase inhibitor.. 19. 2001
Postoperative adjuvant chemoradiation therapy for patients with resected gastric cancer: intergroup 116.. 19. 2001
Re: "Bezwoda: evidence of fabrication in original article".. 18. 2000
Bezwoda: evidence of fabrication in original article.. 18. 2000
Dexrazoxane in anthracycline extravasation.. 18. 2000
Dexrazoxane and the ASCO guidelines for the use of chemotherapy and radiotherapy protectants: a critique.. 18. 2000
Predictors of response to chemotherapy.. 18. 2000
BRCA1/2 germline mutations: a marker for radioresistance or radiosensitivity?. 18. 2000
Gemcitabine is active in relapsed Hodgkin's disease.. 17. 1999
Chemotherapy of advanced non-small-cell lung cancer: "Those who cannot remember the past are condemned to repeat it".. 17. 1999
Radiotherapy with/without cisplatin following chemotherapy in limited small-cell lung cancer.. 16. 1998
BRCA mutations and survival in breast cancer.. 16. 1998
Monitoring methotrexate levels in osteosarcoma.. 16. 1998
Don't be mis-guided when the data are silent and the editorial misses the mark.. 16. 1998
Bleomycin in nonseminomatous germ-cell tumors: cure rate versus morbidity.. 16. 1998
Delayed complication of Port-A-Cath: perforation of the superior vena cava.. 15. 1997
Do all germ cell tumor patients with residual masses in multiple sites require postchemotherapy resections?. 15. 1997
Optimal management of residual mass after chemotherapy in advanced seminoma: there is time for everything.. 14. 1996
Cytoreduction and prognosis in childhood acute lymphoblastic leukemia.. 14. 1996
Adjuvant chemotherapy in pathologic Stage II nonseminomatous testicular cancer: are two cycles of etoposide-cisplatin a standard option?. 14. 1996
Defining new standards for adjuvant therapy of testis cancer: a reply.. 14. 1996
Chemotherapy for colorectal carcinoma: observations regarding recent clinical trials using biochemical modulation.. 13. 1995
Calvert's formula and high-dose carboplatin.. 12. 1994
Photopsia during 3-hour paclitaxel administration at doses > or = 250 mg/m2.. 12. 1994
Combination chemotherapy for metastatic melanoma: the importance of tamoxifen.. 12. 1994
Rethinking management of localized neuroblastoma.. 11. 1993
Use of stereotactic radiosurgery in the treatment of malignant glioma.. 11. 1993
Phase II trials of small-cell lung cancer.. 10. 1992
Reassessment of patient response to monoclonal antibody 3F8.. 10. 1992
Neoadjuvant chemotherapy in head and neck cancer: no way to preserve a larynx.. 10. 1992
Dose-intensity analysis and randomized trials.. 9. 1991
Cyclophosphamide and the heart.. 9. 1991
Pseudo-Philadelphia-positive acute lymphoblastic leukemia (Ph1 + ALL). 5. 1987
Philadelphia chromosome mosaicism in chronic granulocytic leukemia.. 4. 1986
Patients with secondary acute myelocytic leukemia (AML) receiving "timed" sequential chemotherapy.. 1. 1983
Expanding the Arsenal of Clinically Active KRAS G12C Inhibitors. 2022
Reply to T.M. Weis et al. 2019
Targeting DNA Repair in Prostate Cancer. 2018
Patient characteristics and prognosis in metastatic breast cancer. 2009
Disparities in Allograft Access in the Era of Post-Transplant Cyclophosphamide-Based Mismatched Unrelated Donor Transplantation. 2024
Reply to T. Olivier et al. 2022
Reply to K. de Joode et al. 2021
Considerations for the Use of Scalp Cooling Devices in Black Patients. 2020
Reply to N. Fazio. 2020
Reply to A. Katz. 2019
Reply to E. Hindié et al. 2019
Reply to H. Brauch et al. 2019
Reply to I. Pecora et al. 2019
Reply to K.S. Shohdy et al. 2018
Reply to J.L. Blum et al and S. Lange et al. 2017
Population Frequency of Germline BRCA1/2 Mutations. 2016
Should the American Society of Clinical Oncology Ask for Peer Review Before Publishing Its Advocacy Research? 2016
Reply to G. Le Flahec et al. 2016
Reply to A. Braillon, M. Boulin et al, and J.-H. Zhong et al. 2016
Reply to T. Finazzi and H. Kim et al. 2016
Reply to D. Pouessel et al, J.B. Aragon-Ching, and B.A. Adesunloye. 2014
Reply to S. Barni et Al and M. Sun et Al. 2014
Reply to K.I. Pritchard. 2013
Can we really use retrospective subset analyses and surveillance, epidemiology, and end results data to drive clinical practice? 2012
Febrile neutropenia and infection in the ASCENT studies. 2011
T-cell-depleted reduced-intensity conditioning transplantation for lymphoma: do donor lymphocyte infusions really matter? 2011
Addition of octreotide functional imaging to cross-sectional computed tomography or magnetic resonance imaging for the detection of neuroendocrine tumors: added value or an anachronism? 2010
African American women who receive primary anthracycline- and taxane-based chemotherapy for triple-negative breast cancer suffer worse outcomes compared with white women. 2009
Impact of immediate postoperative death on the estimation of a survival benefit from postoperative radiation therapy for cancer of the gallbladder. 2008
Risk of ipsilateral lung cancer after postmastectomy radiotherapy and smoking: does the possible triumph over the actual? 2008
Superiority of reduced-intensity conditioning for Hodgkin's lymphoma. 2008
Circulating tumor cells in breast cancer: fiction or reality? 2008
Dose-dense chemotherapy with trastuzumab is an appropriate option. 2008
Hepatic arterial infusion chemotherapy for metastases from colorectal cancer: is it really the end of an era? 2008
Myeloid toxicity in breast cancer patients receiving adjuvant chemotherapy with pegfilgrastim support. 2006
Lipophilic statins merit additional study for breast cancer chemoprevention. 2006
Inflammatory breast cancer and high-dose chemotherapy: back to the past. 2005
Inflammatory breast carcinoma: the sphinx of breast cancer research. 2004
Benefit of Paclitaxel in estrogen receptor-negative versus estrogen receptor-positive early breast cancer. 2003
Conformal radiotherapy for high-grade gliomas: how much is too much? 2002
Classifying chronic myelomonocytic leukemia. 2001
Allogeneic transplantation for low-grade lymphoma: long-term follow-up. 2000
Institutional review board review of research reported in the journal of clinical oncology. 1999
Prognostic factors in bladder cancer after primary M-VAC. 1995
Timing of radiotherapy in the treatment of early-stage breast cancer. 1993
Amsacrine retains a special role supporting Food and Drug Administration approval. 1992
Rapid-learning system for cancer care. 2010
Consensus report of the national cancer institute clinical trials planning meeting on pancreas cancer treatment. 2009
Cognitive impairment associated with chemotherapy for cancer: report of a workshop. 2004
Summary statement on primary central nervous system lymphomas from the Eighth International Conference on Malignant Lymphoma, Lugano, Switzerland, June 12 to 15, 2002. 2003
Flashback Foreword: Bevacizumab and Irinotecan in Recurrent Glioblastoma.. 41. 2023
You Get (offered) What You (can) Pay for: Explaining Disparities in End-of-Life Cancer Care. 2023
Tarlatamab: New Star on the Horizon for Small-Cell Lung Cancer?. 41. 2023
Targeting Tumor-Rejection Antigens in Melanoma With Tumor-Infiltrating Lymphocytes.. 39. 2021
Neoadjuvant or Adjuvant Therapy for Resectable or Borderline Resectable Pancreatic Cancer: Which Is Preferred?. 38. 2020
Another Victory for Immune Checkpoint Blockade in Melanoma: Adjuvant Ipilimumab Over Interferon.. 38. 2019
De-Cell-eration in Therapy for Diffuse Large B-Cell Lymphoma.. 37. 2019
Cyclin E mRNA: Assessing Cyclin-Dependent Kinase (CDK) Activation State to Elucidate Breast Cancer Resistance to CDK4/6 Inhibitors.. 37. 2019
Risk-Imaging Mismatch: Why Is There a Disconnect?. 36. 2018
Genome-Driven Paradigm for the Development of Selective Fibroblast Growth Factor Receptor Inhibitors.. 35. 2016
Lenalidomide in Adult T-Cell Leukemia/Lymphoma.. 34. 2016
Picking the Right Patient for Human Epidermal Growth Factor Receptor 3-Targeted Therapy in Platinum-Resistant Ovarian Cancer.. 34. 2016
Is Underutilization of Cytoreductive Nephrectomy in Patients With Metastatic Renal Cancer Contributing to Inferior Survival?. 34. 2016
Evaluating Quality Metrics for the Care of Patients With Blood Cancer Who Are Near Death.. 34. 2016
Targeting the Vascular Endothelial Growth Factor Pathway in Gastric Cancer: A Hit or a Miss?. 34. 2016
Lapatinib in Gastric Cancer: What Is the LOGiCal Next Step?. 34. 2015
One and Done: A Week of Radiotherapy for Glioblastoma.. 33. 2015
Walking the Tightrope Between Treatment Efficacy and Price.. 34. 2015
Predictive Value of Positron Emission Tomography/Computed Tomography to Assess Early Treatment Response to Dual Human Epidermal Growth Factor Receptor 2 (HER2) Blockade Without Chemotherapy for HER2-Positive Metastatic Breast Cancer: Are We Ready to Embrace This "Early Metabolic Look" Strategy?. 33. 2015
Tumor Genetic Screening Programs: A Call to Action.. 33. 2015
Can money really be no object when cancer care is the subject?. 33. 2015
Failure of ELM-PC 5: an ineffective drug or an unfit end point?. 33. 2015
Markers for the early detection of prostate cancer: some principles for statistical reporting and interpretation.. 32. 2014
Multigene panel testing: planning the next generation of research studies in clinical cancer genetics.. 32. 2014
Everything old is new again! Neoadjuvant chemotherapy in the treatment of muscle-invasive bladder cancer.. 32. 2014
Evolving treatment paradigms for primary mediastinal diffuse large B-cell lymphoma.. 32. 2014
Take care of yourself: we need you.. 32. 2014
Defining the role of laparoscopic gastrectomy for gastric cancer.. 32. 2014
Allelic polymorphisms of inhibitory killer immunoglobulin-like receptor natural killer cell function can also influence the graft-versus-leukemia response.. 31. 2013
Importance of genetics in the clinical management of chronic myelomonocytic leukemia.. 31. 2013
Treatment of metastatic colon cancer: "the times they are A-changing".. 31. 2013
Evidence-based breast cancer screening guidelines for women who received chest irradiation at a young age.. 31. 2013
Treatment-emergent effects may predict benefit from endocrine therapy.. 31. 2013
The search for an elusive uniform strategy for a heterogeneous disease: lesson learned?. 31. 2013
Evolving panorama of treatment for metastatic pancreas adenocarcinoma.. 31. 2013
Disparities in breast cancer outcomes: receipt of chemotherapy is only part of the story.. 30. 2012
Graft-versus-host disease: have we solved the problem?. 30. 2012
Ifosfamide in the neoadjuvant treatment of osteogenic sarcoma.. 30. 2012
Moving forward one Notch at a time.. 30. 2012
Public health and the tanning bed controversy.. 30. 2012
Refining the use of endocrine therapy for ductal carcinoma in situ.. 30. 2012
Potential pitfalls of the rapid uptake of new technology in surgery: can comparative effectiveness research help?. 30. 2012
Off-label use of oncology drugs: the need for more data and then some.. 30. 2012
The American Society of Clinical Oncology's Blueprint for Transforming Clinical and Translational Cancer Research.. 30. 2012
Factors dictating outcomes in patients with colorectal cancer and peritoneal carcinomatosis: selection, resection, or convection?. 30. 2011
Do women remain at risk even if they do not inherit a familial BRCA1/2 mutation?. 29. 2011
Therapy for pediatric brain tumors and the risk of growth hormone deficiency.. 29. 2011
Virchow 2011 or how to ID(H) human glioblastoma.. 29. 2011
No place like home? Outpatient management of patients with febrile neutropenia and low risk.. 29. 2011
TACE and sorafenib: a good marriage?. 29. 2011
The end of an era: shall we move forward?. 29. 2011
Should the presence of germline BRCA1/2 mutations influence treatment selection in breast cancer?. 29. 2011
The study of collaborative practice arrangements: where do we go from here?. 29. 2011
Targeted therapy for human epidermal growth factor receptor 2-positive breast cancer: can there be too many active drugs?. 29. 2011
Prediction models: revolutionary in principle, but do they do more good than harm?. 29. 2011
Breast cancer tumor size, nodal status, and prognosis: biology trumps anatomy.. 29. 2011
Cabozantinib in medullary thyroid carcinoma: time to focus the spotlight on this rare disease.. 29. 2011
Rectal cancer trials: no movement.. 29. 2011
Kuhn's paradigms: are those closest to treating bladder cancer the last to appreciate the paradigm shift?. 29. 2011
How long is long enough?. 29. 2011
Big costs for little gain in ovarian cancer.. 29. 2011
Carboplatin in clinical stage I seminoma: too much and too little at the same time.. 29. 2011
Treatment of low-risk gestational trophoblastic neoplasia.. 29. 2011
Denosumab: second chapter in controlling bone metastases or a new book?. 28. 2010
New pharmacogenomic paradigm in breast cancer treatment.. 28. 2010
Radiation therapy after R-CHOP for diffuse large B-cell lymphoma: the gain remains.. 28. 2010
A step forward for two-step screening for ovarian cancer.. 28. 2010
Stereotactic body radiation therapy versus wedge resection for medically inoperable stage I lung cancer: tailored therapy or one size fits all?. 28. 2010
Weighing risks and benefits of postchemotherapy retroperitoneal lymph node dissection: not so easy.. 28. 2009
Weighing options for cancer risk reduction in carriers of BRCA1 and BRCA2 mutations.. 28. 2009
Anaplastic glioma: how to prognosticate outcome and choose a treatment strategy. [corrected].. 27. 2009
Clinical dilemma of ductal carcinoma in situ.. 27. 2009
More mastectomies: is this what patients really want?. 27. 2009
Epothilones: better or more of the same?. 27. 2009
Targeting renal cell carcinoma.. 27. 2009
Chemotherapy alone for laryngeal preservation--is it possible?. 27. 2009
Bone marrow aspiration for disseminated tumor cell detection: a must-have test or is the jury still out?. 27. 2009
Progress in mantle-cell lymphoma.. 27. 2008
The drama of the gifted disease.. 27. 2008
Prognostic factors in metastatic breast cancer: successes and challenges toward individualized therapy.. 26. 2008
Refractory thyroid cancer: a paradigm shift in treatment is not far off.. 26. 2008
Individualized treatment selection in patients with head and neck cancer: do molecular markers meet the challenge?. 26. 2008
Combining a peptide vaccine with high-dose interleukin-2.. 26. 2008
Stage I testicular cancer management and necessity for surgical expertise.. 26. 2008
Practice-based evidence of the beneficial impact of positron emission tomography in clinical oncology.. 26. 2008
Determinants of RASistance to anti-epidermal growth factor receptor agents.. 26. 2008
Should intensity-modulated radiation therapy be the standard of care in the conservatively managed breast cancer patient?. 26. 2008
Magnetic resonance imaging in the breast cancer patient: curb your enthusiasm.. 26. 2008
Time to check CHEK2 in families with breast cancer?. 26. 2008
The graying of testis cancer patients: what have we learned?. 25. 2007
Docetaxel, cisplatin, and fluorouracil in gastric cancer: does the punishment fit the crime?. 25. 2007
Skin squamous cell cancer: the time is right for greater involvement of the medical oncologist.. 25. 2007
Surgery after primary chemoradiotherapy in squamous cancer of the esophagus: is the photon mightier than the sword?. 25. 2007
Measurements of proteases or protease system components in blood to enhance prediction of disease risk or outcome in possible cancer.. 25. 2007
Targeting HER2 in prostate cancer: where to next?. 25. 2007
Are nomograms better than currently available stage groupings for bladder cancer?. 24. 2006
Can granulocyte-colony stimulating factor worsen anemia?. 24. 2006
Is tumor immunity the same thing as autoimmunity? Implications for cancer immunotherapy.. 24. 2006
Surgery of the primary tumor in metastatic breast cancer: closing the barn door after the horse has bolted?. 24. 2006
Consolidation for ovarian cancer in remission.. 24. 2006
Don't throw out the baby with the bathwater: on optimizing cure and reducing toxicity in Hodgkin's lymphoma.. 24. 2006
Induction chemotherapy for larynx preservation: patient selection or therapeutic effect?. 24. 2005
Mechanisms of late cardiovascular toxicity from cancer chemotherapy.. 23. 2005
Using practice guidelines to assess cancer care quality.. 23. 2005
Carboplatin for stage I seminoma and the sword of Damocles.. 23. 2005
Mediastinoscopy: an endangered species?. 23. 2005
Just when you thought the fluorouracil debate was over: S-1 and gastric cancer.. 23. 2005
Lymphovascular invasion as an independent predictor of recurrence and survival in node-negative bladder cancer remains to be proven.. 23. 2005
Treating cancer by blocking cell signals.. 23. 2005
"Will weekly work"? Seems to be so..... 23. 2005
Distilling cancer biomarkers from the serum peptidome: high technology reading of tea leaves or an insight to clinical systems biology?. 23. 2005
Bladder cancer "adjuvant-lite": tastes great (works as well) and less filling (less toxic)?. 23. 2005
High-dose therapy and stem-cell rescue for Ewing's family of tumors in second remission.. 23. 2005
High prevalence of complementary and alternative medicine use among cancer patients: implications for research and clinical care.. 23. 2005
MSH6 mutations in hereditary nonpolyposis colon cancer: another slice of the pie.. 22. 2004
T-cell chauvinists versus antibody advocates--can't we all just get along?. 22. 2004
Toward a glioblastoma vaccine: promise and potential pitfalls.. 22. 2004
Cancer screening: how good is good enough?. 22. 2004
Thin melanoma: still "excellent prognosis" disease?. 22. 2004
New target, new drug, old paradigm.. 22. 2004
The phase III candidate: can we improve the science of selection?. 22. 2003
Primary central nervous system lymphoma: a curable brain tumor.. 21. 2003
Topical ONYX-015 in the treatment of premalignant oral dysplasia: another role for the cold virus?. 21. 2003
Poor-risk testicular cancer and high-dose chemotherapy.. 21. 2003
Why do we need another antiemetic? Just ask.. 21. 2003
Another study of how to give fluorouracil?. 21. 2003
Advances in molecular staging of melanoma patients: multimarker analysis of archival lymph node tissue.. 21. 2003
Pemetrexed and cisplatin for malignant pleural mesothelioma: a new standard of care?. 21. 2003
Renal cell carcinoma: a priority malignancy for development and study of novel therapies.. 21. 2003
How can we tell when cancer vaccines vaccinate?. 21. 2003
Sequential single-agent chemotherapy for metastatic breast cancer: therapeutic nihilism or realism?. 21. 2003
Taking stock of volume-outcome studies.. 21. 2003
Primary central nervous system lymphoma: time to ask the question.. 20. 2002
Vaccinating patients with autologous tumor.. 20. 2002
Imatinib GIST keeps finding new indications: successful treatment of dermatofibrosarcoma protuberans by targeted inhibition of the platelet-derived growth factor receptor.. 20. 2002
Epirubicin, cisplatin, and fluorouracil in gastric and esophageal cancer: a step ahead?. 20. 2002
Cooling off hot flashes.. 20. 2002
Prognostic factors for sarcomas: hard and soft.. 20. 2002
Chemoprevention of breast cancer: a model for change.. 20. 2002
High-dose chemotherapy for breast cancer: "how do you know?".. 19. 2001
Preoperative chemoradiotherapy for esophageal cancer.. 19. 2001
Dendritic cells as immunologic adjuvants for the treatment of cancer.. 18. 2000
Germ cell tumors: there is still plenty to learn.. 16. 1998
Lung cancer cure, care, and cost: let the data be your guide.. 15. 1997
Bleomycin in germ cell tumor therapy: not all regimens are created equal.. 15. 1997
Selecting patients with cisplatin-resistant germ cell tumors for high-dose chemotherapy.. 14. 1996
Chemotherapy for colorectal carcinoma: one small step forward, one step backward.. 13. 1995
CNS leukemia: problem of diagnosis, treatment, and outcome.. 13. 1995
Chemotherapy in acute myelogenous leukemia: high dose, higher expectations?. 13. 1995
Brain tumor chemotherapy trials: slow start, but quickly gaining.. 12. 1994
Radiosurgery: a new application?. 10. 1992
The late effects of germ cell tumor chemotherapy: more data are needed.. 10. 1992
Radiosurgery for malignant brain tumors.. 8. 1990
Multimodality therapy of esophageal carcinoma: still an experimental approach.. 5. 1987
Genomic Landscape of Waldenström Macroglobulinemia and Its Impact on Treatment Strategies. 2020
Efficacy of Exercise Therapy on Cardiorespiratory Fitness in Patients With Cancer: A Systematic Review and Meta-Analysis. 2018
Locally Aggressive Connective Tissue Tumors. 2017
Integrating Evidence-Based Medicine for Treatment of Spinal Metastases Into a Decision Framework: Neurologic, Oncologic, Mechanicals Stability, and Systemic Disease. 2017
Structural Barriers to Diagnosis and Treatment of Cancer in Low- and Middle-Income Countries: The Urgent Need for Scaling Up. 2015
Polycythemia Vera: An Appraisal of the Biology and Management 10 Years After the Discovery of JAK2 V617F. 2015
Pediatric Brain Tumors: Innovative Genomic Information Is Transforming the Diagnostic and Clinical Landscape. 2015
Treatment of Brain Metastases. 2015
Advances and challenges in treatment of locally advanced rectal cancer. 2015
Update on metastatic gastric and esophageal cancers. 2015
Immune Checkpoint Blockade in Cancer Therapy. 2015
Dilemmas in treating smoldering multiple myeloma. 2014
Current state of the art and science of patient-clinician communication in progressive disease: patients' need to know and need to feel known. 2014
Breast and ovarian cancer in the older woman. 2014
Cognitive effects of cancer systemic therapy: implications for the care of older patients and survivors. 2014
Surgical considerations in older adults with cancer. 2014
Pain in cancer survivors. 2014
Use of pharmacologic interventions for breast cancer risk reduction: American Society of Clinical Oncology clinical practice guideline. 2013
Leveraging cancer genome information in hematologic malignancies. 2013
New pathologic classification of lung cancer: relevance for clinical practice and clinical trials. 2013
Cancer- and cancer treatment-associated cognitive change: an update on the state of the science. 2012
Communication skills training for oncology professionals. 2012
Evidence-based treatment of delirium in patients with cancer. 2012
Targeting the interleukin-6/Jak/stat pathway in human malignancies. 2012
Thymic malignancies: from clinical management to targeted therapies. 2011
End points and outcomes in castration-resistant prostate cancer: from clinical trials to clinical practice. 2011
Treatment of patients with metastatic urothelial cancer "unfit" for Cisplatin-based chemotherapy. 2011
Review of stem-cell transplantation for myelodysplastic syndromes in older patients in the context of the Decision Memo for Allogeneic Hematopoietic Stem Cell Transplantation for Myelodysplastic Syndrome emanating from the Centers for Medicare and Medicaid Services. 2011
Unraveling the molecular pathophysiology of myelodysplastic syndromes. 2011
Renal impairment in patients with multiple myeloma: a consensus statement on behalf of the International Myeloma Working Group. 2010
Importance of achieving a complete response in multiple myeloma, and the impact of novel agents. 2010
Role of adjuvant therapy after resection of colorectal cancer liver metastases. 2010
Are gold standard depression measures appropriate for use in geriatric cancer patients? A systematic evaluation of self-report depression instruments used with geriatric, cancer, and geriatric cancer samples. 2009
Chronic disease in the Childhood Cancer Survivor Study cohort: a review of published findings. 2009
Ovarian failure and reproductive outcomes after childhood cancer treatment: results from the Childhood Cancer Survivor Study. 2009
The Childhood Cancer Survivor Study: a National Cancer Institute-supported resource for outcome and intervention research. 2009
High-risk populations identified in Childhood Cancer Survivor Study investigations: implications for risk-based surveillance. 2009
Outcomes of adrenalectomy for isolated synchronous versus metachronous adrenal metastases in non-small-cell lung cancer: a systematic review and pooled analysis. 2008
Biomarkers of response to epidermal growth factor receptor inhibitors in Non-Small-Cell Lung Cancer Working Group: standardization for use in the clinical trial setting. 2008
Preoperative therapy in invasive breast cancer: pathologic assessment and systemic therapy issues in operable disease. 2008
Statement of the science concerning locoregional treatments after preoperative chemotherapy for breast cancer: a National Cancer Institute conference. 2008
American Society of Clinical Oncology endorsement of the Cancer Care Ontario Practice Guideline on nonhormonal therapy for men with metastatic hormone-refractory (castration-resistant) prostate cancer. 2007
Long-term health status among survivors of childhood cancer: does sex matter? 2007
Immunologic approaches to ovarian cancer treatment. 2007
Organ preservation for rectal cancer. 2007
Chemotherapy for advanced germ cell tumors. 2006
Superficial and muscle-invasive bladder cancer: principles of management for outcomes assessments. 2006
Targeted therapy for metastatic renal cell carcinoma. 2006
ASCO/SSO review of current role of risk-reducing surgery in common hereditary cancer syndromes. 2006
Cancer genetic testing and assisted reproduction. 2006
Biology of progressive, castration-resistant prostate cancer: directed therapies targeting the androgen-receptor signaling axis. 2005
Role of salvage radical prostatectomy for recurrent prostate cancer after radiation therapy. 2005
Acupuncture-point stimulation for chemotherapy-induced nausea and vomiting. 2005
Genetics of myeloid malignancies: pathogenetic and clinical implications. 2005
Cutaneous adverse effects with HER1/EGFR-targeted agents: is there a silver lining? 2005
Epidermal growth factor receptor inhibitors in the treatment of non-small-cell lung cancer. 2005
Evolving concepts in the pathology and computed tomography imaging of lung adenocarcinoma and bronchioloalveolar carcinoma. 2005
The theoretical basis of transcriptional therapy of cancer: can it be put into practice? 2005
Neoadjuvant chemotherapy before liver resection for patients with unresectable liver metastases from colorectal carcinoma. 2005
Advances in breast conservation therapy. 2005
Lymphatic mapping and sentinel lymph node biopsy for breast cancer: developments and resolving controversies. 2005
Prevention and management of hereditary breast cancer. 2005
Hereditary cancer predisposition syndromes. 2005
Small-cell carcinomas of the gastrointestinal tract: a review. 2004
American Society of Clinical Oncology treatment of unresectable non-small-cell lung cancer guideline: update 2003. 2003
Fallopian tube and primary peritoneal carcinomas associated with BRCA mutations. 2003
Detection and measurement of occult disease for the prognosis of solid tumors. 2003
Sentinel lymph node biopsy for melanoma: controversy despite widespread agreement. 2001
Development of inhalational agents for oncologic use. 2001
How effective is dose-intensive/myeloablative therapy against Ewing's sarcoma/primitive neuroectodermal tumor metastatic to bone or bone marrow? The Memorial Sloan-Kettering experience and a literature review. 2001
Second-line chemotherapy in relapsing or refractory non-small-cell lung cancer: a review. 2000
Neuroblastoma and treatment-related myelodysplasia/leukemia: the Memorial Sloan-Kettering experience and a literature review. 1998
Prognostic factors in patients with pleural mesothelioma: the European Organization for Research and Treatment of Cancer experience. 1998
Proposal for classifying the acute emetogenicity of cancer chemotherapy. 1997
International neuroblastoma staging system stage 1 neuroblastoma: a prospective study and literature review. 1996
Quantitating familial cancer risk: a resource for clinical oncologists. 1994
Single-agent chemotherapy trials in small-cell lung cancer, 1970 to 1990: the case for studies in previously treated patients. 1992
Health Care Transitions Among Adolescents and Young Adults With Cancer. 2024
Cascade Testing for Hereditary Cancer Syndromes: Should We Move Toward Direct Relative Contact? A Systematic Review and Meta-Analysis. 2022
Balancing Risk and Efficiency in Drug Development for Rare and Challenging Tumors: A New Paradigm for Glioma. 2022
Review of Current Policy Strategies to Reduce US Cancer Drug Costs. 2019
Improving Male Reproductive Health After Childhood, Adolescent, and Young Adult Cancer: Progress and Future Directions for Survivorship Research. 2018
Models of Care for Survivors of Childhood Cancer From Across the Globe: Advancing Survivorship Care in the Next Decade. 2018
New Agents, Emerging Late Effects, and the Development of Precision Survivorship. 2018
Circulating Tumor DNA Analysis in Patients With Cancer: American Society of Clinical Oncology and College of American Pathologists Joint Review. 2018
Carcinosarcomas and Related Cancers: Tumors Caught in the Act of Epithelial-Mesenchymal Transition. 2017
Pathologic Angiogenesis of Malignant Vascular Sarcomas: Implications for Treatment. 2017
Sarcoma: The Merging of Science and Clinical Care. 2017
Practical Implications of the 2016 Revision of the World Health Organization Classification of Lymphoid and Myeloid Neoplasms and Acute Leukemia. 2017
Primary CNS Lymphoma. 2017
Clinical and Technical Aspects of Genomic Diagnostics for Precision Oncology. 2017
Obesity and Cancer Mechanisms: Cancer Metabolism. 2016
Pediatric and Adolescent Extracranial Germ Cell Tumors: The Road to Collaboration. 2015
GI Stromal Tumors: 15 Years of Lessons From a Rare Cancer. 2015
Small is beautiful: insulin-like growth factors and their role in growth, development, and cancer. 2010
American Society of Clinical Oncology 2009 clinical evidence review on radiofrequency ablation of hepatic metastases from colorectal cancer. 2009
Role of anthracyclines in the treatment of early breast cancer. 2009
American Society of Clinical Oncology 2007 update of recommendations for the use of tumor markers in breast cancer. 2007
Evidence-based recommendations for local therapy for soft tissue sarcomas. 2007
Costs of cancer care: a view from the centers for Medicare and Medicaid services. 2007
Management of advanced prostate cancer after first-line chemotherapy. 2005
Intracellular signal transduction pathway proteins as targets for cancer therapy. 2005
Mapping molecular networks using proteomics: a vision for patient-tailored combination therapy. 2005
When is a tumor marker ready for prime time? A case study of c-erbB-2 as a predictive factor in breast cancer. 2001
Primary mediastinal B-cell lymphoma: a review of pathology and management. 2001
Are BRCA1- and BRCA2-associated breast cancers different? Prognosis of BRCA1-associated breast cancer. 2000
Dose-dense therapy with weekly 1-hour paclitaxel infusions in the treatment of metastatic breast cancer. 1998
Does tamoxifen cause cancer in humans? 1998
Adjuvant Endocrine Therapy for Women With Hormone Receptor-Positive Breast Cancer: ASCO Clinical Practice Guideline Focused Update. 2018
Interventions to Address Sexual Problems in People With Cancer: American Society of Clinical Oncology Clinical Practice Guideline Adaptation of Cancer Care Ontario Guideline. 2017
Use of Biomarkers to Guide Decisions on Adjuvant Systemic Therapy for Women With Early-Stage Invasive Breast Cancer: American Society of Clinical Oncology Clinical Practice Guideline Focused Update. 2017
Metastatic Pancreatic Cancer: American Society of Clinical Oncology Clinical Practice Guideline. 2016
Adjuvant Endocrine Therapy for Women With Hormone Receptor-Positive Breast Cancer: American Society of Clinical Oncology Clinical Practice Guideline Update on Ovarian Suppression. 2016
Adjuvant endocrine therapy for women with hormone receptor-positive breast cancer: american society of clinical oncology clinical practice guideline focused update. 2014
American Society of Clinical Oncology clinical practice guideline: update on adjuvant endocrine therapy for women with hormone receptor-positive breast cancer. 2010
Recommendations from an international expert panel on the use of neoadjuvant (primary) systemic treatment of operable breast cancer: an update. 2006

VIVO Weill Cornell Medical College

Journal of clinical oncology : official journal of the American Society of Clinical Oncology Journal

Overview

publication venue for

Identity

ISO Abbreviation

Linking ISSN

International Standard Serial Number (ISSN)

Electronic International Standard Serial Number (EISSN)